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The main purpose of this study was to evaluate medication use patterns (i.e., 
dose escalation, medication adherence, persistence, and switching) of rheumatoid 
arthritis (RA) patients on etanercept (ETN), infliximab (IFX) or adalimumab (ADA) 
and the associated healthcare utilization costs using Texas Medicaid data.  Study 
participants were Medicaid beneficiaries (18-63 years) with an RA diagnosis (ICD-9-
CM code 714.0x) who had no claim for a biologic agent in the 6-month pre-index 
period (July 1, 2003 - Dec 31, 2010). The index date was the first date when the 
patient had the first fill for any of the study TNF inhibitors (ETN, ADA or IFX) within 
the study identification period (Jan 1, 2004 – Aug 31, 2010). Data were extracted from 
July 1, 2003 to August 31, 2011. Prescription and medical claims were analyzed over 
an 18-month study period (i.e., 6-month pre-index and 12-month post-index periods). 
The primary study outcomes were adherence, persistence, dose escalation, switching 
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and cost (i.e., total healthcare, RA-related and TNF inhibitor therapy cost). The study 
covariates were demographic factors (age, gender, race/ethnicity), pre-index use of 
other RA-related medications (pain, glucocorticoids and disease modifying 
antirheumatic drugs), total number of non-study RA-related medications used at 
index, pre-index RA and non-RA related visits, pre-index healthcare utilization cost 
and Charlson Comorbidity Index score.  Conditional regression analyses, which 
accounts for matched samples, were used to address the study objectives. 
After propensity score matching, 822 patients (n=274/group) comprised the 
final sample. The mean age (±SD) was 48.9(±9.8) years, and the majority of the 
subjects were between 45 and 63 years (69.2%), Hispanic (53.7%) and female 
(88.0%).  Compared to patients on ETN, the odds of having a dose escalation were ≈ 
5 [Odds Ratio= 4.605 [95% CI= 1.605-12.677], p=0.0031] and ≈ 8 [Odds Ratio=7.520, 
[95% CI= 2.461-22.983], p=0.0004] times higher for IFX and ADA patients, 
respectively, while controlling for other variables in the model. Compared to ETN, 
patients on IFX (p=0.0171) were more adherent while adherence was comparable 
with patients on ADA (p=0.1144). Compared to patients on ETN, the odds of being 
adherent (MPR ≥ 80%) to IFX was ≈ 2 times higher [Odds Ratio= 2.437, [95% 
CI=1.592-3.731], p < 0.0001] while controlling for other variables in the model. 
Persistence to index TNF inhibitor therapy and likelihood to switch or discontinue 
index TNF inhibitor therapy were comparable among the 3 study groups. In addition, 
the duration of medication use (i.e., persistence) prior to switching or discontinuation 
of index therapy was comparable among the 3 study groups.  Furthermore, for each 
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of the cost variables (total healthcare, RA-related and TNF inhibitor therapy cost), 
costs incurred by patients on ETN were significantly lower (p < 0.01) than those 
incurred by ADA patients but significantly higher (p < 0.01) than those incurred by 
IFX patients. Finally, a positive and significant relationship (p < 0.0001) was found 
between RA-related healthcare cost, adherence and persistence to TNF inhibitor 
therapies.  
In conclusion, ETN was associated with lower rates of dose escalation 
compared to ADA or IFX.  However, adherence was better and associated healthcare 
costs were lower with IFX. Clinicians should endeavor to work with each individual 
patient to identify patient-specific factors responsible for poor medication use 
behaviors with TNF-inhibitor therapies. Reducing the impact of these factors and 
improving adherence should be included as a major part of the treatment plan for 
each RA patient. RA patients need to be adequately educated on the importance of 
adhering and persisting to their TNF-inhibitor therapy as poor medication 
adherence/persistence negatively impacts the RA disease process.  
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Chapter 1: INTRODUCTION 
1.1  BACKGROUND/STUDY RATIONALE 
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic 
inflammation of the joints.1  RA is a leading cause of disability and affects about 1 
percent of the adult United States (US) population with a higher prevalence, incidence 
and lifetime risk in women compared to men.2,3 The direct medical cost related to 
management of RA in the US has been estimated to exceed $4 billion annually.4 RA 
negatively impacts patients’ health related quality of life causing significant joint pain, 
disability and limited mobility.3 RA has also been associated with increased mortality 
as it predisposes patients to increased risk for cardiovascular-related diseases, 
cancer, infections and mental health conditions.3 Overall, RA contributes to a 
reduction in a patient’s lifespan by 5 to 10 years.3 Although the etiology of RA remains 
unknown, it has been speculated that its occurrence may result from an interaction 
between environmental exposures and genetic factors. Risk factors for RA include age 
(incidence increases with age and is highest among those between 65 and 74 years), 
being female (incidence is 2 to 3 times higher in women than men), presence of 
specific human leukocyte antigen (HLA) class II genotypes, tobacco use, dietary 
factors, reproductive hormonal and microbial exposures.3  
While a cure for RA is yet to be developed, current treatment goals lie in 
slowing or stopping the progression (i.e., remission) of the disease. Among the 
available treatment options, the tumor necrosis factor (TNF) inhibitors, which are 
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referred to as biologic agents or biological response modifiers (BRMs), have generally 
been recognized to have revolutionized the management of RA as they have been 
shown through randomized clinical trials (RCTs) to significantly improve patients’ 
symptoms as well as retard disease progression.5-9 TNF inhibitors are recommended 
for use in patients who failed to achieve remission or satisfactory response following 
treatment with traditional or conventional disease modifying antirheumatic drugs 
(DMARDs) (e.g., methotrexate). TNF inhibitors have been found to be even more 
effective when used in combination with traditional DMARDs.3,6-11 Among the 
available TNF inhibitors, three agents (Enbrel® (etanercept), Remicade® 
(infliximab) and Humira® (adalimumab) have been extensively studied and used 
with remarkable results. While no clinical trial has been conducted to directly 
compare (i.e., head to head comparison) the three agents, results from the majority 
of the indirect treatment comparison studies suggest that the agents have comparable 
efficacy and safety profiles.12-17 However, they differ in their method of 
administration and flexibility of dosing (see Table 1.1) and these differences may 
possibly result in differences in medication use profiles (adherence, persistence, 
discontinuation, switching and dose escalation) and cost of care for RA patients on 
medications.18-20 
 3 
Table 1.1  Dosing Recommendations for Etanercept, Infliximab and 
Adalimumab in RA Management18-20 
Drug 
(Brand Name) 
Dose & Administration Route 
Etanercept  
(Enbrel®)  
25mg SC twice weekly or 50mg once weekly (self-administered)a,b 
Infliximabc 
 (Remicade®)  
3mg/kg IV over 2 hours at week 0, 2, 6, then every 8 weeks d, with 
dose adjustment up to 10mg/kg 
Adalimumab‡ 
(Humira®) 
40mg SC every 2 weeks (self-administered)a, e 
IV = Intravenous; RA = Rheumatoid arthritis; SC = Subcutaneous;  
a Administered as monotherapy or in combination with other RA therapies (e.g., methotrexate, leflunomide, 
glucocorticoids, salicylates, analgesics, or NSAIDs);  
b Higher doses of etanercept are not recommended since they do not provide any additional benefit and due to 
increased risk of adverse events 
c Infliximab was approved to be administered in combination with methotrexate 
d frequency of administration can also be shortened from every 8 weeks to every 4 weeks; e Can be administered 
at a dose of 40mg weekly 
 
All available studies in the literature which used administrative claims data to 
evaluate RA patients’ adherence to etanercept, infliximab and adalimumab were 
conducted in the US. Studies on medication adherence (measured using varying 
definitions of medication possession ratio [MPR] or proportion of days covered 
[PDC]) reported varied mean adherence (mean MPR) values for each of the TNF 
inhibitors.2,21-25 Curkendall et al. reported an overall mean MPR of 0.52 (±0.31) for 
etanercept and adalimumab users.22 Borah et al. reported mean MPR values ranging 
from 0.65 (±0.31) to 0.73 (±0.26) for patients on etanercept and mean MPR values 
ranging from 0.63 (±0.32) to 0.70 (±0.28) for patients on adalimumab.2 Grijalva et al. 
reported mean MPR (SD not provided) values of 0.83, 0.85 and 0.90 for etanercept, 
adalimumab and infliximab users, respectively.23  A second study by Grijalva et al., 
reported median MPR values of 0.73, 0.72 and 0.68 for etanercept, adalimumab and 
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infliximab use, respectively.24 Li et al. reported mean PDC values (SD not provided) of 
0.57 and 0.64 for etanercept and infliximab patients, respectively.25 When proportion 
of adherent patients (MPR≥0.8 or 80%) were considered, Borah et al. reported 42.0 
to 51.3 percent of etanercept users and 41.0 to 47.1 percent of adalimumab users, as 
being adherent.2 Harley et al. reported 68.4 and 80.9 percent of patients on 
etanercept and infliximab, respectively, as being adherent (MPR>0.80).21 
Furthermore, among new users, the likelihood of being adherent (MPR≥0.8) to 
etanercept was reportedly lower (OR=0.462, 95% CI=0.290-0.736, p < 0.05) 
compared to infliximab, while among existing users, patients were more likely to be 
non-adherent to adalimumab compared to etanercept (OR=1.25, 95% CI=1.05-1.49, 
p=0.01).2,21 
The literature on medication persistence to etanercept, infliximab and 
adalimumab presents conflicting results, and only a few of the US studies2,22,23,25-27 
specified the gap period(s) used in the analyses. Tang et al. and Yazici et al. reported 
significantly higher mean (p=0.005) and median (p < 0.0001) persistence rates, 
respectively, for infliximab compared to etanercept and adalimumab.4,27 Harrison et 
al. found significantly (p < 0.05) higher mean persistence rates among new users of 
etanercept compared to new users of infliximab and adalimumab, but comparable 
(p>0.05) mean duration of therapy and persistence rates among continuing users on 
the 3 drugs.28 Wu et al. and Li et al. reported comparable (p>0.05) discontinuation 
rates among users of the 3 drugs 25,26 while Borah et al. found no significant difference 
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in the likelihood (HR=1.11 p=0.06 CI=1.00-1.23) of medication discontinuation 
among existing patients on adalimumab compared to etanercept.2 
Studies on dose escalation and cost of TNF inhibitor therapy consistently 
indicated that etanercept use was associated with significantly lower rates of dose 
escalation and lower TNF inhibitor therapy cost compared with the use of 
adalimumab and infliximab.26,28-33 Evidence supporting switching effectiveness 
between TNF inhibitors is limited to results obtained from small case series and open-
label studies (non-controlled studies), the majority of which are non-US studies.34-49 
Results from these studies consistently showed that treatment response following a 
switch between TNF inhibitors was comparable with, or better than the response 
observed with the initial TNF inhibitor agent. Furthermore, results from systematic 
reviews/meta-analyses also supported the effectiveness of switching between TNF 
inhibitors (i.e., adalimumab, infliximab and etanercept) irrespective of the reason for 
switching (either due to inefficacy or adverse events) and order of switching.50 
However, treatment response was reported to be slightly better if switching was as a 
result of adverse events rather than inefficacy.50,51 
The majority of the studies reported earlier were conducted using data from 
patients enrolled in private health plans or managed care organizations. Only 3 
studies were identified to have utilized data from patients enrolled under Medicaid 
programs, many of whom are not the typical patients enrolled in clinical trials.23-25 
These patients are of poor socioeconomic status and are more likely to present with 
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more comorbid disease conditions when compared to the general population. 
Furthermore, of the 3 studies which utilized Medicaid data, only one evaluated 
medication adherence and persistence across the three TNF inhibitors of interest (i.e., 
etanercept, infliximab and adalimumab) and none examined dose escalation and the 
healthcare utilization costs associated with the use of these agents. 
1.2  STUDY AIM 
The present study aims to evaluate medication use patterns (e.g., medication 
adherence, persistence, switching and dose escalation) of RA patients on etanercept, 
infliximab or adalimumab and the associated healthcare utilization costs using Texas 
Medicaid data. Etanercept, infliximab and adalimumab were the only biologics chosen 
for this study because they have been widely used and extensively studied.  
1.3  STUDY RELEVANCE 
 The cost of managing chronic disease conditions is one of the major drivers of 
increasing healthcare costs in the U.S.  RA treatment contributes to this with direct 
costs estimated to exceed $4 billion annually.4 Poor medication use behaviors can 
further increase the cost of care as they can undermine the potential benefits of these 
expensive, but effective RA treatments (i.e., TNF inhibitors). Suboptimal medication 
use causes suboptimal treatment response, rapid disease progression and occurrence 
of complications, requiring even more aggressive treatment options.  In the face of 
limited healthcare resources, the need therefore arises to assess RA patients’ TNF 
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inhibitors medication use patterns (e.g., medication adherence, persistence, 
discontinuation, dose escalation and switching) as well as the associated healthcare 
utilization cost. This information can be used to promote better medication use 
behavior, improve treatment outcomes and optimize treatment costs among RA 
patients.   
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Chapter 2: LITERATURE REVIEW 
2.1 CHAPTER OVERVIEW 
This chapter provides a discussion of the literature relevant to the present 
study. The literature review covers the following topics as it relates to rheumatoid 
arthritis (RA): epidemiology, humanistic and economic burden, etiology and risk 
factors, clinical classification and diagnosis, clinical assessments and outcomes. Other 
topics covered include treatment goals, management options, clinical practice 
guidelines and medication use patterns of tumor necrosis factor (TNF) inhibitors 
among RA patients. The chapter concludes with a summary of the literature review, 
study objectives and hypotheses. 
2.1.1 Definition, Morbidity and Mortality of RA  
 Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic 
inflammation and progressive destruction of the joints.1 RA is also associated with 
disabling pain, tenderness, swelling and stiffness in the joints. RA causes progressive 
decline in functional ability and it limits performance of social roles and other 
activities.3,52,53 Untreated or improperly treated RA also increases the risk for 
permanent joint damage and deformity.54 Overall, RA contributes to a mean reduction 
in a patient’s lifespan by 5 to 10 years.3 Compared to the general population, RA 
patients have an increased mortality with standardized mortality ratios varying from 
1.29 to 2.98.55 RA accounts for about 22 percent of all arthritis-related deaths 
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including deaths due to rheumatic conditions.3 Patients with RA are at risk for 
developing cardiovascular events (e.g., ischemic heart diseases, stroke and heart 
failure), gastrointestinal, hematologic and respiratory infections, cancer (e.g., skin 
and lung cancer), skeletal disorders as well as mental health conditions (e.g., 
depression).55-58 RA patients also present with fatigue, sleep disturbances and sexual 
dysfunction.52,59  
2.1.2 Prevalence and Incidence of RA 
 In the developed world (i.e., Europe and the United States (US)), the estimated 
prevalence rate of RA ranges between 0.5 and 1 percent, with a higher prevalence 
rate reported among women compared to men.55 Based on 2005 data from the 
National Health Interview Survey (NHIS) and the Rochester project, an estimated 1.3 
to 1.5 million people in the US present with RA.60,61  The Rochester project indicated 
a 16.1 percent increase in RA prevalence rates per 100,000 population between 1995 
and 2005 among the US adult population (≥18 years).61  Incidence rates for RA 
declined from 61.2 per 100,000 population in the period 1955-1964 to 32.7 per 
100,000 population in the period 1985-1994, but increased to 40.9 per 100,000 
population in the period 1995-2007.61,62 The increase in prevalence and incidence of 
RA in recent years have largely been attributed to changes in the incidence of RA 
among women, which has increased by an annual rate of 2.5 percent from 1995 to 
2007, while incidence rates among men decreased by 0.5 percent.61 Likewise, RA 
prevelance rates among women have increased significantly by about 27.3 percent 
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from 1995 to 2005.61 Furthermore, data from 1980 to 2007 indicated that for both 
men and women, the distribution of RA incidence across different age groups has 
remained relatively stable with the lowest incidence observed among ages 18-34 (8.7 
per 100,000 people) and the highest incidence seen among ages 65-74 (89 per 
100,000). Interestingly, a decline in RA incidence was observed among adults above 
the age of 74.61,62  Limited information exists in the literature on the distribution of 
RA prevalence and incidence by race and it is important to know that the population 
involved in the Rochester project was primarily white (over 90 percent). 61,62 
However, the prevalence rates of arthritis (RA inclusive) by race and ethnicity based 
on a combination of data from the 2002, 2003 and 2006 National Health Interview 
Survey are presented below in Table 2.1.63  
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Table 2.1 Prevalence of Arthritis By Race/Ethnicity 
Race/ Ethnicity Prevalence (%) 
American Indian/Alaska Native 25.2 
Non-Hispanic White 23.8 
Multiracial/Other 20.7 
Non-Hispanic Black 19.4 
Hispanic 11.1 
Asian/Pacific Islander 8.4 
Source: National Health Interview Survey 2002, 2003 and 2006.  
Centers for Disease Control and Prevention. Racial/Ethnic differences: Differences in the prevalence and impact 
of arthritis among racial/ethnic groups in the Unites States. 2011;  
http://www.cdc.gov/arthritis/data_statistics/race.htm. Accessed March 3, 2012 
 
 
2.1.3 Humanistic and Economic Burden of  RA 
Due to the chronic nature of RA, the comorbidities (especially cardiovascular 
and depressive diseases) that occur as the disease progresses and the negative impact 
of RA on patients’ health-related quality of life (HRQoL) and productivity, the burden 
associated with the management of RA is significant. HRQoL parameters affected by 
RA include mental wellbeing, physical and social functioning. RA patients also present 
with pain, stiffness, fatigue and sleep disturbances.64 The impact of RA on these 
HRQoL parameters directly or indirectly negatively influences patients’ productivity.  
In the past two decades, the estimated prevalence of work disability among RA 
patients (based on results from clinical studies) ranged from 22 to 44 percent.65 
Compared to individuals without RA, patients with RA are at increased risk of being 
employed for fewer years or being without a paid job (odds range between 1.2 and 
3.4). 55,65 Among patients with early RA (< 1 year), about 33 percent are at risk of 
losing their jobs in the first 2 years and about 53 percent will lose their jobs within 6 
years.55 Yearly incidence rates for ending employment and ending without resuming 
 12 
employment have also been reported to be about 8.7 and 4 percent, respectively.55  
Given a population average of approximately 11 sick leave days per year, patients 
with established RA reportedly used an average of 46 days, with some using as many 
as 118 sick leave days per year.55 
Birnhaum et al., using administrative databases of both privately- and 
publicly- insured patients (Medicare and Medicaid beneficiaries), estimated the 
direct and indirect costs (i.e., productivity costs or income lost due to presenteeism, 
absenteeism, unpaid work, productivity loss and/or change in employment status 
(see Table 2.2 for definitions)) associated with RA to be about $8.4 billion and $10.9 
billion, respectively.66 RA patients have been reported to incur about 2 to 3 times 
more in average direct medical expenditures per year than individuals of similar age 
and gender without RA.67 Also, RA patients with comorbidities (e.g., cardiovascular 
disease and/or depression) were reported to spend an average of $2,000 to $3,000 
more in annual healthcare costs than similar RA patients with no comorbid 
conditions.68 Wolfe et al. estimated an annual median income loss of between $2,319 
and $3,407 (i.e., 9.3% to 10.0% loss) among employed US RA patients.69 Li et al. 
reported an average annual productivity cost per patient of CAN$11,553 (≈US$8,665) 
among employed Canadian patients with arthritis with loss due to reduced 
performance at work (i.e., presenteeism) being the major contributor (see Table 
2.3).70  
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  Table 2.2 Types of Productivity Loss 
Productivity Categories Definition 
Absenteeism Days absent from work due to illness 
Presenteeism Reduced or impaired performance at work due to illness 
Unpaid work Production losses when not paid 
Productivity loss Activities postponed or taken over due to illness 
Change in employment status Reduced work hours or having to work part-time, 
unemployment or early retirement due to illness 
Source: Zhang W, Anis AH. The economic burden of rheumatoid arthritis: beyond health care costs. Clin 
Rheumatol. 2011; 30 (Suppl 1):S25-S32.  
 
 
  Table 2.3  Productivity Loss Associated with Arthritis 
Productivity Categories Costa/person/year % of Total 
Reduced performance at work 
(Presenteeism) 
$4,724 41.0 
Wage loss from stopping or changing jobs $4,309 37.0 
Decreased hours $1,398 12.0 
Absenteeism $1,212 10.0 
Total lost productivity $11,553 100.0 
a Costs are in Canadian dollars 
Source: Li X, Gignac MA, Anis AH. The indirect costs of arthritis resulting from unemployment, reduced 
performance, and occupational changes while at work. Med Care. 2006; 44(4):304-310. 
  
2.1.4 Etiology and Risk Factors for RA 
While the etiology of RA remains unknown, it has been speculated that it may 
be caused by an interaction between environmental exposures, genetic factors and 
chance.58 Genetic factors have been reported to account for about 50 percent of the 
risk of developing RA.71 The presence of specific human leukocyte antigen (HLA) class 
II genotype (e.g., HLA-DRB1 alleles) has been confirmed in patients who tested 
positive for rheumatoid factor (RF) or anti-citrullinated protein antibodies.58 Factors 
that cause bronchial distress (e.g., smoking and exposure to silica) also increase 
patients’ risk of developing RA, especially if the patient is susceptible to HLA-DR4 
alleles.58 Smoking has been associated with the development of erosive disease and 
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vasculitis which are part of the joint destruction process.72 Furthermore, citrulline-
producing cells, which are indicative that a citrullination process is occurring, have 
been identified in the bronchoalveolar lavage fluid of smokers.72 The citrullination 
process is an early step in the cell death process involving the modification of the 
amino acid arginine into citrulline.72,73 It is an important process as the presence of 
anti-citrullinated protein antibodies or anti-cyclic citrullinated peptide (anti-CCP) is 
predictive of both the presence and severity of RA.72 Smoking and HLA-DRB1 alleles 
(especially homozygotes) act synergistically, increasing a patient’s risk of developing 
anti-citrullinated protein antibodies.58,71,73 A combination of rheumatoid factor (RF) 
and anti-citrullinated protein antibodies has been reported to yield a better diagnosis 
of RA.74 
Exposure to microbial agents (e.g., Escherichia coli, proteus species, 
cytomegalovirus and Epstein-Barr virus) and their products (heat-shock proteins) 
have also been associated with the development of RA. Complexes formed during 
infection may activate the release of rheumatoid factor which is a biomarker for the 
diagnosis of RA and is associated with its development.58 Other associated risk factors 
for the development of RA include: presence of periodontal diseases due to 
Porphyromonas gingivalis, dietary factors, age (incidence increases with age and 
highest among those between 65 and 74 years), being female (incidence is 2-3 times 
higher in women than men) and exposures to specific reproductive hormones.3,58 
Other reported potential environmental risk factors for which available supporting 
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evidence is weak include low socioeconomic status, coffee intake, vitamin D status, 
alcohol intake and oral contraceptive use.71 
2.1.5 Classification and Diagnosis of RA 
 RA has generally been classified as either early or established RA.  RA is 
considered to be early during the first 24 months of diagnosis, but  greater emphasis 
is placed on the first 12 months.72 Identifying RA early is critical for early suppression 
of the inflammatory process, as undiagnosed or untreated RA increases the risk of 
persistent inflammation and progressive damage to the joints.72 On the other hand, 
patients with a mild form of early RA may not benefit from treatment if the disease is 
unlikely to progress. This is because patients with early RA tend to enter a period of 
remission (Figure 2.1) regardless of whether they receive treatment or not, and the 
likelihood of achieving spontaneous remission is even higher among patients with 
mild early RA disease.72 
 Figure 2.1 ACR Criteria for Defining Remission 
  
 
 
 
ACR= American College of Rheumatology; ESR= Erythrocyte sedimentation rate. 
Source: Goetz I, Carter GC, Lucero M, et al. Review of treatment response in rheumatoid arthritis: assessment of 
heterogeneity. Curr Med Res Opin. 2011;27(4):697-711. 
At least 5 of the following conditions below must be met for ≥ 2 consecutive months 
 Morning stiffness for a duration ≤ 15 minutes 
 No fatigue 
 No joint pain 
 No joint tenderness or pain with motion 
 No soft-tissue swelling in joints or tendon sheaths 
 An ESR level of  ≤ 30 mm/hr (females) or ≤ 20mm/hr (males) 
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In 1987, the American College of Rheumatology (ACR) introduced criteria for 
classifying RA (Figure 2.2).75 However, the criteria performed poorly in classifying 
patients with early inflammatory arthritis as having RA. It was also ineffective in 
identifying patients with early RA who subsequently developed established RA.71  The 
criteria were believed to have failed in classifying/identifying early RA primarily due 
to the process through which they were developed (i.e., from studies of patients with 
established RA).72,76 The criteria also relied solely on ‘physician’s opinion’ as the ‘gold 
standard’ but physicians have been reported to have difficulty identifying early RA 
solely on clinical criteria.72,75 Furthermore, two (i.e., rheumatoid nodules and severe 
erosive joint damage) of the seven ACR criteria necessary for establishing an RA 
diagnosis take months or even years to appear after the onset of synovitis.71,76  
 In an approach to address the difficulty in classifying early RA, a review by 
Dixon et al. suggested that immediate classification of patients with early 
inflammatory arthritis be avoided given that a considerable follow-up period is 
required to determine if these patients will have a seropositive or seronegative RA 
and/or present with other disorders.77  They classified the development of RA into 
four stages which include: (a) the period leading to the onset of arthritis; (b) the 
period during which persistence or remission occurs; (c) the period when the 
arthritis evolves into a specific form of arthritis; and (d) finally the outcome of the 
arthritis.77 Since the duration of these stages varies across patients, with some 
patients having the stages follow a rapid succession and others having them 
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prolonged over several months or years, they further suggested that the concept of 
early arthritis be discontinued and patients be classified as either having an 
undifferentiated inflammatory arthritis or established RA.77   
Over the past few years, prediction models have been designed with the aim 
of predicting outcomes in patients with early arthritis who do not currently meet the 
1987 ACR criteria.78-81 However, these models were found to be somewhat 
complicated.71 In 2010, the ACR and European League Against Rheumatism (EULAR) 
developed new criteria intended to classify/diagnose both early and established RA.82 
The new criteria (2010 ACR/EULAR criteria) were developed using a three-phase 
approach. The first phase involved collecting data from patients with early RA 
regarding the factors associated with their physicians’ decisions to start 
methotrexate therapy. This was followed by a consensus-driven approach to refine 
these factors based on input from current clinical thinking. The final phase involved 
summarizing all the data to develop a prediction model and cut-off value for the 
probability score.71   
The 2010 ACR/EULAR criteria for classifying/diagnosing both early and 
established RA are based on an assessment of the patient’s joint involvement, 
autoantibody status, acute-phase reactants, and symptom duration (Figure 2.2).82 
The diagnostic accuracies of the 2010 ACR/EULAR criteria have been compared with 
those of the 1987 ACR criteria.83,84 While no statistically significant differences were 
observed between the two criteria, the 2010 ACR/EULAR was reported to show some 
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improvements and was also slightly more sensitive when compared to the 1987 ACR 
criteria.83,84 
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Figure 2.2 Conventional (1987), Early (2007) and New Classification (2010) 
Criteria for Rheumatoid Arthritis 
 
 
1987 ACR Criteria 
1) Morning stiffness (at least 1hr)* 
2) Arthritis of 3 or more joint 
areas* 
3) Arthritis in hand joints (≥ 1 
swollen joint)* 
4) Symmetrical arthritis* 
5) Rheumatoid nodules 
6) Serum rheumatoid factor 
7) Radiographic changes 
(erosions) 
 
 
 
 
 
 
Four of these 7 criteria must be 
present.  
*Criteria 1-4 must be present for at 
least 6 weeks  
 
2010 ACR/EULAR Criteria 
1) Joint involvement (0-5) 
 One medium-to-large joint (0) 
 Two to ten medium-to-large joints (1) 
 One to three small joints (large joints not counted) (2) 
 Four to ten small joints (large joints not counted) (3) 
 More than ten joints (at least one small joint) (5) 
2) Serology (0-3) 
 Negative RF and negative ACPA (0) 
 Low positive RF or low positive ACPA (2) 
 High positive RF or high positive ACPA (3) 
3) Acute-phase reactants (0-1) 
 Normal CRP and normal ESR (0) 
 Abnormal CRP or abnormal ESR (1) 
4) Duration of symptoms (0-1) 
 Less than 6 weeks (0) 
 6 weeks or more (1) 
Points are shown in parentheses. Cut point for 
rheumatoid arthritis is 6 points or more. Patients can 
also be classified as having rheumatoid arthritis if 
they have: (a) erosions; (b) long-standing disease 
previously satisfying the classification criteria 
Early Arthritis Prediction 2007 
1) Age (multiply by 0.02) 
2) Gender (female 1) 
3) Distribution of involved joints 
 Small joints hands and feet (0.5);   Symmetrical (0.5); Upper limbs (1);  Upper and lower limbs (1.5) 
4) Morning stiffness (visual analogue scale) 
 26-90 mm (1) ;   > 90mm (2) 
5) Number of tender joints 
 Four to ten (0.5); 11 or more (1) 
6) Number of swollen joints 
 Four to ten (0.5);  11 or more (1) 
7) C-reactive protein (mg/L)  
 Five to 50 (0.5);  51 or more (1.5) 
8) RF positive (1) 
9) ACPA positive (2) 
Points are shown in parentheses. Cut point for rheumatoid arthritis is 8 points or more 
ACPA= anti-citrullinated protein antibodies; ACR= American College of Rheumatology; CRP= C-reactive protein; EULAR= 
European League Against Rheumatism; ESR= erythrocytes sedimentation rate; RF= rheumatoid factor. ACR 1987 criteria (left 
panel) were designed to classify established rheumatoid arthritis (RA). ACR/EULAR 2010 criteria (right panel) are intended 
to classify both early and established RA. Prediction models such as the van de Helm model (lower panel) represent an 
intermediate phase designed to identify patients with early undifferentiated arthritis who are most likely to subsequently 
meet criteria for RA; such models are somewhat more complex than the new criteria.                                                                                                                                                    
Source: Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010; 376 (9746):1094-1108. 
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2.1.6 Clinical Assessments and Outcomes in the Management of RA  
 Clinical assessment in the management of RA entails an evaluation of the 
patient’s disease activity, extra-articular disease and comorbidities.71 Disease activity 
assessments involve evaluation of: (1) core measures; (2) fatigue and radiographical 
damage; (3) combined status indices; and (4) change in status.71 Core measures 
assessed include: (a) tender and swollen joint counts (e.g., counts of the 28 joints in 
the hands, knees and upper limbs); (b) laboratory measures (e.g., erythrocyte 
sedimentation rate [ESR] and C-reactive protein [CRP]); (c) patient-based measures 
(e.g., global assessment, pain appraisal, measures of fatigue and disability).71 
Radiographical techniques (e.g., ultrasound and magnetic resonance imaging) are 
used in assessing both reversible and irreversible structural changes (e.g., justa-
articular erosions). Combined status indices (e.g., the disease activity score (DAS); 
disease activity score 28 (DAS28); clinical disease activity score; and simple disease 
activity score) use a combination of information from 2 or more of the core measures 
described above in assessing patients’ disease activity status.71 For example the 
DAS28 combines information from patient’s global assessment, ESR and counts of the 
28 tender and swollen joints of the arms, hands and knees. DAS28 values 2.6-3.2; 3.3-
5.1; and >5.1 refers to low, moderate and high disease activity levels, respectively, 
while a DAS28 <2.6 refers to a state of remission.85 Change in status measures are used 
in clinical trials to determine improvement in patients’ disease activity status based 
on ACR improvement criteria. They are also used to measure the efficacy of the 
treatment agents. They are expressed as ACR20, ACR50 and ACR70, which indicates 
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a 20, 50, and 70 percent, respectively, improvement from baseline in swollen joint 
count, tender joint count, and at least three of the following five measures (patient’s 
global assessment of disease activity, physician’s global assessment of disease 
activity, patient’s assessment of pain, acute phase reactant and disability).71,86 In 
addition, some clinical trials also use response criteria developed by EULAR to 
determine the efficacy of therapeutic agents.86 The EULAR response criteria are based 
on patients’ performance on the DAS or DAS28. The DAS consists of the Ritchie 
articular index, the 44 swollen joint counts, the ESR and a general health assessment 
on a Visual Analog Scale (VAS). Based on EULAR response criteria, achieving a DAS ≤ 
2.4 is indicative of a ‘good response’; a DAS > 2.4 but ≤ 3.7 is indicative of a ‘moderate 
response’; while a DAS > 3.7 shows a ‘lack of response’ to therapy.86 See Table 2.4 for 
the response criteria for the DAS28. 
Table 2.4 EULAR Response Criteria Based on the DAS28 
Current DAS28 Improvement in DAS28 
 >1.2 0.6-1.2 < 0.6 
<3.2 Good response Moderate response No response 
3.2-5.1 Moderate response Moderate response No response 
>5.1 Moderate response No response No response 
DAS28= Disease Activity Score 28.  
Source: Lutt JR, Deodhar A. Rheumatoid arthritis - Strategies in the management of patients showing an 
inadequate response to TNF alpha antagonists. Drugs. 2008; 68(5):591-606. 
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Extra-articular diseases and comorbidities assessed in RA are presented in 
Figure 2.3.  Important outcomes in RA management include persistent joint 
inflammation, progressive joint damage and functional decline.  Others include 
patient-related factors (e.g., fatigue, work disability), presence of comorbidities (e.g., 
cardiovascular, infection, cancer), extra-articular diseases (e.g., vasculitis, lung 
disease, rheumatoid nodules and Sjögren’s syndrome) and premature mortality.71  
Figure 2.3  Extra-articular Diseases and Comorbidities Assessed in RA†  
 
Extra-articular Diseases 
a) Cutaneous 
 Leg ulceration 
 Vasculitic rashes 
 Palmar erythema 
 Pyoderma gangrenosum 
 
b) Cardiac 
 Pericarditis 
 Conduction defects 
 Valvular heart diseases 
 
c) Vasculitis 
 Systemic 
 Nail fold 
 
d) Neurological 
 Mononeuritis muitiplex 
 Nerve entrapment 
 Cervical myelopathy 
 Peripheral neuropathy 
 
e) Ocular 
 Scleritis 
 Keratoconjunctivitis sicca 
 Episcleritis 
 
f) Pulmonary 
 Fibrosing alveolitis 
 Pleural effusion 
 Pulmonary nodules 
 
g) Amyloidosis & Nodules 
Comorbidities‡ 
a) Cardiovascular 
 Myocardial infarction 
 Stroke 
 Hypertension 
 Heart failure 
 Peripheral vascular disease 
 
b) Infection 
 Bacterial 
 General 
 
c) Cancer 
 Skin cancer 
 Lung cancer 
 Lymphoma and lympho-
proliferative diseases 
 
d) Others 
 Depression 
 Gastrointestinal disease 
 Renal disease 
 Psoriasis 
 Osteoporosis 
 
 
‡Some of the diseases are associated 
mainly with rheumatoid arthritis (e.g., 
cardiovascular); some are associated with 
the treatment (e.g., gastrointestinal 
diseases); and some with both the disease 
and the treatment (e.g., infection) 
 † Rheumatoid Arthritis  
Source: Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010; 376 (9746):1094-1108. 
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2.1.7 Disease Progression in RA 
 The clinical course of RA can range from a mild and self-limiting disease to one 
that is severe and progressive, causing significant disability. The progression and 
disease activity of RA vary widely among patients, thereby necessitating the need for 
early identification.87  Early identification presents patients with the opportunity of 
benefitting from intensive or aggressive therapy with a high likelihood of changing 
the course of the disease.87 While the presence of bone and cartilage erosions are 
useful predictors of disease progression to severe RA in patients with established RA, 
they have not been helpful in predicting disease progression among patients with 
early RA.87 Monitoring for the presence of serum RF, anti-CCP antibodies, elevated 
levels of acute phase reactants (e.g., ESR and CRP levels) and markers of bone and 
cartilage turnover have also been proposed to better predict the destructive course 
of RA.87 However, the diagnostic sensitivity and specificity of these biomarkers have 
been reported to be insufficient in providing guidance for therapeutic decision 
making.87 In an approach to address this limitation, a suggestion to use a group of 
multiple biomarkers that enables detailed stratification of the disease was proposed. 
According to Lindstrom et al., these biomarkers need to be improved to have the 
required specificity and sensitivity necessary to accurately identify patients who are 
at risk of developing erosive RA.87  
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In determining the progression of RA disease in affected patients, the ACR 
developed classification criteria based on patients’ global functional status and the 
radiographical appearance of their joints on X-ray (see Table 2.5).86   
Table 2.5 ACR Classification of RA Severity 
Class/Stage Based on Global 
Functional Status 
Based on X-ray 
Appearance of Joints 
I 
 
Completely able to perform 
usual activities of daily 
living (self-care, vocational 
and       avocational) 
No damages seen on X-rays, 
although there may be signs 
of bone thinning 
II 
 
 
Able to perform usual self-
care and vocational 
activities, but limited in 
avocational activities 
1) On X-ray, evidence of 
bone thinning around a 
joint with or without slight 
bone damage 
2) Slight cartilage damage 
possible 
3) Joint mobility may be 
limited; no joint deformities 
observed 
4) Atrophy of adjacent 
muscle 
5) Abnormalities of soft 
tissue around joint possible 
III 
 
 
Able to perform usual self-
care activities, but limited 
in vocational and 
avocational activities 
1) On X-ray, evidence of 
cartilage and bone damage 
and bone thinning around 
the joint 
2) Joint deformity without 
permanent stiffening or 
fixation of the joint 
3) Extensive muscle 
atrophy 
4) Abnormalities of soft 
tissue around joint possible 
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Table 2.5 ACR Classification of RA Severity (Contd) 
Class/Stage Based on Global 
Functional Status 
Based on X-ray 
Appearance of Joints 
IV 
 
Limited in ability to 
perform usual self-care, 
vocational and avocational 
activities 
1) On X-ray, evidence of 
cartilage and bone damage 
and osteoporosis around 
joint 
2) Joint deformity with 
permanent fixation of the 
joint (referred to as 
ankylosis) 
3) Extensive muscle 
atrophy 
4) Abnormalities of soft 
tissue joint possible 
ACR= American College of Rheumatology 
Usual self-care activities include dressing, feeding, bathing, grooming, and toileting. 
Avocational (recreation and/or leisure) and vocational activities (work, school, homemaking) are patient-
desired and age-and gender-specific 
Source: Goetz I, Carter GC, Lucero M, et al. Review of treatment response in rheumatoid arthritis: assessment of 
heterogeneity. Curr Med Res Opin. 2011;27(4):697-711. 
 
2.1.8 Management of RA 
RA like many chronic disease conditions presently has no cure. A 
multidisciplinary team approach involving rheumatologists, nurse specialists, 
occupational therapists, podiatrists, dieticians, pharmacists, physical therapists, 
psychologists, occupational therapists, rehabilitation specialists and orthopedic 
surgeons is highly recommended in RA management.88,89 Current treatment goals are 
focused on slowing or stopping disease progression (i.e., achieving clinical remission) 
while controlling associated inflammatory symptoms (e.g., pain, tenderness, swelling 
and stiffness in the joints as well as fatigue) and halting joint erosions. Treatments 
are also geared towards improving joint function, work productivity and health-
related quality of life, preventing joint destruction and disabilities as well as reducing 
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morbidity and mortality.74  Management of RA can be broadly classified into non-
pharmacological and pharmacological interventions.  
2.1.8.1 Non-Pharmacological Therapies in the Management of RA 
Non-pharmacological therapies used in the management of rheumatoid 
arthritis (RA) are generally recommended as adjunct or supportive therapies to 
pharmacological treatment.71,90 Their use varies depending on the stage and 
progression of the disease, both of which are functions of regular clinical assessment 
of the disease.90 Other factors considered include patient’s personality, treatment 
objectives and the environment.90 Examples of these non-pharmacological therapies 
include physical therapy, psychotherapy/mind-body medicine, therapeutic patient 
education, physiotherapy, occupational therapy, exercise/aerobic activities, diet, 
balneotherapy/hydrotherapy/spa treatment, acupuncture, massage, foot care, joint 
protection, thermotherapy, transcutaneous electric nerve stimulation (TENS), 
splints, use of assistive devices and adaptations of the environment.71,90-92 Finally, 
surgical treatments or reconstructive surgery (e.g., joint replacement procedures), 
which are also non-pharmacological options, are used in maintaining or restoring 
function in situations of significant functional impairment or unacceptable level of 
pain.71,74 
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2.1.8.2 Pharmacological Therapies in the Management of RA 
 Pharmacological therapies for the management of RA can be broadly classified 
into symptomatic/supportive treatment and disease modifying therapies.  
Symptomatic/Supportive Treatment Therapies in RA Management 
  As discussed earlier, patients with RA experience pain, tenderness, swelling 
and stiffness of the joints due to the on-going inflammatory process. RA patients have 
over the years benefitted from the use of analgesic and non-steroidal anti-
inflammatory drugs (NSAIDs). Analgesic agents only reduce pain while NSAIDs 
including cyclooxygenase-2 inhibitors effectively improve inflammatory symptoms. 
However, they have been of limited use in the management of RA due to their inability 
to modify the disease process (i.e., stop or slow disease progression) in the long term 
and there are concerns about their safety because these therapies predispose patients 
to renal damage, gastrointestinal toxicity and cardiovascular morbidities.71,74,93-95  
Low-dose glucocorticoids (e.g., ≤10mg of prednisone or equivalent) have also 
been found to be effective due to their potent anti-inflammatory and 
immunomodulatory effects.74 They have been reported to reduce the rate of joint 
erosion and vasculitis in early RA and are recommended as beneficial for short-term 
treatment in combination with a standard therapy.71,96,97 Higher does can also be 
administered over a short period of time either orally or via intramuscular injection 
as ‘bridge therapy’ pending the onset of action of disease modifying antirheumatic 
drugs.74 In addition, they are also highly effective as local treatment for individual 
 28 
active joints when administered via intra-articular injection.71 They have also been of 
limited use due to their serious side effects, examples of which include blood glucose 
abnormalities, osteoporosis, Cushingoid manifestations, infections, cataracts and 
elevated cardiovascular  risks.74 
Disease Modifying Therapies in the Management of Rheumatoid Arthritis  
Disease modifying therapies administered in the management of RA can be 
broadly classified into traditional or conventional disease modifying antirheumatic 
drugs (DMARDs) and biologic agents or biological response modifiers (BRM).  
Traditional or Conventional Disease Modifying Antirheumatic Drugs (DMARDs) 
The DMARD class is a heterogeneous collection of drugs with diverse 
mechanisms of action.71 These medications have been used in the treatment of RA for 
decades and have been found to be effective at reducing inflammatory symptoms 
(e.g., pain and swelling) and acute-phase markers.71 They modify the disease process 
by limiting the progression of joint damage and also improve joint function. DMARDs 
generally have slow onset of action which range from several weeks to months. 
Examples include methotrexate (MTX), sulfasalazine, leflunomide, 
hydroxychloroquine, chloroquine, gold (rINN sodium aurothiomalate), 
cyclosphosphamide, cyclosporine, azathioprine and minocycline.71,74  
Of these drugs, MTX is the most widely used due to its long-term effectiveness, 
acceptable safety profile and low cost. MTX remains the standard by which newer 
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DMARDs are evaluated.71,74 Other commonly used DMARDs include sulfasalazine, 
leflunomide and hydroxychloroquine (see Table 2.6).71,74 While these agents have 
been shown to be efficacious (e.g., improvement in clinical and radiographic 
outcomes) when administered as either mono- or combination therapies, limited 
evidence exists to support the effectiveness of one particular DMARD over the 
other.16,98-103 Commonly reported adverse events with the use of MTX (at its usual 
dose of ≤ 25mg/week) include hepatotoxicity, gastrointestinal toxicities and 
myelosuppresion.74 Pulmonary and renal toxicity have also been observed at higher 
doses of MTX and, as such, periodic monitoring of peripheral blood cell count, liver 
and kidney function is required.74 Leflunomide use is associated with alopecia, 
headache, gastrointestinal symptoms and elevated liver enzymes. Adverse events 
associated with sulfasalazine use include photosensitivity, myelosuppresion, 
hematological and gastrointestinal toxicities.74 Patients on hydroxychloroquine 
present with skin reactions, alopecia, dizziness, myopathy, headache, central nervous 
system toxicity and gastrointestinal reactions and in rare situations, ocular toxicity 
including retinopathy may occur.74 Due to the severity of the adverse events 
associated with the use of DMARDs, the American College of Rheumatology (ACR) in 
2008 issued recommendations regarding safety monitoring of these agents (Table 
2.7).104  
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Table 2.6 Overview of  DMARDs Commonly Used  in RA Management 
Drug Class Drug (Brand 
Name) & FDA 
Approval Date 
Mode of Action Dose and 
Administration 
Route 
Half life 
(t1/2) 
Dihydrofolate 
reductase 
inhibitor 
Methotrexate 
(Trexall®) 
(1988)* 
Inhibits 
metabolism of folic 
acid 
7.5-25mg 
weekly oral or 
in subcutaneous 
injections 
3- 15 hours 
(dose 
dependent) 
Sulfa Sulfasalazine 
(Azulfidine®) 
(1950)* 
 
Not completely 
clear 
1-3g daily oral 
in divided doses 
5-10 hours 
Pyrimidine 
synthesis 
inhibitor 
Leflunomide 
(Arava®) 
(1998)* 
 
Inhibits 
mitochondrial 
enzyme 
dihydroorotate 
dehydrogenase 
(DHODH) 
10-20mg daily 
oral 
14 days 
Anti-malaria Hydroxychloroquine 
(Plaquenil®;   
Quineprox®) 
(1955)* 
Inhibits stimulation 
of the toll-like 
receptor (TLR) 9 
family receptors 
200-400mg 
daily oral 
1-2 months 
DMARDs= disease modifying antirheumatic drugs; FDA= Food and Drug Administration; RA= rheumatoid 
arthritis. 
*The approval date indicated is the approval date for the agent’s primary indication. For all the agents, RA was 
not the primary indication for which they were originally approved. 
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Table 2.7 ACR 2008 Recommendations for Optimal Laboratory Monitoring 
Intervals* for Complete Blood Count, Liver Transaminase Levels 
and Serum Creatinine Levels for RA Patients Receiving DMARDs  
Agent Monitoring Interval Based on Duration of Treatment 
 < 3 Months 3-6 Months > 6 Months 
Methotrexate 2-4 weeks 8-12 weeks 12 weeks 
Sulfasalazine 2-4 weeks 8-12 weeks 12 weeks 
Leflunomide 2-4 weeks 8-12 weeks 12 weeks 
Hydroxychloroquine None after baseline None None 
ACR= American College of Rheumatology; DMARDs= disease modifying antirheumatic drugs; RA = rheumatoid 
arthritis.  
*More frequent monitoring is recommended within the first 3 months of therapy or after increasing the dose.  
Source:  Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the 
use of non-biologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 
2008; 59(6):762-784. 
 
 
Biologic Agents or Biological Response Modifiers (BRM) 
Biologic agents act by targeting specific inflammatory proteins, cytokines and 
cellular interactions involved in the pathophysiology of RA.54,105  Their introduction 
has generally been recognized to have revolutionized the management of RA as they 
have been shown to significantly improve patients’ symptoms, physical functioning 
and quality of life while slowing the progression of the disease. 5-10,106-126  
Furthermore, the biologic agents’ clinical responses are rapid with improvements 
observed within a few weeks of therapy initiation.7,111,117,118 While biologics are 
effective in early RA management, their use is recommended in patients with 
moderate or severe RA who failed to achieve remission or satisfactory response 
following treatment with traditional DMARDs (e.g., methotrexate).74 This is primarily 
due to their substantial cost impact and long-term safety concerns.74 Biologics also 
differ in their mode of administration, mechanism of action and frequency of dosing 
(Table 2.8).54 These differences, together with other factors (e.g., cost, insurance 
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coverage, patient and physician preferences) impact the choice of biologic agent used 
in clinical practice. Examples of these agents include anakinra, etanercept, 
adalimumab, infliximab, golimumab, certolizumab, rituximab, abatacept and 
tocilizumab.54  
Among the available biologic agents, the tumor necrosis factor (TNF) 
inhibitors are the most widely used because of their remarkable efficacy. They act by 
preventing TNF-α, a proinflammatory cytokine, from binding to its receptor.54 Of the 
five currently available TNF inhibitors, four (i.e., adalimumab, infliximab, 
certolizumab  and golimumab) are monoclonal antibodies (MAbs) that bind directly 
to TNF-α while one (etanercept) is a synthetic TNF-receptor immunoglobulin (IgG1) 
fusion protein that binds specifically to TNF-α and TNF-β (lymphotoxin).54 They have 
been shown through randomized controlled trials (RCTs) to be efficacious in the 
management of RA patients.5-10,106-116 These agents demonstrated better outcomes 
(clinical and radiographic benefit) when administered in combination with 
traditional or conventional DMARDs (e.g., methotrexate or leflunomide) compared to 
monotherapy. 3,6-11,112  While there is no direct head-to-head comparison among the 
available TNF inhibitors, results from the majority of indirect treatment comparison 
studies suggested that the agents have comparable efficacy and safety profiles.12-17,127  
Commonly reported adverse events with the use of TNF inhibitors include injection-
site or infusion reactions (e.g., stinging and burning) and infections (e.g., tuberculosis 
(TB)).71,74,127 Long-term safety concerns of TNF inhibitors include increased risks for 
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serious bacteria (e.g., abscesses, sepsis and cellulites), fungal (e.g., candidiasis) and 
viral (e.g., herpes zoster) infections.71,127  Other serious but rare events of concern 
that may occur include autoimmunity, demyelinating disease and hepatotoxicity.71,74 
Cancer/ increased risk for lymphoma have also been associated with TNF inhibitor 
use.71,74 However, evidence substantiating this relationship is weak as patients with 
severe RA are at high risk of developing lymphoma due to the RA inflammatory 
disease process.54,58,71,128  Due to the risk for TB and hepatitis (B and C) infections, 
regular and appropriate screening is required for patients on TNF inhibitors.71,74  
Patients should also be screened for latent TB and be given preventive TB therapy if 
found to be positive prior to initiating TNF inhibitor therapy.74 
The other biologic agents include anakinra, abatacept, rituximab and 
tocilizumab. Anakinra is a recombinant protein that binds to the interleukin (IL) -1 
type-1 receptors, thereby preventing IL-1-mediated signal transduction in target 
cells.54 Although it is efficacious in the treatment of RA,119,120 it is not frequently used 
due to the availability of better therapies.74 Compared to the TNF inhibitors, it has 
fewer clinical benefits and more frequent injection site reactions.74,129 Abatacept is a 
cyctotoxic T lymphocyte-associated antigen-4 immunoglobulin (CTLA-4Ig) G1 fusion 
protein that affects T-cell activation due to its blockage of the co-stimulatory signal 
required for the activation process.54 Rituximab is an anti-CD20 antibody that causes 
selective depletion of CD20+ B cells.54  Abatacept and rituximab, usually in 
combination with MTX, are mostly reserved for patients who fail to respond 
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adequately to TNF inhibitors.54,74 Efficacy of these agents has also been demonstrated 
through RCTs.117,118,121 Furthermore, combining abatacept (due to its unique 
mechanism of action) with TNF inhibitors is discouraged as such combinations have 
no significant incremental benefit over TNF monotherapy.130 The side effect profile 
of abatacept and rituximab is comparable with those of TNF inhibitors.54 However, 
patients on rituximab with concurrent or prior usage of other immunosuppressive 
therapies are at risk of developing John Cunningham (JC) virus infection which causes 
progressive multifocal leukoencephalopathy.54  
Tocilizumab is the newest biologic agenta approved by the FDA for 
management of RA.74 It is an anti IL-6 receptor monoclonal antibody with efficacy and 
safety/tolerability profiles comparable to other biologic agents.74 Biologic agents in 
development include: denosumab, which is an inhibitor of the receptor-activator of 
NF-KB ligand (RANKL); ocrelizumab and oftatumumab which are anti-CD20 B-cell 
blockers; and the kinase inhibitors (i.e., Janus Kinase inhibitors (JAK) and Spleen 
Tyrosine Kinase (SYK) inhibitors) which target specific inflammatory pathways. 
Others include agents targeting alternative inflammation/T-cells activation pathways 
and those blocking other B-cell targets (i.e., toll-like receptors, B lymphocyte 
stimulator and other surface receptors and markers).74 
 
                                                          
a Tofacitinib (Xeljanz® by Pfizer) recently approved (2013) for moderate to severe RA is not a 
biologic. It is an orally administered JAK inhibitor which works differently from the biologics.    
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Table 2.8 Overview of Biologic Agents Used in the Management of RA 
Drug Class Drug (Brand 
Name) & FDA 
Approval 
Date 
Structure Mode of 
Action 
Dose and 
Administration 
Route 
Half life 
(t1/2) 
TNF 
Inhibitors 
Etanercept  
(Enbrel®) 
(1998) 
Soluble fusion 
protein 
(dimer) of 2 
recombinant 
p75 TNF-α 
receptor 
proteins, with 
each molecule 
linked to the 
Fc portion of 
human IgG1 
Prevent 
binding of 
TNF-α to 
its 
receptor 
25mg SC twice 
weekly or 50mg 
once weekly 
(self-
administered 
4 days 
Infliximab 
(Remicade®) 
+ MTX (1999) 
Chimeric MAb 
with Fc region 
of human IgG1 
joined to 
variable 
region of 
mouse anti-
TNF-α 
antibody 
3mg/kg IV over 
2 hours at week 
0, 2, 6, then 
every 8 weeks, 
with dose 
adjustment up 
to 10mg/kg, if 
necessary 
8-10 
days 
Adalimumab 
(Humira®) 
(2003) 
Recombinant 
human IgG1 
MAb to TNF-α 
40mg SC every 2 
weeks (self-
administered) 
≈ 14 
days 
Certolizumab 
pegol 
(Cimza®) 
(2009) 
Pegylated 
humanized 
monoclonal 
anti-TNF Fab’ 
fragment 
400 mg SC 
(liquid or 
lyophilized) at 
week 0, 2 and 4, 
followed by 
200mg every 
other week (or 
400mg every 4 
weeks) 
14 days 
Golimumab  
(Simponi®)+ 
MTX (2009) 
Human anti-
TNF receptor 
MAb 
50mg SC once a 
month 
≈ 14 
days 
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Drug Class Drug 
(Brand 
Name) & 
FDA 
Approval 
Date 
Structure Mode of 
Action 
Dose and 
Administration 
Route 
Half 
life 
(t1/2) 
IL-1 
inhibitor 
Anakinra 
(Kineret®) 
(2001) 
Recombinant 
IL-1 inhibitor 
Prevents IL-
1 from 
binding to 
its receptor 
100mg SC daily ≈ 14 
days 
T-cell co-
stimulation 
blocker 
Abatacept  
(Orencia®) 
(2005) 
Recombinant 
fusion protein 
consisting of 
the 
extracellular 
domain of 
human CTLA-
4 and part of 
the Fc domain 
of human IgG1 
Prevents the 
co-
stimulatory 
signal 
required for 
T-cell 
activation 
500-1000mg IV 
over 300 minutes, 
depending on 
body weight at 
week 0, 2 and 4, 
then every 4 
weeks 
17 days 
B-cell 
targeted 
therapy 
Rituximab  
(Rituxan®) 
+ MTX 
(2006) 
Chimeric 
human/mouse 
anti-CD20 
MAb 
Binds to 
CD20, a cell 
marker 
expressed 
on mature-
and pre-B-
cells, but 
not on other 
cells, 
including 
plasma 
cells; leads 
to selective 
depletion of 
CD20+B 
cells via 
several 
mechanisms 
Two separate 
1000mg IV 
infusions, 2 weeks 
apart (IV 
methylpredisolone 
100mg or 
equivalent is 
recommended 30 
minutes before 
administering 
rituximab to 
prevent serious 
reaction) 
19 days 
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Drug Class Drug 
(Brand 
Name) & 
FDA 
Approval 
Date 
Structure Mode of 
Action 
Dose and 
Administration 
Route 
Half life 
(t1/2) 
Biologics newly approved in the US 
IL-6 
inhibitor 
Tocilizumab 
(Actemra®) 
(2010) 
Humanized 
anti-IL-6 
receptor 
MAb 
Prevents IL-
6 from 
binding to 
both 
membrane-
expressed 
and soluble 
IL-6 
receptors 
4mg/kg IV or 
8mg/kg IV 
every 4 weeks 
as monotherapy 
or in 
combination 
with DMARDs 
 
RANKL 
inhibitor 
Denosumab 
(phase II)† 
Human anti-
RANKL MAb 
Binds 
RANKL and 
inhibits 
RANKL 
action 
Twice yearly SC 
injections of 
denosumab plus 
MTX 
 
CTLA-4=cyctotoxic T lymphocyte-associated antigen-4; DMARDs= disease modifying antirheumatic drugs; 
FDA= US Food and Drug Administration. †Denosumab is approved in the United States for the treatment of 
postmenopausal osteoporosis (approved as Prolia®  June 2010) and for the prevention of skeletal-related events 
in patients with bone metastases from solid tumors (approved as Xgeva®  November 2010) but it is not 
currently indicated for the treatment of RA; IgG= immunoglobulin; IL= interleukin; IV= intravenous; MAb= 
monoclonal antibody; MTX= methotrexate; RA=rheumatoid arthritis; RANKL= receptor-activator of NF-KB 
ligand; SC= subcutaneous; TNF= tumor necrosis factor. 
Source: Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. 
Clin Ther. 2011; 33 (6):679-707. 
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2.1.9 Clinical Practice Guidelines for the Management of RA 
A number of clinical practice guidelines have been developed over the years 
to help in the effective management of RA. Among those commonly used are 
recommendations by the British Society for Rheumatology (BSR), British Health 
Professionals in Rheumatology (BHPR), the American College of Rheumatology 
(ACR), the European League Against Rheumatism (EULAR), and the UK’s National 
Institute for Health and Clinical Excellence (NICE). While there are variations in the 
recommendations, all organizations supported the following key messages: 1) early 
referral of patients to specialists; 2) rapid control of inflammatory symptoms using 
the lowest effective dose of NSAIDs or short-term low dose glucocorticoids; 3) early 
initiation of traditional DMARD therapy for active disease; and 4) use of biologic 
agents in situations of suboptimal response to traditional DMARD therapy.74 Further 
discussions in this section will be limited to the recommendations by ACR and EULAR 
because they have been the most commonly used clinical practice guidelines.  
ACR Recommendations 
The recommendations provided by ACR to guide therapeutic decisions were 
based on three important clinical features: (1) disease activity which is categorized 
as low, moderate or high; (2) presence of predetermined relevant prognostic factors 
(e.g., functional limitation, presence of RF or anti-CCP antibodies, extra-articular 
disease and bony erosions on radiography); and (3) the duration of the disease [(i.e., 
short (< 6 months), intermediate (6-24 months), or long (> 24 months) for non-
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biologic DMARD therapies and < 6 months or ≥ 6 months for biologic DMARD 
therapies)].104  Table 2.9 presents a summary of ACR recommendations for the use of 
traditional DMARDs in RA. Recommendations regarding the use of biologic DMARD 
therapies restrict TNF inhibitor use to the following situations: (a) early RA, in 
combination with MTX in patients who present with high disease activity for 3-6 
months and have not received any prior DMARD therapy; (b) early RA, in combination 
with MTX in patients who present with high disease activity for less than 3 months 
and poor prognosis. In addition, such patients should have no cost or insurance 
coverage limitations; (c) intermediate and longer duration RA, in patients with either 
a moderate disease activity and poor prognosis or high disease activity, who 
responded poorly to MTX monotherapy; and (d) intermediate and longer duration 
RA, in patients with moderate or high disease activity, who had prior treatment 
failure with MTX combination therapy or sequential administration of other non-
biologic DMARD. 104 Abatacept and rituximab are recommended for patients with 
moderate or high disease activity, poor prognosis and suboptimal response to 
combinations of MTX with other DMARDs or sequential administration of other non-
biologic DMARDs.104 Combinations among biologic DMARDs are not recommended 
due to risk of increased adverse events and lack of evidence regarding incremental 
benefits.   
The 2012 update of the 2008 ACR recommendation included newer TNF-
inhibitors (e.g., golimumab, certolizumab pegol and tocilizumab) to its list of 
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recommended biologics and provided more details as regard switching between 
therapies in management of established RA.131  Figures 2.4 and 2.5 provides a 
summary of the 2012 update of the 2008 ACR recommdendations in management of 
early and established RA. 
Table 2.9 2008 ACR Recommendations for the Use of DMARDs 
Disease Duration <  6 Months 
Disease Activity Poor Prognostic Features 
 Present Absent 
Low LEF or MTX  MTX, LEF, SSZ, HCQ or MIN 
Moderate or High LEF, MTX or combinations 
of DMARDs† including MTX 
MTX, LEF, SSZ, or 
combinations of DMARDs 
including MTX 
Disease Duration   6-24 Months 
Disease Activity Poor Prognostic Features 
 Present Absent 
Low LEF, MTX  or combinations 
of DMARDs including MTX 
MTX, LEF, SSZ or HCQ  
Moderate or High LEF, MTX or combinations 
of DMARDs‡ including MTX 
MTX, LEF, SSZ, or               
combinations of DMARDs‡#§ 
   
Disease Duration   > 24 Months 
Disease Activity Poor Prognostic Features 
 Present Absent 
Low or Moderate LEF, MTX or combinations 
of DMARDs including MTX 
MTX, LEF, SSZ, or 
combinations of  DMARDs 
including MTX 
High LEF, MTX or combinations 
of DMARDs including MTX 
MTX, LEF, SSZ, or 
combinations of DMARDs 
including MTX 
DMARDs= disease modifying antirheumatic drugs; HCQ=hydroxychloroquine LEF= leflunomide; MIN= 
minocycline; MTX= methotrexate; SSZ= sulfasalazine. 
Combinations of DMARDs including SSZ are also recommended for the following: (1) †patients with high disease 
activity with features of poor prognosis; (2) ‡patients with moderate disease activity regardless of prognostic 
features; and (3) #patients with high disease activity without features of poor prognosis. 
§Combinations of DMARDs including HCQ are recommended for patients with high disease activity without 
features of poor prognosis 
Source:  Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the 
use of non-biologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 
2008; 59(6):762-784. 
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Figure 2.4 2012 Update of the 2008 ACR Recommendations for the 
Management of Early RA (Disease Duration < 6 Months) 
 
 
 
DMARDs= disease modifying antirheumatic drugs; HCQ=hydroxychloroquine; MTX= methotrexate 
†Patients were catergorized based on the presence or absence of ≥ 1 of the following poor prognostic features: 
functional limitation (e.g., Health Assessment Questionnaire score or similar valid tools), extraarticular disease 
(e.g. Felty’s syndrome, presence of rheumatoid nodules, RA vasculitis), bony erosions by radiography and positive 
rheumatoid factor or anti-cyclic citrullinated peptide antibodies. 
‡Combination DMARD therapy with 2 DMARDs, which is most commonly MTX based, with some exceptions (e.g., 
MTX + HCQ, MTX+ Leflunomide, MTX + Sulfasalazine (SSZ) and SSZ + HCQ), and triple therapy (MTX + HCQ + SSZ). 
Source: Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology 
recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of 
rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012; 64(5):625-639.  
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Figure 2.5 2012 Update of the 2008 ACR Recommendations for the 
Management of Established RA (Disease Duration ≥ 6 Months) 
 
 
 
DMARDs=Disease modifying antirheumatic drugs; HCQ=Hydroxychloroquine; LEF=Leflunomide; 
MTX =Methotrexate 
Depending on a patient’s current medication regimen, the management algorithm may begin at an appropriate 
rectangle in the figure, rather than only at the top of the figure. DMARDs include HCQ, LEF, minocycline (MIN), 
MTX and sulfasalazine (SSZ). Azathioprine and cyclosporine were considered but not included. DMARD 
monotherapy refers to treatment in most instances with HCQ, LEF, MTX or SSZ. In few instances, where 
appropriate, MIN may also be used as DMARD monotherapy. Anti-tumor necrosis factor (anti-TNF) biologics 
include adalimumab, certrolizumab pegol, etanercept, infliximab and golimumab. Non-TNF biologics include 
abatacept, rituximab and tocilizumab.  
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†Patients were catergorized based on the presence or absence of ≥ 1 of the following poor prognostic features: 
functional limitation (e.g., Health Assessment Questionnaire score or similar valid tools), extraarticular disease 
(e.g., Felty’s syndrome, presence of rheumatoid nodules, RA vasculitis), bony erosions by radiography and positive 
rheumatoid factor or anti-cyclic citrullinated peptide antibodies. 
‡Combination DMARD therapy with 2 DMARDs, which is most commonly MTX based, with some exceptions (e.g., 
MTX + HCQ, MTX+ LEF, MTX + SSZ and SSZ + HCQ), and triple therapy (MTX + HCQ + SSZ). 
§ Reassess after 3 months and proceed with escalating therapy if moderate or high disease activity in all instances 
except after treatment with a non-TNF biologic (rectangle D), where reassessment is recommended at 6 months 
due to a longer abticipated time to peak effect. 
¶ Lef can be added in patients with low disease activity after 3-6 months of MIN, HCQ, MTX or SSZ. 
# If after 3 months of intensified DMARD combination therapy or after a second DMARD has failed, the option is 
to ass or switch to an anti-TNF biologic. 
** Serious adverse events were defined per the US Food and Drug Administration (FDA; see below); all other 
adverse events were considered nonserious adverse events. 
†† Reassessment after treatment with a non-TNF biologic is recommended at 6 months due to anticipation that a 
longer time to peak effect is needed for non-TNF compared to anti-TNF biologics. 
‡‡ Any adverse event was defined as per the US FDA as any undesirable experiences associated with the use of a 
medical product in a patient. The FDA definition of serious adverse event includes death, life-threatening event, 
imitial or prolonged hospitalization, disability, congenital anomaly, or an adverse event requiring intervention to 
prevent impairment or damage. 
Source: Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology 
recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of 
rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012; 64(5):625-639. 
 
 
EULAR Recommendations 
The latest recommendations by EULAR were based on 3 overarching 
principles. These principles identified: (1) the need for rheumatologists to be the 
primary care provider for RA patients; (2) the importance of having a treatment 
approach that is aimed at providing the best care and based on a shared decision 
between the patient and the rheumatologist; and (3) the need for the rheumatologist 
to consider both the medical costs and productivity costs associated with the 
management of RA.132 While the previously published EULAR recommendations 
focused on management of patients with early RA or undifferentiated arthritis, the 
latest EULAR recommendations apply to all patients with RA and also provided 
detailed guidance on the use of pharmacological compounds.132,133 However, both 
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sets of recommendations recognize the importance of initiating DMARD therapy as 
soon as RA is diagnosed.132,133 Figure 2.6 presents the current EULAR 
recommendations for the management of RA.    
Figure 2.6 EULAR Recommendations for the Management of RA 
 Treatment with synthetic DMARDs should be started as soon as the diagnosis of RA is made 
 Treatment should be aimed at reaching a target of remission or low disease activity as soon as 
possible in every patient; as long as the target has not been reached, treatment should be adjusted 
by frequent (every 1 to 3 months) and strict monitoring 
 MTX should be part of the first treatment strategy in patients with active RA 
 When MTX contraindications (or intolerance) are present, the following DMARDs should be 
considered as part of the (first) treatment strategy: LEF, SSZ or  injectable gold 
 In DMARD naïve patients, irrespective of the addition of GCs, synthetic DMARD monotherapy 
rather than combination therapy of synthetic DMARDs may be applied 
 GCs added at low to moderately high doses to synthetic DMARD monotherapy (or combinations 
of synthetic DMARDs) provide benefit as initial short-term treatment but should be tapered as 
rapidly as clinically feasible 
 If the treatment target is not achieved with the first DMARD strategy, addition of a biological 
DMARD should be considered when poor prognostic factors are present; in the absence of poor 
prognostic factors, switching to another synthetic DMARD strategy should be considered 
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 Figure 2.6 EULAR Recommendations for the Management of RA (Contd) 
 In patients responding insufficiently to MTX and/or other synthetic DMARDs with or without 
GCs, biological DMARDs should be started; current practice would be to start a TNF inhibitor 
(adalimumab, certolizumab, etanercept, golimumab, infliximab) which should be combined 
with MTX 
 Patients with RA for whom a first TNF inhibitor has failed, should receive another TNF 
inhibitor, abatacept, rituximab or tocilizumab 
 In cases of refractory severe RA or contraindications to biological agents or the previously 
mentioned synthetic DMARDs, the following synthetic DMARDs might be also considered, 
as monotherapy or in combination with some of the above: azathioprine, cyclosporin A (or 
exceptionally cyclosphosphamide) 
 Intensive medication strategies should be considered in every patient, although patients with 
poor prognostic factors have more to gain 
 If a patient is in persistent remission, after having tapered GCs, one can consider tapering 
DMARDs, especially if this treatment is combined with a synthetic DMARD 
 In cases of sustained long-term remission, cautious titration of synthetic DMARD dose could 
be considered, as a shared decision between patient and doctor 
 DMARD naïve patients with poor prognostic markers might be considered for combination 
therapy of MTX plus a biological agent 
 When adjusting treatment, factors apart from disease activity, such as progression of structural 
damage, comorbidities and safety concerns should be taken into account 
DMARD= disease modifying antirheumatic drug; EULAR= European League Against Rheumatism; GCs= 
glucocorticoids; LEF= leflunomide; MTX= methotrexate; RA= rheumatoid arthritis;   SSZ= sulfasalazine; 
TNF= tumor necrosis factor 
Source: Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of 
rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 
2010;69(6):964-975. 
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2.1.10  Medication Use Patterns in the Management of RA 
2.1.10.1 Medication Adherence: Brief Overview 
The World Health Organization (WHO) defined adherence as “the extent to 
which a person’s behavior (i.e., taking medication, following a diet and/or executing 
lifestyle changes) corresponds with agreed recommendations from a health care 
provider.”134 A patient’s adherence (or compliance) to medication can be defined as 
the extent to which the patient takes his/her medications as prescribed (with respect 
to the interval, dose and dosing regimen) by his/her health care provider.135,136   
Medication persistence on the other hand is defined as the duration or length of time 
a patient consistently takes a prescribed medication from initiation to 
discontinuation of therapy.136,137 Medication adherence and persistence captures two 
important aspects of a patient medication taking behavior, namely regularity and 
continuity.138  
Poor medication adherence has been reported as a factor responsible for 
therapeutic failures or poor health outcomes in patients, especially among those with 
chronic medical conditions (e.g., RA) who require a lifetime use of medications.138 
Generally, patients with chronic conditions (especially after the first six months of 
therapy) tend to present with lower adherence rates when compared to those with 
acute disease conditions.135,137 Poor or suboptimal adherence to prescribed 
medications has also been associated with increases in healthcare utilization and 
healthcare costs. 135 It is responsible for approximately 33 to 69 percent of 
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medication-related hospital admissions at an estimated at $100 billion per year in 
avoidable/preventable healthcare costs.135 This is because non-adherence increases 
the risk for rapid disease progression, development of complications, occurrence of 
preventable hospitalizations and emergency department visits, ambulatory care 
visits, increased visits to physicians and other healthcare providers, unnecessary 
change in treatment regimens, further diagnostic processes, premature disability and 
ultimately death.135,138,139 Factors associated with poor or suboptimal medication 
adherence include the patient’s lack of adequate understanding of the disease and its 
complications, the asymptomatic nature of some diseases, unpleasant side effects of 
medications, complexity of treatment, high medication cost, missed appointments, 
the patient’s lack of confidence in immediate or future benefits of treatment, cognitive 
impairment, inadequate follow-up or discharge planning, psychological problems 
(especially depression), barriers to care or medication and poor relationship with 
health care provider. Other factors include poor socioeconomic status, gender and 
race.135 Commonly used methods for measuring patients’ adherence to prescribed 
medications are presented in Table 2.10.  
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Table 2.10 Methods for Measuring Medication Adherence 
Methods Examples 
 
Direct measurement methods 
 Directly observed therapy (DOT) 
 Drug levels or metabolites in blood 
 Blood biomarkers  
 
 
Indirect measurement methods 
 Patient self-reports 
 Pill counts 
 Prescription refill rates 
 Patient clinical response 
 Electronic medication monitors 
 Patient diaries 
 Physiologic markers 
Source: Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497. 
2.1.10.2 Medication Adherence and Persistence in the Management of RA 
As in all disease conditions (most especially chronic diseases), the importance 
of adherence and persistence to prescribed therapies in the management of RA 
cannot be overemphasized. Despite the risk for increased joint pain and functional 
impairment, RA patients have been generally reported to have problems adhering to 
their prescribed RA therapies (i.e., pharmacological regimens). Reported adherence 
and persistence rates to prescribed RA therapies ranged between 20 and 80 
percent.137,138 Factors identified to be associated with poor medication taking 
behavior among RA patients include low socioeconomic status (i.e., education and 
income level), younger age, lack of social support, medication side-effects, presence 
of comorbidities, increased disability, inadequate knowledge/understanding of the 
disease and its treatment, poor quality of contact with healthcare provider, being of 
ethnic minority descent, as well as poor prior medication-taking behaviors and 
beliefs.137  
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Among the RA therapies discussed earlier, more attention has increasingly 
been focused on use of biologic agents (especially TNF inhibitors) in clinical settings, 
as poor medication use behaviors among patients can significantly undermine the 
potential benefits of these RA treatments. Among the available TNF inhibitors, three 
agents (Enbrel® (etanercept); Remicade® (infliximab); and Humira® 
(adalimumab)) have been extensively studied and due to their importance in RA 
management, further discussions in this section will be limited to these three biologic 
agents.  
All available studies in the literature which used administrative claims data to 
evaluate RA patients’ adherence to etanercept, infliximab and adalimumab were 
conducted in the US, with adherence measured using varying definitions of 
medication possession ratio (MPR) or proportion of days covered (PDC).2,21-23,25  MPR 
is defined as the sum of total days’ supply for all fills divided by the number of days 
in the study period. PDC is defined as the proportion of days a patient has a drug 
available in the specified interval or study period. Three of the available studies 
utilized Medicaid data,23-25 while the other 3 studies were conducted using data from 
patients enrolled in private health plans or managed care organizations.2,21,22   
For studies conducted with Medicaid data, Li et al. reported significantly (p < 
0.05) higher mean adherence among infliximab users compared to etanercept users, 
with mean PDC (SD not provided) values of 0.64 and 0.57 reported for infliximab and 
etanercept users, respectively.25 The other two Medicaid studies used methotrexate 
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(MTX) as the reference agent with no comparison made among the 3 TNF 
inhibitors.23,24 Grijalva et al. reported mean MPR (SD not provided) values of 0.83, 
0.85 and 0.90 for etanercept, adalimumab and infliximab users, respectively.23 Lower 
mean MPR values were observed when etanercept, adalimumab and infliximab were 
individually administered in combination with MTX (mean MPR (SD not provided) 
values were 0.64, 0.66 and 0.72, respectively).24 The second study by Grijalva et al., 
reported median MPR values of 0.73, 0.72 and 0.68 for etanercept, adalimumab and 
infliximab use, respectively.24  
For studies that utilized commercial databases, Curkendall et al. reported an 
overall mean MPR of 0.52 (±0.31) for etanercept and adalimumab users.22 Borah et 
al. reported mean MPR values ranging from 0.65 (±0.31) to 0.73 (±0.26) for patients 
on etanercept and mean MPR values ranging from 0.63 (±0.32) to 0.70 (±0.28) for 
patients on adalimumab.2 In addition, the proportion of adherent patients 
(MPR>0.80) ranged from 42.0 to 51.3 percent among etanercept users and 41.0 to 
47.1 percent among adalimumab users.2 Harley et al. reported 68.4 and 80.9 percent 
of patients on etanercept and infliximab, respectively, as being adherent 
(MPR>0.80).21  Furthermore, among new users, the likelihood of being adherent 
(MPR≥0.8) to etanercept was reportedly lower (OR=0.462, 95% CI=0.290-0.736, p < 
0.05) compared to infliximab, while among existing users, patients were more likely 
to be non-adherent to adalimumab compared to etanercept (OR=1.25, 95% CI=1.05-
1.49, p=0.01).2,21 
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Commonly used terms for describing medication persistence across studies 
include persistence, treatment retention, treatment continuation, drug survival and 
time to drug discontinuation.138 The literature on medication persistence to 
etanercept, infliximab and adalimumab presents conflicting results and only a few 
studies2,22,23,25-27 specified the gap period(s) used in the analyses. A brief overview of 
the results of the persistence studies conducted in the US is presented in the 
subsequent paragraphs. 
For studies conducted with Medicaid data, Li et al. found comparable (p>0.05) 
12-month discontinuation rates between infliximab (48.3%) and etanercept (50.0%) 
users using a 60-day gap.25  Sensitivity analyses using 30-, 90- and 120-day gaps also 
yielded comparable discontinuation rates between infliximab (65.3%, 40.9% and 
33.6%, respectively) and etanercept users (67.9%, 40.7%, and 34.5%, respectively). 
25 Grijalva et al. reported median persistence of 175 days, 134 days and 85 days for 
etanercept, adalimumab and infliximab users, respectively, based on a 12-month 
follow-up period, using a 90-day gap period. MTX was the reference agent and no 
comparison was made among the 3 TNF inhibitors.   
Regarding commercial data studies, Tang et al. reported significantly 
(p=0.005) higher mean persistence rates among infliximab patients (78.0%) 
compared to patients on etanercept (72.8%) and adalimumab (70.8%) based on a 1-
year follow-up period.4 Harrison et al. found a significantly (p < 0.05) higher mean 
duration of therapy (in days) and persistence rate among naïve users of etanercept 
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(301 days ± 91; 82.5%) compared to naïve users of infliximab (281 days ± 106; 
77.0%) and adalimumab (280 days ± 102; 76.7%), but comparable mean durations 
of therapy (in days) and persistence rates among continuing users on the 3 drugs 
based on a 1-year follow-up period.28 Wu et al. reported comparable (p>0.05) 12-
month discontinuation rates among users of infliximab (37.8%), etanercept (44.6%) 
and adalimumab (44.4%) using a 60-day gap.26  Borah et al. reported comparable 
mean time (SD not provided) to discontinuation of therapy between drug-naïve 
patients on either etanercept (211 days) or adalimumab (211 days), as well as 
between existing patients on either etanercept (237 days) or adalimumab (232 days) 
based on a one-year follow-up period using a 30-day gap.2 In addition, the likelihood 
of discontinuing medication use was not significantly different (HR=1.11 p=0.06 95% 
CI=1.00-1.23) between existing adalimumab users compared to etanercept users.2 
Yazici et al., in a subanalysis, reported a significantly (p < 0.0001) higher median 
persistence in days among infliximab users (464 days) compared to etanercept 
(347.5 days) and adalimumab (365 days) users based on an 18-month follow-up 
period using a 30-day gap.27  
For studies conducted in Europe, continuation rates for infliximab 
(administered with or without traditional DMARDs) ranged from 48.0 to 90.9 percent 
based on a 12-month follow-up period 41,140-151 and from 47.5 to 80.7 percent based 
on a 24-month follow-up period.142,145-147,151 Similarly, continuation rates for 
etanercept (administered with or without traditional DMARDs) ranged from 42.0 to 
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89.0 percent based on a 12-month follow-up period 34,41,141,142,144,148,149,152 and from 
50.8 to 79.0 percent based on a 24-month follow-up period.142,153 Studies on 
adalimumab (administered with or without traditional DMARDs) reported 
continuation rates ranging from 60.0 to 87.4 percent based on a 12-month follow-up 
period41,142,144,152 and 60.2 percent based on a 24-month follow-up period.142  
Furthermore, a study by Punzi et al. which used a 36-month follow-up period 
reported significantly (p < 0.001) lower continuation rates among infliximab patients 
(57.5%) compared to patients on etanercept (74.7%) and adalimumab (72.0%).1  
A summary of studies conducted in the US and Europe on medication 
adherence and persistence to etanercept, adalimumab and infliximab is presented in 
Table 2.11.  Overall, the results from the adherence and persistence studies suggest 
the following: (1) mean adherence values vary widely acrossed studies depending on 
how adherence was measured; (2) adherence to etanercept and adalimumab is 
comparable among biologic-naïve or new patients; (2) biologic-naïve patients tend to 
adhere better to infliximab compared to etanercept; (3) existing or continuing 
patients on biologics tend to adhere better to etanercept compared to adalimumab; 
(4) persistence/discontinuation rates vary widely depending on the follow-up 
periods and the allowable gap periods used in the study; (5) results on 
persistence/discontinuation remain largely inconsistent with some of the studies 
indicating comparable persistence/discontinuation rates among users of the 3 TNF 
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inhibitors, while others showed either infliximab or etanercept having a better 
outcome.   
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Table 2.11   Summary of Studiesa on Adherence and Persistence to Etanercept, Adalimumab and Infliximab 
Study Study 
Agents 
Datasource/ 
Analysis/ 
Country 
Sample size/ 
Brief description 
of sample 
Adherence/ 
Compliance 
Measurement 
Adherence/ 
Compliance 
Results 
Persistence 
Measurement 
Persistence 
Results 
Claims Data 
Borah et al.2 ADA and ETN Claims data 
(private 
commercial) 
 
Retrospective  
 
US  
3,829/ mean age 
(±SD) was 49.9 years 
(SD not provided) 
and females (77.1%) 
made up the majority 
of the sample.  
MPR was defined 
as total day’s 
supply divided by 
365.  Adherence 
was defined as 
MPR ≥80%. 
For naïve users: 
Mean MPR was 
63.0% (±0.32) for 
ADA and 65% 
(±0.31) for ETN 
(p=0.3855). The 
proportion of 
adherent patients 
was 41.0% for ADA 
and 42.0% for ETN 
(p=0.7312). 
For existing users: 
Mean MPR was 
70.0% (±0.28) for 
ADA and 73.0% 
(±0.26) for ETN 
(p=0.0066). The 
proportion of 
adherent patients 
was 47.0% and 
51.3% for ADA and 
ETN users, 
respectively 
(p=0.0514). ADA 
users were more 
likely to be non-
adherent compared 
to ETN users 
(OR=1.25, 95% 
CI=1.05-1.49, 
p=0.01). 
Time to 
treatment 
discontinuationb 
from index 
based on a 12-
month follow-up 
period. A 60-day 
gap period was 
used. 
Mean time (SD not 
provided) to 
discontinuation of 
therapy was 
comparable between 
naïve users on either 
ETN (211 days) or 
ADA (211 days) as 
well as between 
existing users on 
either ETN (237 
days) or ADA (232 
days).The likelihood 
to discontinue 
medication use was 
not significantly 
different (HR=1.11 
p=0.06 95% CI=1.00-
1.23) between 
existing ADA and 
ETN users. 
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Study 
Study 
Agents 
Datasource/ 
Analysis/ 
Country 
Sample size/ 
Brief description 
of sample 
Adherence/ 
Compliance 
Measurement 
Adherence/ 
Compliance 
Results 
Persistence 
Measurement 
Persistence Results 
Tang et al.4 ADA+MTX, 
ETN+MTX  
and 
IFX+MTX 
Claims data 
(majority (90.3%)  
private 
commercial and 
Medicare) 
 
Retrospective 
 
US 
1,242/ mean age was 
50.0 years (SD not 
provided) and 
females (77.7%) 
comprised the 
majority of the 
sample.  
N/A N/A Treatment 
persistenceb was 
defined as the 
number of days 
between the first 
and last filled 
prescriptions or 
administered 
drugs and 
reported as a 
percentage of 
the 1-year 
period after 
treatment 
inititiation.  No 
gap period was 
specified. 
The IFX group had 
significantly (p=0.005) 
higher mean persistence 
days and rates (284.8 days 
(95% CI=276.2-293.4); 
78.0%) compared to 
patients on ETN (265.6 
days (95% CI=256.1-
275.1); 72.8%) and ADA 
(258.5 days (95% 
CI=238.0-279.0); 70.8%). 
Wu et al.26 ADA, ETN 
and IFX 
Claims data 
(private 
commercial) 
 
Retrospective 
 
US 
808/ mean age (±SD) 
was 50.1 years (SD 
not provided) and 
females (75.4%) 
comprised the 
majority of the 
sample.  
N/A N/A Treatment 
discontinuation 
was defined as 
the first 
occurrence of a 
gap in the index 
medication 
administration 
of more than 60 
days during the 
12-month study 
period. 
ADA (44.4%), ETN 
(44.6%) and IFX (37.8%) 
had comparable (p>0.05) 
discontinuation rates.   
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Study 
Study 
Agents 
Datasource/ 
Analysis/ 
Country 
Sample size/ 
Brief description 
of sample 
Adherence/ 
Compliance 
Measurement 
Adherence/ 
Compliance 
Results 
Persistence 
Measurement 
Persistence Results 
Grijalva et al.23 12 regimens 
including 
biologic (e.g., 
ADA, ETN 
and IFX) and 
traditional 
DMARDs in 
mono- and 
combination 
therapy 
Claims data 
(Medicaid) 
 
Retrospective 
 
US   
14,932/ median age 
(range) was 54 years 
(41-66) and females 
(79.4%) comprised 
the majority of the 
sample.   
MPR was defined 
as aggregated 
number of days 
supply obtained 
during an episode 
divided by the 
length of the 
episode, 
excluding the last 
prescription fill. 
Monotherapy: 
Mean MPR was 
83.0% for ETN, 
85.0% for ADA and 
90.0% for IFX.  
Compared to MTX 
(mean MPR=0.80), 
each agent showed 
significantly higher 
mean MPR (p < 
0.01). 
Combination 
therapy with MTX: 
Mean MPR was 
64.0% for ETN, 
72.0% for ADA and 
66.0% for IFX. 
Compared with MTX 
(monotherapy), 
individual 
combinations with 
MTX showed 
significantly lower 
mean MPR (p < 
0.01). 
Time to 
treatment 
discontinuationb 
from index 
based on a 12-
month follow-up 
period. A 90-day 
gap period was 
used. 
Monotherapy: Median 
persistence was 175 days 
for ETN, 134 days for ADA 
and 85 days for IFX. 
Compared to MTX (median 
persistence=150 days), 
only IFX use was 
associated with a higher 
likelihood of 
discontinuation (adjusted 
HR=1.37; 95% CI=1.09-
1.73; p=0.007). 
Combination with MTX: 
Median persistence was 
147 days with ETN, 219 
days with ADA and 155 
days with IFX. Compared 
with MTX (monotherapy), 
only the combination of 
ADA with MTX showed 
lower likelihood of 
discontinuation (adjusted 
HR=0.63; 95% CI=0.48-
0.84; p=0.002). 
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Study 
Study 
Agents 
Datasource/ 
Analysis/ 
Country 
Sample size/ 
Brief description 
of sample 
Adherence/ 
Compliance 
Measurement 
Adherence/ 
Compliance 
Results 
Persistence 
Measurement 
Persistence Results 
Li et al.25 IFX,  ETN and 
ANA 
Claims data 
(Medicaid)  
 
Retrospective 
 
US   
2,638/ mean age 
(±SD) was 58.0 years 
(SD not provided) 
and females (88.4%) 
comprised the 
majority of the 
sample.  
PDC was defined 
as the number of 
days covered with 
biologic divided 
by the fixed time 
interval of 365 
days from date of 
index biologic 
therapy initiation 
(i.e., 12-month 
post-index). 
Adherence was 
defined as PDC≥ 
0.8. 
Mean PDC (SD not 
provided) values 
were 0.57 for ETN 
users and 0.64 for 
IFX users (p < 0.05);  
32.0% of ETN users 
and 43.0% of IFX 
users were 
adherent (p < 0.05). 
Treatment 
discontinuation 
rates at 12 
months using a 
90-day gap 
period. 
Sensitivity 
analyses were 
conducted for 
30, 60 and 120-
day gap periods. 
Discontinuation rates 
were comparable (p>0.05) 
for ETN (40.7%) and IFX 
(40.9%) users using a 90-
day gap period. Sensitivity 
analyses using 30, 60 and 
120-day gaps were robust. 
Yazici et al.27 ETN, IFX and 
ADA 
Claims data 
(private 
commercial) 
 
Retrospective 
 
US   
9,074/ mean age 
(±SD) was 49.0 years 
(±11.97) and females 
(74.1%) comprised 
the majority of the 
sample. 
N/A N/A Treatment 
persistence was 
defined as days 
of continous 
therapy from the 
date of first TNF 
claim. A 30-day 
gap period was 
used.  
Persistence with IFX was 
significantly greater than 
that of ETN or ADA. In a 
subanalysis of 4,260 
patients, median 
persistence was 
significantly higher (p < 
0.0001) for IFX users 
(464.0 days) compared to 
ETN (347.5 days) and ADA 
(365.0 days) users  
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Study 
Study 
Agents 
Datasource/ 
Analysis/ 
Country 
Sample size/ 
Brief description 
of sample 
Adherence/ 
Compliance 
Measurement 
Adherence/ 
Compliance 
Results 
Persistence 
Measurement 
Persistence Results 
Harrison et al.28 ETN, IFX and 
ADA 
Claims data 
(private 
commercial) 
 
Retrospective 
 
US   
4,628/ mean age 
(±SD) was 55.2 years 
(±5.0) for naïve 
patients and 56.6 
years (±4.4) for 
continuing patients 
and females (76.6%) 
comprised the 
majority of the 
sample. 
N/A N/A Duration of 
therapy in days 
from index 
based on 12-
months follow-
up period. No 
gap period was 
specified. 
For naïve users: The 
mean duration of therapy 
was significantly higher (p 
< 0.05) for ETN users (301 
days ±91) compared to 
IFX (281 days ±106) and 
ADA (280 days ±102) 
users. 
For continuing users: 
Mean duration of therapy 
was comparable (p>0.05) 
among ETN (333 days 
±39), IFX (332 days ±42) 
and ADA (335 days ±41) 
users. 
Grijalva et al.24 ETN, IFX, 
ADA, MTX, 
LEF, SSZ, 
HCQ and GC 
Claims data 
(Medicaid) 
 
Retrospective 
 
US   
14,586 (28,906 new 
episodes of 
medication use)/ 
median age was 55.0 
years and females 
(76%)  comprised 
the majority of the 
sample 
MPR was defined 
as percentage of 
person-time 
exposed to the 
initial regimen 
during episodes. 
MPR was 
calculated for 
episodes with 
180 person-days 
of available 
follow-up. 
Median MPR values 
of 0.73, 0.72 and 
0.68 were reported 
for ETN, ADA and 
IFX initiation, 
respectively. 
Compared to MTX 
(0.59), none of the 
TNF inhibitors 
increased 
hospitalization risk 
for the PER 
analyses. However, 
IFX increased 
hospitalization risk 
in the PEI analyses 
(HR 1.46; 95% CI 
1.19-1.80).  
N/A N/A 
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Study 
Study 
Agents 
Datasource/ 
Analysis/ 
Country 
Sample size/ 
Brief description 
of sample 
Adherence/ 
Compliance 
Measurement 
Adherence/ 
Compliance 
Results 
Persistence 
Measurement 
Persistence Results 
Curkendall et 
al.22 
ETN and 
ADA 
Claims data 
(private 
commercial) 
 
Retrospective 
 
US   
2,285/ mean age 
(±SD) was 54.0 years 
(±12.00) and females 
(75.0%) comprised 
the majority of the 
sample. 
MPR was defined 
as total days 
supply of the 
medication 
divided by total 
days of follow-up. 
Individual mean 
drug MPR was not 
reported. However, 
an overall mean 
MPR of 0.52 (±0.31) 
was reported.  
Time to 
treatment 
discontinuation 
from index 
based on a 12-
month follow-up 
period. A 30-day 
gap period was 
used.  
No individual drug or 
overall persistent rate was 
reported. Persistence was 
used as a factor in the 
regression analysis. 
Harley et al.21 ETN, IFX and 
MTX 
Claims data 
(Medicare and 
private 
commercial) 
 
Retrospective 
 
US   
2,662 (62.7% of 
sample were MTX 
users)/ mean age 
(±SD) was 52.3 years 
(SD not provided) 
and females (73.3%) 
comprised the 
majority of the 
sample. 
Actual number of 
therapy 
administrations 
or filled 
prescriptions 
divided by the 
expected number. 
 
 
 
 
 
 
Adherence (≥80%) 
of the expected 
dosages was 
significantly lower 
for ETN (OR=0.462; 
95% CI=0.290-
0.736) compared to 
IFX.  
N/A N/A 
Chart review 
Punzi et al.1 ADA, ETN 
and IFX 
Chart review 
(Rheumatology 
center)  
 
Retrospective 
 
Italy 
703/ mean age (±SD) 
was 53.4 years 
(±13.09) and females 
(80.8%) comprised 
the majority of the 
sample. 
N/A N/A Treatment 
discontinuation 
ratesb at 36 
months   
At 36 months, 74.7%, 
72.0% and 57.7% of ETN, 
ADA and IFX users, 
respectively, were still on 
therapy. The 
discontinuation rate of IFX 
(42.5%) was significantly 
higher (p < 0.001) 
compared with either ETN 
(25.3%) or ADA (28.0%).  
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Study 
Study 
Agents 
Datasource/ 
Analysis/ 
Country 
Sample size/ 
Brief description 
of sample 
Adherence/ 
Compliance 
Measurement 
Adherence/ 
Compliance 
Results 
Persistence 
Measurement 
Persistence Results 
Duclos et al.142 IFX, ETN and 
ADA 
Chart review 
(Rheumatology 
unit)  
 
Retrospective 
 
France 
770c / mean age 
(±SD) for the entire 
sample was 49.3 
years (±15.00) and 
females (60.4%) 
were the majority. 
For the RA 
population (n=440), 
mean age (±SD) was 
55.1 years (±13.90) 
and the proportion of 
females was 80.5%.  
N/A N/A Treatment 
continuation 
rates at 12, 24 
and 36 months 
Overall, the percentage of 
patients receiving the 
same treatment at month 
12, 24 and 36 was 64.0%, 
50.3% and 39.4%, 
respectively. 
Retention rates were 
comparable (p=0.48) 
among the 3 TNF 
inhibitors. Retention rates 
were 63.2%, 63.9% and 
68.2% at 12 months and 
47.5%, 50.8% and 60.2% 
at 24 months for IFX, ETN 
and ADA, respectively.  
Wendling et 
al.146 
IFX Chart review 
(Rheumatology 
unit) 
 
Retrospective 
 
France 
41/ mean age (±SD) 
was 54.0 years (SD 
not provided) and 
females (73.2%) 
comprised the 
majority of the 
sample. 
N/A  N/A Treatment 
continuation 
ratesb at 6, 12, 
24 and 36 
months 
The proportions of 
patients still on IFX were 
82%, 74%, 67% and 20% 
after 6, 12, 24 and 36 
months, respectively.d 
Levalampi et 
al.152 
ETN and 
ADA 
Chart review 
(Rheumatology 
center) 
 
Retrospective 
 
 Finland 
96e / mean age (±SD) 
was 48.0 years (SD 
not provided but 
range was 17-75 
years) and females 
(64.6%) comprised 
the majority of the 
sample. 
N/A N/A Treatment 
continuation 
rates at 12 
months 
The continuation rate was 
74% with ETN users and 
60% with ADA users at 12 
months of follow-up.d 
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Agents 
Datasource/ 
Analysis/ 
Country 
Sample size/ 
Brief description 
of sample 
Adherence/ 
Compliance 
Measurement 
Adherence/ 
Compliance 
Results 
Persistence 
Measurement 
Persistence Results 
Brocq et al.154 ETN, ADA 
and IFX 
Chart review 
(Teaching 
hospital) 
 
Retrospective 
 
France 
304/ mean age (±SD) 
was 58.0 years (SD 
not provided) and 
females (81.3%) 
comprised the 
majority of the 
sample 
N/A N/A Treatment 
continuation 
ratesb at 12 and 
24 months 
Continuation rates were 
high with ETN (87% after 
12 months and 68% after 
24 months) and ADA 
(83% and 66%) but 
significantly lower with 
IFX (68% and 46%; 
p=0.0001 vs. ETN and p < 
0.01 vs. ADA). 
Agarwal et al.155 IFX Chart review 
(Rheumatology 
center) 
 
Retrospective 
 
US 
183/ mean age (±SD) 
was 59.3 years 
(±14.4) and females 
(87.0%) comprised 
the majority of the 
sample. 
N/A N/A Treatment 
discontinuation 
rates 
Discontinuation rate for 
IFX was 48% after 12 
months and 67% after the 
entire study period.d 
Clinical follow-up (Prospective) 
Figueiredo et 
al.143 
IFX Clinical follow-up 
 
Prospective 
 
France 
152/ mean age (±SD) 
was 53.3 years (SD 
not provided but 
range was 24-82 
years) and females 
(79.0%) comprised 
the majority of the 
sample. 
N/A N/A Treatment 
continuation 
ratesb 
The continuation rate 
(survival) was 78% at 12 
months of follow-up. 
Voulgari et al.145 IFX Clinical follow-up 
 
Prospective 
 
Greece 
84/ mean age (±SD) 
was 59.0 years 
(±8.00) and females 
(72.6%) comprised 
the majority of the 
sample. 
N/A N/A Treatment 
discontinuation 
ratesb at 12, 24 
and 36 months 
Discontinuation rates 
were 15.5%, 27.0% and 
41.0% at 12, 24 and 36 
months, respectively. d  
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Datasource/ 
Analysis/ 
Country 
Sample size/ 
Brief description 
of sample 
Adherence/ 
Compliance 
Measurement 
Adherence/ 
Compliance 
Results 
Persistence 
Measurement 
Persistence Results 
Kristensen et 
al.148 
ETN and IFX 
monotherap
y or in 
combination 
with either 
MTX or other 
DMARDs.   
Clinical follow-up 
 
Prospective 
 
Sweden 
1,161/ mean age 
(±SD) was 56.4 years 
(SD not provided) 
and females (77.3%) 
comprised the 
majority of the 
sample. 
N/A N/A Level of drug 
adherence 
defined as 
proportion of 
patients 
remaining on 
therapy during 
observation 
period. b 
For Monotherapy users: 
The level of adherence to 
therapy at 4 years (1 year) 
was 18% (47%) for IFX 
and 53% (74%) for ETN. 
For combinations with 
MTX:  The level of 
adherence to therapy at 5-
year (4-year; 1-year) was 
36% (38%; 69%) for IFX 
and 65% (75%; 89%) for 
ETN.  
The values for the 4-year 
and 1-year periods were 
significantly (p < 0.001) 
higher when compared to 
monotherapy users for 
both IFX and ETN. 
For combinations with 
other DMARDs:  The level 
of adherence to therapy at 
4 years (1 year) was 27% 
(58%) for IFX and 71% 
(85%) for ETN.  
The values for the 4-year 
and 1-year periods were 
significantly lower 
(p=0.002) when compared 
to combination with MTX 
for IFX users but higher 
(p=0.015) when compared 
to monotherapy for ETN 
users.  
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Datasource/ 
Analysis/ 
Country 
Sample size/ 
Brief description 
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Adherence/ 
Compliance 
Measurement 
Adherence/ 
Compliance 
Results 
Persistence 
Measurement 
Persistence Results 
Buch et al.150 IFX Clincal follow-up 
 
Prospective 
 
UK 
309/ mean age (±SD) 
was 57.0 years 
(±15.82) and females 
(73.0%) comprised 
the majority of the 
sample. 
N/A N/A Treatment 
discontinuation 
rate  
Discontinuation rate was 
over 55% at 12 months 
among primary 
responders to IFX 
(n=117). 
Vander Cruyssen 
et al.151 
IFX Clinical follow-up 
 
Prospective 
 
Belgium 
511/ no information 
on patients’ 
characteristics was 
provided. 
N/A N/A Treatment 
continuation 
ratesb at 48 
months 
Among the initial 511 
patients included in the 
study, 479 could be 
evaluated; of these, 295 
(61.6%) were still 
receiving IFX treatment at 
year 4 of follow-up. 
Lass et al.34 ETN Clinical follow-up 
 
Prospective 
 
Finland 
49/ mean age (±SD) 
was 52.3 years (SD 
not provided) and 
females (87.8%) 
comprised the 
majority of the 
sample. 
N/A N/A  Treatment 
discontinuation 
ratesb 
Of the 49 patients that 
were switched from IFX to 
ETN, 20 (40.8%) 
discontinued therapy.  The 
mean duration of follow-
up was 16 months (±3) 
and the mean time to 
discontinuation was 4 
months (±2).  
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Brief description 
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Adherence/ 
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Adherence/ 
Compliance 
Results 
Persistence 
Measurement 
Persistence Results 
Du Pan et al.156 ADA, ETN 
and IFX 
Clinical follow-up 
 
Prospective 
 
Switzerland 
2,364/ mean age 
(±SD) was 54.0 years 
(SD not provided) 
and females (77.9%) 
comprised the 
majority of the 
sample. 
N/A N/A Drug survival 
ratesb at 12 and 
24 months 
A statistically significant 
difference (adjusted p < 
0.001) was noted in the 
discontinuation rates 
between the 3 anti-TNF 
agents.  After 1 (2) years, 
78% (58%); 82% (65%) 
and 84% (66%) were still 
receiving IFX, ETN and 
ADA, respectively. There 
was a trend in favor of a 
lower risk of 
discontinuation of anti-
TNF agents in 
combination with MTX 
(HR=0.85, 95% CI= 0.70-
1.02).  
Ostergaard et 
al.157 
IFX and ETN Clinical follow-up 
 
Prospective 
 
Denmark 
417/ mean age (±SD) 
was 53.5 years (SD 
not provided) and 
females (74.3%) 
comprised the 
majority of the 
sample. 
N/A N/A Median drug 
survival timeb 
Median drug survival time 
for IFX and ETN was 127 
and 197 weeks, 
respectively.  Survival at 1 
year for IFX and ETN was 
71% and 73%, 
respectively (p=0.04). 
 
Agarwal et al.158 IFX, ADA and 
ETN 
Clinical follow-up 
 
Prospective 
 
US 
503/ mean age (±SD) 
was 55.4 years 
(±13.5) and females 
(85.0%) comprised 
the majority of the 
sample. 
N/A N/A Treatment 
discontinuation 
rates 
Overall, 42% of the 
patients discontinued 
treatment with TNF 
inhibitors, with a mean 
length of follow-up of 
roughly 39 months.  
Discontinuation rates to 
individual TNF inhibitor 
were not reported. 
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Analysis/ 
Country 
Sample size/ 
Brief description 
of sample 
Adherence/ 
Compliance 
Measurement 
Adherence/ 
Compliance 
Results 
Persistence 
Measurement 
Persistence Results 
Clinical follow-up (Retrospective) 
Gomez-Reino et 
al.41 
IFX, ETN and 
ADA 
Clinical follow-up 
 
Retrospective 
 
Spain 
488/ paient 
characteristics were 
not provided for this 
sample 
N/A N/A Treatment 
discontinuation 
ratesb 
Survival of the second TNF 
antagonist decreased to 
0.68 and 0.60 at 12 and 24 
months, respectively. 
Survival was greater in 
patients treated with IFX 
(HR=3.22; 95% CI=2.13-
4.87). 
Zink et al.141 ETN, IFX and 
ANA as 
monotherap
y or in 
combination 
with either 
MTX or other 
DMARDs.  
There was 
also a control 
group 
comprising 
of patients 
on mono and 
combination 
DMARDs 
therapy 
Clinical follow-up 
 
Retrospective 
 
Germany 
1,523(39.3% of 
sample was in the 
control group) / 
mean age (±SD) was 
53.8 years (SD not 
provided) for 
patients on biologics 
and 56.5 years 
(±11.4) for the 
control group. 
Females (78.3%) 
comprised the 
majority of the 
sample. 
N/A N/A Treatment 
continuation 
ratesb after 12 
months 
Treatment continuation 
rates between ETN (69%; 
95% CI=62%-75%) and 
IFX (65%; 95% CI=58%-
73%) were found to be 
comparable (p>0.05) in 
the first 12 months of 
observation.  
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Geborek et al.159 ETN, IFX and 
LEF 
Clinical follow-up 
 
Retrospective 
 
Sweden 
369  
(33 of these patients 
were on 2 TNF-
inhibitors and 1 was 
on 3 drugs) / mean 
age (±SD) was 56.9 
years (SD not 
provided) and 
females (79.4%) 
comprised the 
majority of the 
sample. 
N/A N/A Drug survival 
ratesb (or 
continuation 
rates) 
There were no significant 
differences (p>0.05) in 
treatment continuation 
rates between ETN (79%) 
and ADA patients (75%) 
after 20 months. 
Favalli et al.160 IFX Clinical follow-up 
 
Retrospective 
 
Italy 
95/ mean age (±SD) 
was 57.3 years (±7.8) 
and females (86.3%) 
comprised the 
majority of the 
sample. 
N/A N/A Treatment 
discontinuation 
rates 
Overall discontinuation 
rate at 12 months was 
17%. 
Levalampi et 
al.161 
IFX Clinical follow-up 
 
Retrospective 
 
Finland 
104e / mean age 
(±SD) was 45.0 years 
(SD not provided but 
range was 18-75 
years) and females 
(62.0%) comprised 
the majority of the 
sample. 
N/A N/A Treatment 
continuation 
rates 
Overall continuation rate 
at 6 months was 71%. 
Registry 
Chevillotte-
Maillard et al.140 
IFX Registry 
 
Retrospective 
 
France 
83  
(72.3% of sample had 
RA) / mean age 
(±SD) was 53.9 years 
(±13.00) and females 
(66.3%) comprised 
the majority of the 
sample. 
N/A N/A Withdrawal 
rateb based on a 
12-month 
follow-up period 
Withdrawal rate was 
36.1%. 
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Flendrie et al.144 ETN, IFX and 
ADA 
Registry 
 
Retrospective 
 
Netherlands  
230/ mean age (±SD) 
was 55.5 years 
(±12.40) and females 
(67.0%) comprised 
the majority of the 
sample. 
N/A N/A Drug survival 
ratesb  
Median survival time was 
37 months and maximum 
follow-up time for ADA, 
IFX and ETN was 69, 35 
and 30 months, 
respectively.  
One year survival rate was 
comparable (p>0.05) 
among ADA (73%), IFX 
(66%) and ETN (74%) 
users. 
Strangfeld et 
al.149 
ETN, ADA 
and IFX in 
combination 
with either 
MTX or LEF 
Registry 
 
Retrospective 
 
Germany 
1,769/ mean age 
(±SD) was 53.5 years 
(SD not provided) 
and females (75.5%) 
comprised the 
majority of the 
sample. 
N/A N/A Treatment 
discontinuation 
rateb at 36 
months 
After 36 months, the 
discontinuation rates 
between combinations of 
ETN with MTX (46.3%) 
and ETN with LEF 
(53.4%) were comparable 
(p>0.05). Similar results 
were obtained between 
combinations of ADA with 
MTX (51.3%) and ADA 
with LEF (63.1%); as well 
as between combinations 
of IFX with MTX (61.5%) 
and IFX with LEF (67.1%). 
Feltelius et al.153 ETN Registry 
 
Prospective 
 
Sweden 
1,073 (76.4% of the 
sample was recruited 
in the first year) / 
mean age (±SD) was 
52.0 years (SD not 
provded) and 
females (76.6%) 
comprised the 
majority of the 
sample. 
N/A N/A Treatment 
discontinuation 
rate at 24 
months 
After two years, 21% (n = 
172) of the patients 
recruited in the first year 
had discontinued the 
treatment. 
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Hetland et al.162 ADA, ETN 
and IFX 
Registry 
 
Retrospective 
 
Denmark 
2,326/ median age 
(range) was 57.0 
years (15-89) and 
females (73.7%) 
comprised the 
majority of the 
sample. 
N/A N/A Adherence rate 
was defined in 
terms of drug 
survival ratesb  
The drug survival rate (or 
continuation rates) was 
highest for ETN and 
lowest for IFX. At 48 
months, the unadjusted 
drug adherence rates 
were as follows: For ADA, 
52% (95% CI=46-57%); 
for ETN, 56% (95% 
CI=51-62%); and for IFX, 
41% (95% CI=37-44%) (p 
< 0.0001) 
Marchesoni et 
al.163 
ADA, ETN 
and IFX 
Registry 
 
Retrospective 
 
Italy 
1,064 / mean age 
(±SD) was 55.8 years 
(±12.96) and females 
(83.2%) comprised 
the majority of the 
sample. 
N/A N/A Drug survival 
ratesb  
After 36 months, the 
likelihood of survival (or 
continuation rates) on 
ETN (62.5%) was 
significantly (p=0.027) 
higher than the likelihood 
of survival (or 
continuation) on IFX 
(49.1%) or ADA (53.6%). 
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Finckh et al.164 IFX, ADA and 
ETN 
Registry 
 
Retrospective 
 
Switzerland 
1,198/ mean age 
(±SD) was 53.5 years 
(SD not provided) 
and females (74.3%) 
comprised the 
majority of the 
sample. 
N/A N/A Treatment 
discontinuation 
ratesb 
The discontinuation rates 
were not significantly 
different 
between the treatments 
(p=0.67) 
The HR of discontinuing 
treatment was 1.11 (99% 
CI= 0.89 to 1.40) for IFX 
compared with ETN and 
ADA; 0.97 (99% CI= 0.71 
to 1.15) for ADA 
compared with IFX and 
ETN; and 0.91 (99% CI= 
0.71 to 1.15) for ETN 
compared with IFX and 
ADA. 
Actual discontinuation 
percentages were not 
provided. 
Genta et al.165 IFX, ADA and 
ETN 
Registry 
 
Retrospective 
 
Switzerland 
66/ mean age (±SD) 
was 60.5 years 
(±13.00) and females 
(65.0%) comprised 
the majority of the 
sample.  
N/A N/A Treatment 
discontinuation 
rates 
Overall discontinuation 
rate at 6 months was 24%.  
Discontinuation rates to 
individual TNF inhibitor 
were not reported. 
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Others 
Ducoulombier et 
al.147 
IFX Open label trial 
 
Prospective 
 
France 
50/ mean age (±SD) 
was 49.1 years 
(±11.1) and females 
(78.0%) comprised 
the majority of the 
sample. 
N/A N/A Treatment 
continuation 
rates at 24 
months 
The 2-year continuation 
rate for IFX was 70%. 
ADA = Adalimumab; ETN = Etanercept; GC = Glucocorticoid; HCQ = Hydroxychloroquine; HR = Hazard Ratio; IFX = Infliximab; LEF = Leflunomide;  
MPR = Medication possession ratio; MTX = Methotrexate; PEI = Persistent exposure ignored; PER = Persistent exposure required; PDC = Proportion of days 
covered; RA = Rheumatoid arthritis; SD = Standard deviation; SSZ = Sulfazalazine; TNF = Tumor necrosis factor; a US and European RA studies only; bObtained 
by conducting survival analysis; cInflammatory arthritis including rheumatoid arthritis; dNo statistical comparison was conducted; eIncludes patients with 
rheumatoid arthritis and spondylarthropathies.  
Summary pattern was adapted from:  Koncz T, Pentek M, Brodszky V, Ersek K, Orlewska E, Gulacsi L. Adherence to biologic DMARD therapies in rheumatoid 
arthritis. Expert Opinion on Biological Therapy. 2010; 10(9):1367-1378. 
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2.1.11  Medication Switching among TNF Inhibitors in RA Management 
Due to the complexity of the disease process as well as differences in patient 
characteristics, responses to TNF inhibitors tend to vary across patients. Some 
patients may: completely fail to respond to therapy (primary lack of efficacy), exhibit 
a suboptimal response (partial response), have difficulty maintaining an initially good 
response over the course of treatment (secondary loss of efficacy or acquired drug 
resistance), or experience intolerable adverse events.166,167  These unfavorable 
outcomes may necessitate the need to discontinue current therapy and switch to 
another. However, a major challenge lies in the limited range of options clinicians may 
have to choose from since in many instances the initiation of TNF inhibitor therapy 
will have occurred following treatment failure with multiple traditional DMARDs.35 
While the newer biological agents (e.g., abatacept, rituximab, tocilizumab and 
golimumab) have been shown through RCTs to be efficacious compared to placebo in 
RA patients who failed to respond to prior TNF inhibitor therapy, 114,117,118,168,169 there 
has been no direct (head-to-head) comparison among these agents to help clinicians 
decide on the most appropriate option regarding both efficacy and safety.127 An 
indirect pair-wise comparison (meta-analysis) conducted by Schoels et al. suggested 
similar ACR20 response rates at 24 weeks for abatacept, rituximab and tocilizumab 
but lower rates for golimumab.170 ACR50 and ACR70 response rates were reported 
to be similar across the four agents, suggesting that they have comparable efficacy in 
RA patients who failed to respond to prior TNF inhibitor therapy.170     
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Due to the differences in the pharmacokinetic profiles and specific 
characteristics (e.g., molecular structures, sites of action, dosing regimens, drug 
neutralizing autoantibody induction, type and frequency of adverse events) of TNF 
inhibitors, medication switching across TNF inhibitors has been recommended.  
However, evidence supporting switching effectiveness between TNF inhibitors is 
limited to results obtained from small case series and open-label studies (non-
controlled studies).34-40,42-49,171,172 Results from these studies consistently showed 
that treatment response following a switch between TNF inhibitors was comparable 
with, or better than the response observed with the initial TNF inhibitor agent. In 
addition, treatment responses were found to be comparable with the response 
observed among patients naïve to TNF inhibitor therapy.85 Results from systematic 
reviews/meta-analyses also supported the effectiveness of switching between TNF 
inhibitors (i.e., adalimumab, infliximab and etanercept) irrespective of the reason for 
switching (either due to inefficacy or adverse events) and order of switching.50,51 
However, treatment response was reported to be slightly better if switching was as a 
result of adverse events rather than inefficacy.50,51  
According to the systematic review/meta-analysis (n= 32 studies) by Remy et 
al., the pooled proportions of responders following a switch to a second TNF inhibitor 
were 55.1 percent (95% CI= 48.2-62) and 74.9 percent (95% CI=72.3-77.5), 
respectively, based on ACR20 and EULAR response criteria. Response rates with 
ACR50 and ACR70 were 31.5 percent (95% CI=29-34.1) and 13.8 percent (95% 
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CI=10.1-18.1), respectively. When the efficacy of a switch was analyzed (n=19 
studies) based on the reason to switch, the pooled proportions of responders based 
on ACR20 and EULAR response criteria were 62.4 percent (95% CI=57.0-67.7) and 
69.4 percent (95% CI=46.7-88.0), respectively for patients who switched due to 
adverse events and 52.6 percent (95% CI=43.9-61.1) and 66.3 percent (95% CI=55.8-
76.1), respectively for those who switched due to lack of efficacy. Overall survival rate 
(persistence) on a second TNF inhibitor was reported to be 80.4 percent (95% 
CI=65.8-91.7) at 3 months, 84.6 percentb (95% CI=76.2-91.5) at 6 months and 61.8 
percentc (95% CI=50.8-72.3) at 12 months. Survival rates at 3 months were slightly 
higher if the switch was due to inefficacy rather than due to adverse events, but were 
comparable at 12 months.  In addition, analyses involving switches between specific 
TNF inhibitors showed a higher proportion of responders among those who switched 
from infliximab to adalimumab (ACR20=63.9% (95% CI=60.2-67.4) and 
EULAR=74.0% (95% CI=62.1-84.3)) compared to those who switched from 
infliximab to etanercept (ACR20=45.6% (95% CI=40.3-51.1) and EULAR=59.3% 
(95% CI=52.7-65.7)). However, at ACR50 and 70, the proportions of responders were 
similar regardless of whether the switch was to etanercept or adalimumab. For 
patients who switched from etanercept to either infliximab or adalimumab, the 
                                                          
b Of those that persisted at 3 months   
c Of those that persisted at 6 months 
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pooled proportions of responders based on ACR20 and EULAR criteria were 58.6% 
(95% CI=52.2-64.9) and 76.7% (95% CI=34.1-99.6), respectively.50  
2.1.12 Dose Escalation and Impact on Cost of TNF Inhibitor Therapy in RA 
Management 
An approach to addressing inadequate treatment response (partial or 
secondary loss of efficacy) to TNF inhibitors may require escalating the administered 
dose. This may be achieved by either increasing the infused dose or reducing the 
dosing interval (increasing frequency of dosing) or both. The rationale for dose 
escalation has been partly explained based on the premise that inadequate treatment 
responses (partial or secondary loss of efficacy) occur due to the development of 
autoantibodies to TNF inhibitors, which, over the course of treatment, reduces their 
efficacy. However, the literature lacks sufficient evidence to support this claim. A 
higher likelihood of development of autoantibodies to infliximab and adalimumab 
compared to etanercept have also been reported.173  
A major implication of dose escalation in the management of RA actually lies 
in its impact on the cost of the TNF inhibitor therapy (which impacts the overall cost 
of care of the RA patient) and patient safety.174 While dose escalation is 
recommended18,19,175 and occurs more often with the use of infliximab and 
adalimumab in improving treatment response, 26,28-30,176,177 it is not recommended for 
patients on etanercept as it has not been associated with any significant improvement 
in treatment response rates.20,178 Studies on dose escalation and cost of TNF inhibitor 
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therapy showed that etanercept use was associated with significantly lower rates of 
dose escalation and lower TNF inhibitor therapy cost compared with the use of 
adalimumab and infliximab.26,28-33,177 Furthermore, Gu et al. reported that the 
difference in total cost of care between patients who had higher starting doses (or 
escalated doses) and those who did not was significantly (p < 0.001) higher for 
adalimumab users compared to etanercept users ($4,154 vs. $683) (SD not 
provided).31 Similarly, Moot et al. found a significant (p < 0.001) difference in total 
cost of care between dose escalators and non-escalators treated with either 
adalimumab (€5,872 (95% CI=3,862 - 7,882) ≈ $9,248 (95% CI= 6,079 - 12,414)) or 
infliximab (€2,126 (95% CI= 411-3,840) ≈ $3,348 (95% CI= 647 – 6,047)) but not for 
etanercept (€2,266 (95% CI= -878 – 5410) ≈ $3,568 (95% CI= -1,382 – 8,518)).177   
2.1.13  Summary of Literature Review 
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic 
inflammation of the joints.1  RA remains a leading cause of disability and affects about 
1 percent of the adult United States (US) population with a higher prevalence, 
incidence and lifetime risk in women compared to men.2,3 Current treatment goals 
involve slowing or stopping the progression (i.e., remission) of the disease. Among 
the available treatment options, the TNF inhibitors have generally been recognized to 
have revolutionized the management of RA as they have been shown through RCTs 
to significantly improve patients’ symptoms as well as retard the progression of the 
disease.5-9 Among the available TNF inhibitors, three agents (Enbrel® [etanercept], 
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Remicade® [infliximab] and Humira® [adalimumab]) have been extensively studied 
and used in clinical practice with remarkable results. While clinical trials that directly 
compare these agents are lacking, results from the majority of the indirect treatment 
comparison studies suggested they have comparable efficacy and safety profiles.12-14 
However, they differ in their method of administration and flexibility of dosing and 
these differences may possibly result in differences in their medication use profiles 
(e.g., medication adherence, persistence, discontinuation, and dose escalation) and 
cost of care of RA patients on these medications.18-20 Studies have been conducted in 
the US to evaluate the medication use patterns of RA patients on these TNF inhibitors 
(etanercept, infliximab and adalimumab).2,4,21-31 However, only 3 of these US 
studies23-25 utilized data from patients enrolled under Medicaid programs, many of 
whom are not the typical patients enrolled in RCTs. These patients are of poor 
socioeconomic status and usually present with comorbid disease conditions. 
Furthermore, none of the 3 studies examined dose escalation and the associated 
healthcare utilization costs.  
2.1.14  Study Objectives and Hypotheses 
The present study aims to evaluate medication use patterns (medication 
adherence, persistence, discontinuation, switching and dose escalation) of RA 
patients on etanercept, infliximab or adalimumab and the associated healthcare 
utilization costs using Texas Medicaid data. Etanercept, infliximab and adalimumab 
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were the only biologics chosen for this study because they have been widely used and 
extensively studied.   
The covariates considered in the study include demographic factors (age, 
gender, race/ethnicity), pre-index use of other RA-related medications (e.g., NSAIDs, 
cyclooxygenase-2-inhibitors, narcotic analgesics, tramadol, glucocorticoids and 
traditional DMARDs), total number of non-study RA-related medications used at 
index, Charlson Comorbidity Index score, pre-index RA and non-RA related visits, pre-
index healthcare utilization cost and specialty of prescribing physician.  
2.1.14.1 Specific Research Objectives and Hypotheses 
1) To describe and compare baseline socio-demographics and clinical characteristics 
of Texas Medicaid RA patients on etanercept (ETN), adalimumab (ADA) or 
infliximab (IFX). 
2) To describe medication dosing patterns among ETN, ADA and IFX users. 
3) To determine if the likelihood of having a dose escalation among ETN users differs 
significantly compared to ADA and IFX users while controlling for covariates. 
H1: The likelihood of having a dose escalation is significantly lower among 
RA patients on ETN compared to patients on ADA and IFX while controlling 
for covariates. 
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4)   To determine if medication use patterns (adherence, persistence, 
discontinuation, and switching) among ETN users differ significantly compared to 
ADA and IFX users while controlling for covariates. 
Ho2A: There is no significant difference in medication adherence to ETN 
compared to ADA and IFX while controlling for covariates. 
Ho2B: The likelihood of being adherent (MPR≥0.80 or 80%) to ETN does 
not differ significantly compared to ADA and IFX while controlling for 
covariates. 
Ho3: There is no significant difference in medication persistence to ETN 
compared to ADA and IFX while controlling for covariates. 
Ho4: The likelihood of discontinuing ETN does not differ significantly 
compared to ADA and IFX while controlling for covariates. 
Ho5: There is no significant difference in duration of medication use (i.e., 
persistence) prior to discontinuation of ETN compared to ADA and IFX 
while controlling for covariates. 
Ho6: There is no significant difference in the likelihood of switching from 
index TNF inhibitor therapy to another biologic agent among ETN users 
compared to ADA and IFX users while controlling for covariates. 
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Ho7: There is no significant difference in duration of medication use (i.e., 
persistence) prior to switching from index TNF inhibitor therapy among 
ETN users compared to ADA and IFX users while controlling for covariates. 
5) To determine if total healthcare utilization cost (medical and medication costs) 
for ETN users differs significantly compared to ADA and IFX users while 
controlling for covariates. 
H8: Total healthcare utilization cost is significantly lower for ETN patients 
compared to patients on ADA and IFX while controlling for covariates. 
6) To determine if RA-related healthcare utilization cost (medical and medication 
costs) for ETN users differs significantly compared to ADA and IFX users while 
controlling for covariates.  
H9: RA-related healthcare utilization cost is significantly lower for ETN 
patients compared to patients on ADA and IFX while controlling for 
covariates. 
H11: TNF inhibitor therapy cost is significantly lower for ETN patients 
compared to patients on ADA and IFX while controlling for covariates. 
7) To determine if RA-related healthcare utilization cost is associated with 
adherence/persistence to TNF inhibitors (ETN, ADA or IFX) while controlling for 
covariates. 
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H15: RA-related healthcare utilization cost is significantly and positively 
related to TNF medication adherence while controlling for covariates. 
H16: RA-related healthcare utilization cost is significantly and positively 
related to TNF medication persistence while controlling for covariates. 
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CHAPTER 3: METHODOLOGY 
 3.1  CHAPTER OVERVIEW 
This chapter provides a detailed description of the study methodology. 
Information provided covers the following: study design; data source; study 
population; data extraction and study timeframe; the inclusion and exclusion criteria 
for developing the study cohort; and the study variables. Also presented are the 
operational definitions of the study variables, statistical analytical methods that were 
employed to address the study objectives as well as the sample size calculations.   
3.1.1 Institutional Review Board Approval  
Approval for the present study was obtained from the Institutional Review 
Boards (IRB) of The University of Texas at Austin (IRB protocol number: 2012-02-
0110) and Texas Health and Human Services Commission prior to its commencement. 
A waiver of informed consent was obtained because this is a retrospective database 
study containing de-identified data which presents no more than a minimal risk to 
the welfare and privacy of subjects. 
3.1.2 Study Design and Data Source 
This was a retrospective study involving the use of a secondary database. 
Demographic, medical and prescription claims records of Texas Medicaid RA patients 
between the ages of 18 and 63 years on TNF inhibitors (etanercept, adalimumab and 
infliximab) within the timeframe ranging from July 2003 to August 2011 was 
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obtained from the Texas Medicaid prescription and medical claims data files.  The 
next paragraph provides a brief description of the Medicaid program. 
The Medicaid program is a healthcare program jointly sponsored by the state 
and federal governments.179 The program was established through Title XIX of the 
Social Security Act on July 30, 1965 and provides health insurance coverage especially 
for low-income families, individuals with chronic disabilities, blind persons, low-
income pregnant women, elderly people or seniors, non-disabled children and 
caretakers of dependent children.179 The Medicaid program is administered by the 
states, with federal oversight through the Centers for Medicare and Medicaid Services 
(CMS). Participating states are mandated by the CMS to provide a set of basic 
healthcare services to enrollees and since it is an entitlement program, there is no 
restriction to the number of people who can be enrolled provided they meet the 
eligibility criteria for the program.179 Based on the most recent available data (i.e., 
2009-2010 data), the Texas Medicaid program provided health insurance coverage 
for approximately 3.7 million (≈14.8%) non-elderly residents (i.e., 64 years of age and 
below).180 Among these non-elderly beneficiaries of the Texas Medicaid program, 
children (i.e., ≤ 18 years of age) constitute the majority (74.5%).180 Examples of 
services provided by the Texas Medicaid program include: physician services, 
inpatient and outpatient hospital services, long-term care, lab and X-ray services and 
pharmacy services.  
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3.1.2.1 Inclusion/Exclusion Criteria 
Texas Medicaid recipients who met the following eligibility criteria were 
included in the study: (a) subjects between the ages of 18 and 63 years at the index 
date; (b) continuously enrolled for at least 6 months before and 12 months after the 
index date; (c) have a diagnosis for RA in the 6-month pre-index period (International 
Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 
714.0x); (d) have no claim for a biologic agent (e.g., abatacept, adalimumab, anakinra, 
certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab) 
indicated for RA within the 6-month pre-index period; and (e) have at least one claim 
for any of the study TNF inhibitors (etanercept, adalimumab or infliximab) indicated 
for the treatment of RA within the 12-month post-index period.  
Subjects with a diagnosis for psoriasis (ICD-9-CM 696.1x), psoriatic arthritis 
(ICD-9-CM 696.0x), ankylosing spondylitis (ICD-9-CM 720.0x), ulcerative colitis (ICD-
9-CM 556.0, 556.1, 556.2, 556.3, 556.5, 556.6, 556.8 or 556.9), Crohn’s diseases (ICD-
9-CM 555.0x, 555.1x, 555.2x, 555.9x, 565.1x, or 569.81), juvenile idiopathic arthritis 
(ICD-9-CM 714.3x), non-Hodgkin’s lymphoma (ICD-9-CM 200.xx or 202.xx) or 
chronic lymphocytic leukemia (ICD-9-CM 204.1x) were excluded as the TNF 
inhibitors are also used to treat these indications. The age range was restricted to 63 
years to avoid including patients with dual eligibility status (i.e., Medicaid and 
Medicare). 
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3.1.2.2 Index Date 
The index date was defined as the date within the identification period (Figure 
3.1) when the patient had the first fill for any of the study TNF inhibitors (etanercept, 
adalimumab or infliximab) without any fills during the prior 6 months. The index date 
was unique for each subject and falls within January 1, 2004 and August 31, 2010.   
3.1.2.3 Data Collection/ Study Timeframe 
Information extracted from the Texas Medicaid medical and prescription 
claims files include: de-identified unique patient identification numbers, gender, 
race/ethnicity, date of enrollment, date of end of enrollment, ICD-9-CM codes 
(diagnostic codes), the National Drug Code (NDC), the Generic Sequencing Number 
(GCN), the American Hospital Formulary Service (AHFS) number, the date a 
prescription was dispensed, the quantity of drug supplied, the number of days for 
which the drug was supplied and the amount paid for drug supplied. Data was 
extracted within the time frame of July 1, 2003 to August 31, 2011. Subjects were 
identified during the index period from January 1, 2004 to August 31, 2010 (Figure 
3.1). Prescription claims data for each subject was analyzed over an 18-month study 
period (i.e., the 6-month pre-index and 12-month post-index periods).  
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Figure 3.1  Data Extraction and Subject Identification Period 
                                          Identification / index period  
 
 
 
July 1, 2003          January 1, 2004                                            August 31, 2010             August 31, 2011     
 
 
   
 
 
 
 
 
 
     Pre-index period                                   Post-index period 
                                                                    
 
                                                                       Index Date 
 
 
3.1.3 Study Variables  
3.1.3.1 Dependent Variables                                            
The dependent variable categories for the study include: (1) dose escalation; 
(2) medication use patterns (i.e., adherence, persistence, discontinuation, and 
switching); (3) medication dosing patterns; (4) total healthcare utilization costs 
(medical and medication costs) (5) RA-related healthcare utilization costs (medical 
and medication costs) and (6) TNF inhibitor therapy costs. These categories are 
further described below.  
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Dose Escalation 
Dose escalation can be assessed using a variety of methods. These include: (1) 
last prescription dose versus index prescription dose;28,30,174 181-183 (2) average actual 
dose versus recommended dose;30,184 (3) multiple (>2) instances of a subsequent 
dose exceeding the index dose;30,185 (4) when average of all subsequent doses exceed 
a predetermined percentage (e.g., 115%, 130% or 150%) of the index dose;30,186 and 
(5) the time-trend method.28,30,31   The advantages as well as the disadvantages of 
each method are discussed in the subsequent paragraphs. 
The first method (i.e., last prescription dose versus index prescription dose) 
compares the weekly dose of the last prescription with that of the index prescription. 
While this has the advantage of ease of computation, it fails to utilize the entire data 
in its analysis of dose escalation and as such the result may not be representative of 
the “actual medication use pattern” across the course of treatment.30 The second 
method (i.e., average actual dose versus recommended dose) measures the average 
weekly dose (i.e., (total dispensed quantities in the study period in mg/ total days 
supply) x 7) and compares with the manufacturer recommended weekly dose.30 
While this method has the advantage of ease of computation, it overestimates dose 
escalation especially in patients who started therapy on a high dose. In addition, it 
does not necessarily measure dose escalation, but rather dose deviation from 
manufacturer’s recommended dose. It also fails to incorporate the time component 
necessary to understand changes that occur in the course of therapy.30  
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The third method estimates dose escalation by identifying 2 or more instances 
when the patient’s weekly dose of subsequent prescriptions exceeds that of the index 
prescription. This has the advantage of using all the available data as well as capturing 
dose changes over the course of treatment. The drawbacks of this method of 
estimating dose escalation include: failure in distinguishing between changes over 
time and true dose escalation; the complexity of the analysis and the subjectivity 
involved in deciding the number of incidences.30  The fourth method of estimating 
dose escalation calculates the ratio between the average weekly dose of all 
subsequent prescriptions and the weekly dose of the index prescription to determine 
if it exceeds a predetermined percentage (e.g., 115%, 130% or 150%). While this 
approach has the advantage of using all the available data as well as capturing dose 
changes over the course of treatment based on a predetermined threshold, it presents 
challenges similar to those discussed under the third method.30 The last and fifth 
method (i.e., time-trend approach) computes patient’s weekly dose and compares 
each week’s dose with the subsequent week’s dose or a recommended or index dose. 
It allows the use of the entire available data as well as provides information on dose 
escalation over a specified period of time. Its drawback lies in the complexity of the 
analytical process. This approach is highly recommended since it provides a more 
transparent and comprehensive picture of medication use pattern in clinical 
practice.30  
For the present study, the fourth method was used to assess dose escalation.  
Based on the fourth method, patients were classified as having a dose escalation if the 
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average weekly dose for all their subsequent prescriptions exceeds the weekly dose 
of their index prescription by 150 percent. The cut-off value of 150 percent was 
chosen as it is the most conservative of all the recommended values (e.g., 115%, 130% 
or 150%). 30  
  
Medication Adherence 
Two commonly employed approaches in estimating medication adherence 
with the use of quantitative data are the medication possession ratio and proportion 
of days covered.  Medication possession ratio (MPR) can be defined as the sum of total 
days’ supply for all fills divided by the number of days in the study period (Figure 3.2). 
The proportion of days covered (PDC) can be defined as the proportion of days a 
patient has a drug available in the specified interval or study period.  The PDC method 
involves evaluating each day in the specified interval or study period to determine if 
a patient has the dispensed study drug(s) based on the initial prescription fill date(s) 
and the days’ supply, and then assigns a value of 1 or 0 indicating the presence or 
absence of the study drug(s) for each study day. The PDC is calculated by counting 
each day within the study period for which the study drug(s) was available and then 
divide the sum by the number of days in the study period (Figure 3.3).187 
Studies have shown that MPR and PDC result in similar adherence values for 
cases of simple drug use (i.e., use of one drug); however, MPR may overestimate 
adherence in cases of drug switches, therapeutic duplication, or multiple drug use 
within the same therapeutic class. 187,188 Since the former (simple drug use) is the case 
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for the present study, MPR was utilized in estimating medication adherence across 
the study TNF inhibitors. Based on the obtained MPR values, mean adherence (mean 
MPR) and proportion of adherent and non-adherent patients (using a 0.80 cut-off 
point with MPR ≥ 0.80 referred to as adherent) was determined for each TNF 
inhibitor. Sensitivity analyses were conducted using 0.70 and 0.90 percent cut-off 
values. 
 
Figure 3.2 Formula for Calculating Medication Possession Ratio (MPR) 
MPR =   Sum of total days supply for all fills a x 100 / Number of days in study period b,c 
a For dual or triple therapy the numerator is divided by 2 or 3, respectively 
b It is typically a clinically meaningful number of days and should be the same for all intervals and patients 
c The denominator may be substituted with [(last dispense date – first dispense date) + last days supply] 
 
 
Figure 3.3 Formula for Calculating Proportion of Days Covered (PDC) 
†PDC = Number of days when drug(s) was available / Number of days in the study         period 
†PDC value is always between 0 and 1  
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Medication Persistence, Discontinuation and Switching 
Medication persistence can be defined as the number of days of continuous 
therapy during the follow-up period (i.e., post-index period).137  Pre-specified gap 
periods were allowed between prescriptions to account for early or delayed refills of 
prescriptions. Since there is no standard gap period, a 60-day gap period was used 
but sensitivity analyses were conducted using 30-, 45-, 90- and 120-day gap periods. 
These gap periods have been used in previous studies involving TNF inhibitors 
medication use.2,22,23,25-27  Using a 60-day gap period, a patient was considered to be 
persistent for the period of time (in days) when there was no more than a 60-day gap 
between two consecutive prescriptions. Other parameters of interest include rates at 
which patients discontinue or switch from index TNF inhibitor therapy.  
Medication discontinuation of index TNF inhibitor therapy was assumed to 
have occurred if there was greater than a 60-day gap period following a prescription 
or presence of a switch from the index TNF inhibitor therapy. Sensitivity analyses 
were conducted using 30-, 45-, 90- and 120-day gap periods. Medication switching 
was assumed to have occurred if a patient had a RA biologic agent that was different 
from the index TNF inhibitor therapy. Since these agents can not be used 
concomitantly, patients were assumed to be on one TNF inhibitor therapy at a specific 
point in time. Table 3.1 illustrates the use of the parameters discussed under this 
section. 
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Table 3.1 An Example Illustrating the Calculation of Medication Persistence, 
Discontinuation and Switching 
Patient Months (30 days/month) 
 1 2 3 4 5 6 7 8 9 10 11 12 
A D1 D1     D1 D1 D1 D1 D1 D1  
B D1 D1 D1 D1 D1 D1   D2 D2 D2  
C D2 D2 D2 D2 D2  D1 D1 D1 D1 D1 D1 
D D2 D2 D2  D1 D1 D1      
E D1 D1 D1 D1  D2 D2 D2 D2 D2 D2 D2 
F D1  D2 D2 D2        
G D2 D2     D2 D2 D2 D2 D2 D2 
 
Days persistent (continous days) without greater than a 60-day gap for the index drug based on a 
180-day follow-up period 
 For D1 (index): A = 60 days; B = 180 days; E = 120 days; and F = 30 days. 
 For D2 (index): C =150 days; D = 90 days; and G = 60 days. 
 Mean persistence for patients on D1 = (60+180+120+30)/4 = 97.5 days. 
 Mean persistence for patients on D2 = (150+90+60)/3 = 100.0 days. 
Medication discontinuation over a 180-day period (Greater that a 60-day gap following index drug or 
introduction of a new drug*†)  
 For D1 (index): Patients A, B, E and F discontinued therapy (4  out of 4 patients) 
 For D2 (index): Patients C, D and G discontinued therapy ( 3 out of 3 patients) 
Switching§ from index medication to another study medication during a 180-day study period 
 Patients B,  E and F switched from D1(index) to D2 ( 3 out of 4 patients) 
 Patients C and D switched from D2(index) to D1 (2 out of 3 patients) 
A, B, C, D, E, F and G are the patients; D1 and D2 are the study drugs; *Index drug is the first study drug the 
patient was placed on; †Drugs D1 and D2 can not be used concomitantly; §Starting a new study drug that is 
different from the index drug 
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Total Healthcare Utilization Costs 
Total healthcare utilization costs were the direct costs (i.e., medical and 
medication costs combined) to Texas Medicaid in the post-index period for users on 
each of the study TNF inhibitors, adjusted to 2011 US dollars (using the medical 
consumer price index from the U.S. Bureau of Labor Statistics current data).  
 
RA-related Healthcare Utilization Costs 
RA-related healthcare costs were the total RA-related direct costs (i.e., medical 
and medication costs combined associated with ICD-9-CM code 714.0x) to Texas 
Medicaid in the post-index period for users on each of the study TNF inhibitor, 
adjusted to 2011 US dollars (using the medical consumer price index from the U.S. 
Bureau of Labor Statistics current data).  
3.1.3.2 Independent Variables and Covariates 
The main independent variable for the study was the type of TNF inhibitor 
(etanercept, adalimumab and infliximab). The study covariates controlled for in the 
multivariate analysis included demographic factors (age, gender, race/ethnicity), 
pre-index use of other RA-related medications (e.g., NSAIDs, cyclooxygenase-2-
inhibitors, narcotic analgesics, tramadol, corticosteroids and non-biologic agents), 
total number of non-study RA-related medications at index, Charlson Comorbidity 
Index score, pre-index RA and non-RA related visits, pre-index healthcare utilization 
cost and specialty of prescribing physician.  
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Charlson Comorbidity Index (CCI) Score 
 The pathogenesis (disease process) of RA as well as its treatment often 
predisposes patients to developing comorbidities (see Figure 2.3 for examples of RA-
related comorbidities).71 Comorbidities are frequently measured in epidemiological 
studies as they often reflect the severity of the disease as well as the overall health 
status of the patient.4,189 In outcome research studies involving the use of 
administrative databases, comorbidities can be measured using either diagnosis- or 
prescription medication-based scores.189,190 Prescription medication-based scores 
(e.g., chronic disease score (CDS)) are used when only prescription claims data are 
available.189 Diagnosis-based scores (e.g., Charlson Comorbidity Index (CCI) and its 
adaptations (e.g., Deyo, Ghali, Dartmouth-Manitoba and D’Hoores)) are used if 
diagnosis records or data (e.g., ICD-9 CM or ICD-10 CM codes) are available along with 
prescription claims data.191-195 While the CCI was developed based on review of 
medical records, adaptations of the CCI (e.g., Deyo, Ghali, Dartmouth-Manitoba and 
D’Hoores) were developed by matching the diagnosis included in the CCI with similar 
ICD-9 diagnoses and procedures.191-194  The CCI score is derived based on the sum of 
weights (from 1 to 6) assigned to a predefined set of comorbidities for which a patient 
has claims data available.195,196 The assigned weights (see Table 3.2) were obtained 
from relative risk estimates associated with each comorbid condition in a Cox 
proportional hazards regression model using clinical data.189,190,196  
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Since the present study has diagnosis data (i.e., ICD-9 CM codes) along with 
prescription claims data, adaptations of the CCI were used to compute the 
comorbidity scores for the study population. The two most commonly used 
adaptations of the CCI are the Deyo and the Dartmouth-Manitoba adaptations.196  
They differ from each other based on how they translated the CCI to ICD-9-CM 
codes.196 The Deyo adaptation is stricter in its interpretation of the Charlson’s 
comorbidity definitions compared to the Dartmouth-Manitoba adaptation which 
included conceptually similar conditions not explicitly mentioned by Charlson et 
al.191,194,196  However, both adaptations have been shown to demonstrate comparable 
agreement in identifying Charlson comorbidities and CCI score with comparable 
discriminative ability in predicting mortality.193,196-198 The D’Hoores adaptation on 
the other hand differed from the Deyo and the Dartmouth-Manitoba adaptations as it 
only used the first 3 digits of the ICD-9 codes in its interpretation of the Charlson 
index.192 Lastly, the adaption by Ghali et al. differed as it was based on assigning 
study-specific data-derived weights to the original Charlson comorbidity variables as 
interpreted by Deyo and colleagues.191,193 For the present study the Dartmouth-
Manitoba adaptation was used because it is the least restrictive of two commonly 
used CCI adaptations.196   
A summary of the operational definitions of the independent variables and 
covariates is presented in Table 3.3.   
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Table 3.2 Charlson Comorbidity Index Components, Weights and 
Adaptations 
Comorbid 
Conditions 
Weights Deyo et al. 
codes 
Dartmouth-
Manitoba codes 
D’Hoore et al. 
codes 
Myocardial infarction 1 410.xx, 412* 410.xx, 412* 410, 411 
Congestive heart 
failure 
1 428.x 402.01, 402.11, 
402.91, 425.x, 428.x, 
429.3, 404.01, 404.03, 
404.11, 404.13, 
404.91, 404.93 
398, 402, 428 
Peripheral vascular 
disease 
1 441.x*, 443.9*, 
785.4*, V43.4*, 
38.48(P) 
440.x*, 441.x*, 442.x*, 
443.1-443.9*, 447.1*, 
785.4*, 38.13-
38.14(P)*, 38.16(P)*, 
38.18(P)*, 38.33-
38.34(P)*, 38.36(P)*, 
38.38(P)*, 38.43-
38.44(P)*, 38.46(P)*, 
38.48(P)*, 39.22-
39.26(P)* 
440-447 
Cerebrovascular 
disease 
1 430-437.x, 438* 362.34, 430-436, 437-
437.1, 437.9, 438, 
781.4, 784.3, 997.0, 
38.12(P), 38.42(P) 
430-433, 435 
Dementia 1 290.x* 290.x*, 331-331.2* 290, 291, 294 
Chronic pulmonary 
disease 
1 490-496*, 500-
505*, 506.4* 
415.0*, 416.8-416.9*, 
491.x-494*, 496* 
491-493 
Connective tissue 
disease 
1 710.0-710.1*, 
710.4*, 714.0-
714.2*, 714.81*, 
725* 
710.x, 714.x 710, 714, 725 
Ulcer disease 1 531.4x-531.7x*, 
532.4x-532.7x*, 
533.4x-533.7x*, 
534.4x-534.7x*, 
531.0x-531.3x, 
532.0x-532.3x, 
533.0x-533.3x, 
534.0x-534.3x, 
531.9, 532.9, 
533.9, 534.9 
531.xx-534.xx 531-534 
Mild liver disease 1 571.2*, 571.4*, 
571.5*, 571.6* 
571.2*, 571.5-571.6*, 
571.8-571.9* 
571, 573 
Diabetes 1 250.0x-250.3x*, 
250.7x* 
250.0x-250.3x* 250 
Diabetes  with end 
organ damage 
2 250.4x-250.6x* 250.4x-250.9x*† 
Hemiplegia 2 342.x*, 344.1* 342.x, 344.x 342, 434, 436, 437 
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Comorbid 
Conditions 
Weights Deyo et al. 
codes 
Dartmouth-
Manitoba codes 
D’Hoore et al. 
codes 
Moderate or severe 
renal disease 
2 582.x*, 583.0-
583.7*, 585*, 
586*, 588.x* 
585-586*, V42.0*, 
V45.1*, V56.x*, 
39.27(P)*, 39.42(P)*, 
39.93-39.95(P)*, 
54.98(P)* 
403, 404, 580-586 
Any tumor 2 140.x-172.x, 
174.x-195.x, 
200.xx-208.xx 
140.x-171.x*, 174.x-
195.x*, 200.xx-208.x*, 
273.0*, 273.3*, 
V10.46*, 60.5(P)*, 
62.4-62.41(P) 
140-195 
Leukemia 2 204-208 
Lymphoma 2 200, 202, 203 
Moderate or severe 
liver disease 
3 572.2-582.8*, 
456.0-456.2x* 
572.2-572.4*, 456.0-
456.2x*, 39.1(P)*, 
42.91(P)*† 
070, 570, 572 
Metastatic solid tumor 6 196.x-199.x 196.x-199.x*† 196-199 
AIDS 6 042.x-044.x 042.x-044.x  
(P) follows all ICD-9-CM codes that describe procedures rather than diagnoses (Vol.III). 
* The codes with asterisks are included in the definition of a comorbidity if they are listed during either index or 
prior hospital discharges ; other codes are included only if recorded prior to the index discharge. Each asterisk 
applies to all codes within the indicated range. 
†In the Dartmouth-Manitoba algorithm, these comorbidities take precedence over less severe comorbidities 
involving the same organ system. 
Adapted from:  
Needham DM, Scales DC, Laupacis A, Pronovost PJ. A systematic review of the Charlson comorbidity index using 
Canadian administrative databases: a perspective on risk adjustment in critical care research. J Crit Care. 2005; 
20(1):12-19 
Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: 
differing perspectives. J Clin Epidemiol. 1993; 46(10):1075-1079; discussion 1081-1090 
D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with 
administrative data bases. J Clin Epidemiol. 1996; 49(12):1429-1433 
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Table 3.3 Operational Definition of Study Variables 
Variables Operational Definition 
Dependent Variable 
Dose escalation1 When average of all subsequent weekly dose (i.e., (total 
dispensed quantities for all subsequent prescriptions in 
mg/ total days supply for all subsequent prescriptions) 
x 7); is greater than the weekly dose of the index 
prescription by 1.5 (150%) 
1 = Dose escalation (if above criterion is met) 
0 = No dose escalation (if above criterion is not met) 
Medication adherence2 TNF3 medication adherence in the post-index period4 
measured using MPR5 
1 = Non-Adherent (MPR< 0.8 or 80%) 
0 = Adherent (MPR≥0.8 or 80%) 
Medication persistence (MP) Number of days of continuous therapy on index 
medication without a specified gap in the post-index 
period4. A 60-day gap period will be used but sensitivity 
analyses was conducted using 30-, 45-, 90- and 120-day 
gap periods 
1 = Non-persistent (MP <292 days)6 
0 = Persistent (MP≥292 days)6 
Medication discontinuation Presence of greater than a 60-day gap period between 
consecutive prescriptions or a switch from an index 
TNF3 inhibitor therapy. Sensitivity analyses was 
conducted using 30-,  45-, 90- and 120-day gap periods 
1 = Discontinued index medication  
0 = Did not discontinue index medication 
Medication switch Starting a RA biologic agent that is different from the 
index TNF3 inhibitor  therapy 
1 = Switched from index medication 
0 = Did not switch from index medication  
Medication dosing patterns Initial dose, dose category changes (i.e., patients moving 
to higher doses) 
Post-index total healthcare utilization 
cost 
Total direct medical and medication costs7 in the post-
index period4, adjusted to 2011 US dollars  
Post-index RA8 related healthcare 
utilization cost 
Total RA-related direct medical and medication costs7 
(associated with ICD-9-CM code 714.0x)9 in the post-
index period4, adjusted to 2011 US dollars  
TNF3  medication cost Total cost7 of the index TNF inhibitor medication in the 
post-index period4, adjusted to 2011 US dollars  
 
Independent Variables 
Type of TNF3 inhibitor prescribed 1 = Etanercept (ETN) 
2 = Adalimumab (ADA) 
3 = Infliximab (IFX) 
Covariates 
Age10 Age of  the subject at index date 
Gender10 1 = Female 
0 = Male 
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Variables Operational Definition 
Race/ Ethnicity10 1 = White 
2 = Black 
3 = Hispanic 
4 = Others 
Use of other RA8 related medications10 Presence of a prescription for at least one medication in 
each group of non-study RA related medications in the 
pre-index period 
1 = DMARD11 medication 
0 = No DMARD11 medication 
1 = Glucocorticoid medication 
0 = No glucocorticoid medication 
1 = Pain medication 
0 =No pain medication 
Total number of non-study RA8 related 
medications10 
Total number of non-study RA8 related medications 
(NSAIDs,  cyclooxygenase-2-inhibitors, narcotic 
analgesics, tramadol, glucocorticoids and non-biologic 
DMARDs) at index date 
Charlson Comorbidity Index 
score10(Dartmouth-Manitoba codes) 
The sum of weights related to each comorbid condition 
at index (See Table 3.2) 
Pre-index RA8-related visits10 Visits associated with ICD-9-CM9 code 714.0x 
Pre-index non-RA8 related visits10 Other visits not associated with ICD-9-CM9 code 714.0x 
Pre-index total healthcare utilization 
cost7,10 
Total direct medical and medication costs7 in the pre-
index period12, adjusted to 2011 US dollars  
Specialty of  prescribing physician10,13 1 = Rheumatologist 
2 = General or Family practice practitioner 
3 = Others 
1 In addition, the average weekly dose for all subsequent prescriptions must be greater than 50mg for patients on 
etanercept (ETN) or 20mg for patients on adalimumab (ADA) 
2 Based on the obtained MPR values, mean adherence (mean MPR), and proportion of adherent patients (using 
0.80 or 80% cut-off point with MPR≥ 0.80 or  80% referred to as being adherent) were determined for each TNF 
inhibitor. Sensitivity analysis will be conducted at 70 and 90 percent cut-off values 
3Tumor necrosis factor 
4Twelve months follow-up period from the index date 
5Medication possession ratio= Sum of days supply for all fills x 100 ÷ Number of days in study period 
6Using a 80% cut-off as used with adherence (80% x 365days= 292 days) 
7Costs to the Texas Medicaid program 
8Rheumatoid arthritis 
9 International Classification of Diseases, Ninth Revision, Clinical Modification 
10 Included as variables for the propensity scoring matching  
11Disease modifying antirheumatic drugs 
12Six months period (July 1, 2003 to Dec., 31, 2003) prior to the index date (January 1, 2003 to August 31, 2010);  
13 Specialty of prescribing physician was dropped due to greater than 10 percent of subjects have missing 
information on this variable  
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3.1.4 Statistical Analysis 
All data manipulation and statistical analyses were performed using SAS for 
Windows, Version 9.2 (SAS Institute, Cary, NC). All statistical analyses were two-
tailed and the significance level was set a priori at p < 0.05. Frequencies, skewness, 
kurtosis and normality tests were computed to check for data abnormalities and 
normality distribution. Due to baseline differences in the study covariates among the 
study groups, a propensity score technique was used.199 Propensity scores were 
generated using multinomial logistic regression and the study groups were matched 
using a 3-way match (nearest neighbor) with caliper set at 0.05.200 To determine if a 
balance was achieved among the matched groups, differences between matched pairs 
were evaluated on each of the study covariates using the paired t-test or signed-rank 
test for continuous data and the McNemar's test for binary data.199 Bonferroni 
correction was used to control for type 1 error due to multiple comparisons. 
Descriptive statistics (mean, standard deviation and frequency) were used to 
summarize baseline socio-demographics, clinical characteristics and healthcare 
utilization cost patterns. Based on the type (categorical or continuous) and the 
distribution of data, appropriate statistical tests, which accounted for the matched 
nature of the final study sample, were conducted. Specific analytical test(s) for each 
study objective/hypothesis are presented in Table 3.4.   
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Table 3.4 Summary of Hypotheses, Study Measure(s) and Statistical Techniques 
Objectives/ Hypotheses Dependent Variablea Measurement 
Level 
Independent 
Variable 
Measurement 
Level 
Statistical Analysis 
Objective 1: To describe and compare 
baseline socio-demographics and 
clinical characteristics of Texas 
Medicaid RA patients on etanercept 
(ETN), adalimumab (ADA) or 
infliximab (IFX) 
bAge Continuous Type of TNF 
inhibitor 
Nominal Descriptive statistics‡ & 
ANOVA 
bGender Nominal Descriptive statisticsc & 
Pearson Chi-square (X2) 
bRace Nominal Descriptive statisticsc & 
Pearson Chi-square (X2) 
bUse of other RA-related 
medications 
Nominal Descriptive statisticsc & 
Pearson Chi-square (X2) 
bTotal number of non-
study RA-related 
medications 
Continuous Descriptive statisticsc & 
ANOVA 
bCharlson Comorbidity 
Index 
Continuous Descriptive statisticsc & 
Kruskal-Wallis 
bTotal number of RA-
related visits 
Continuous Descriptive statisticsc & 
Kruskal-Wallis 
bTotal number of  non 
RA-related visits 
Continuous Descriptive statisticsc & 
Kruskal-Wallis 
bPre-index total 
healthcare utilization 
cost 
Continuous Descriptive statisticsc & 
Kruskal-Wallis 
bSpeciality of prescribing 
physician 
Nominal Descriptive statisticsc & 
Pearson Chi-square (X2) 
Objective 2: To describe medication 
dosing patterns (initial or starting dose 
and dose category changes) among 
ETN, ADA and IFX users. 
Initial or starting dose Nominal Descriptive statisticsc  
Dose category changes Nominal Descriptive statisticsc  
Objective 3: To  determine if the likelihood of having a dose escalation among ETN users differs  significantly compared to ADA and IFX users while 
controlling for covariatesd  
H1: The likelihood of having a dose 
escalation is significantly lower among RA 
patients on ETN compared to patients on 
ADA and IFX while controlling for 
covariatesd 
 
Dose escalation 
(dichotomous- i.e., Yes or 
No)  
Nominal Type of TNF 
inhibitor  
Nominal Conditional logistic 
regressione 
(Regression analysis) 
 
 102 
Objectives/ Hypotheses Dependent Variablea Measurement 
Level 
Independent 
Variable 
Measurement 
Level 
Statistical Analysis 
Objective 4: To determine if medication use patterns (adherence, persistence, discontinuation and switching) among ETN users differ significantly 
compared to ADA and IFX users while controlling for covariatesd  
Ho2A: There is no significant difference in 
medication adherence to ETN compared to 
ADA and IFX while controlling for 
covariatesd 
Medication adherence 
(MPR) 
Continuous Type of TNF 
inhibitor  
Nominal GLM model estimated 
with GEEf 
(Regression analysis) 
Ho2B: The likelihood of being adherent 
(MPR≥80%) to ETN does not differ 
significantly compared to ADA and IFX 
while controlling for covariatesd 
Medication adherence 
(dichotomous- MPR< 
0.80 or 80% and MPR≥ 
0.80 or 80%) 
Nominal Type of TNF 
inhibitor 
Nominal Conditional logistic 
regressione 
(Regression analysis) 
 
Ho3: There is no significant difference in  
medication persistence to ETN compared 
to ADA and IFX while controlling for 
covariatesd 
Medication persistence  Continuous Type of TNF 
inhibitor 
Nominal GLM model estimated 
with GEEf 
(Regression analysis)  
Ho4: The likelihood of discontinuing ETN 
does not differ significantly compared to 
ADA and IFX while controlling for 
covariatesd 
Medication 
discontinuation 
(dichotomous- Yes or 
No) 
Nominal Type of TNF 
inhibitor 
Nominal Conditional logistic 
regressione 
(Regression analysis) 
Ho5: There is no significant difference in 
duration of medication use prior to 
discontinuation of ETN compared to ADA 
and IFX while controlling for covariatesd 
Medication persistence 
(Survival time) 
Continuous Type of TNF 
inhibitor  
Nominal Cox proportional 
hazards regressiong 
(Regression analysis) 
Ho6: There is no significant difference in 
the likelihood of switching from index TNF 
inhibitor therapy to another biologic agent 
among ETN users compared to ADA and 
IFX users while controlling for covariates. d 
Medication switching 
(dichotomous- Yes or 
No) 
Nominal Type of TNF 
inhibitor 
Nominal Conditional logistic 
regressione 
(Regression analysis) 
Ho7: There is no significant difference in 
duration of medication use prior to 
switching from index TNF inhibitor 
therapy among ETN users compared to 
ADA and IFX users while controlling for 
covariatesd 
Medication persistence Continuous Type of TNF 
inhibitor  
Nominal GLM model estimated 
with GEEf 
(Regression analysis) 
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Objectives/ Hypotheses Dependent Variablea Measurement 
Level 
Independent 
Variable 
Measurement 
Level 
Statistical Analysis 
Objective 5: To determine if  total healthcare utilization cost for ETN users  differs  significantly compared to ADA and IFX users while controlling 
for covariatesd  
H8:Total healthcare utilization cost  is 
significantly lower for ETN patients 
compared to patients on ADA and IFX 
while controlling for covariatesd 
Total healthcare cost  Continuous Type of TNF 
inhibitor  
Nominal GLM model estimated 
with GEEf 
(Regression analysis) 
Objective 6: To determine if  RA-related  healthcare utilization cost for ETN users  differs  significantly compared to ADA and IFX users while 
controlling for covariatesd 
H9:RA-related healthcare utilization costh 
is significantly lower for ETN patients 
compared to patients on ADA and IFX 
while controlling for covariatesd 
RA-related healthcare 
cost 
Continuous Type of TNF 
inhibitor 
Nominal GLM model estimated 
with GEEf 
(Regression analysis) 
H10: TNF medication cost is significantly 
lower for ETN patients compared to 
patients on ADA and IFX while controlling 
for covariatesd 
TNF medication cost Continuous Type of TNF 
inhibitor  
Nominal GLM model estimated 
with GEEf 
(Regression analysis) 
Objective 7: To determine if RA-related healthcare utilization cost is associated with adherence/persistence to TNF inhibitors (ETN, ADA or IFX) 
while controlling for covariatesd 
H11: RA-related healthcare utilization cost 
is significantly and positively related to 
TNF medication adherence while 
controlling for covariatesd 
RA-related healthcare 
utilization cost 
Continuous Medication 
adherence 
(MPR) 
Continuous GLM model estimated 
with GEEf 
(Regression analysis) 
H12: RA-related healthcare utilization cost 
is significantly and positively related to 
TNF medication persistence while 
controlling for covariatesd  
RA-related healthcare 
utilization cost 
Continuous Medication 
persistence 
Continuous GLM models  estimated 
using GEEf 
(Regression analysis) 
ADA= adalimumab; ANOVA= analysis of variance; ETN= etanercept; GEE= generalized estimating equation; GLM=generalized linear model; IFX= infliximab; 
MPR= Medication possession ratio; RA= rheumatoid arthritis; TNF= Tumor necrosis factor; 
aDoes not apply to the variables under the first objective; bThese are baseline covariates and are not dependent variables; cMean, standard deviation and 
frequency; dCovariates include age, gender, pre-index use of other RA-related medications, total number of other RA-related medications use at index, Charlson 
Comorbidity index, pre-index total RA-related visits, pre-index total non-RA related visits, pre-index RA-related healthcare utilization cost, specialty of 
prescribing physician; eUsed instead of  the traditional logistic regression to account for the matched nature of the sample; fUsed instead of multiple regression 
to account for the matched nature of the sample; gMatched nature of the sample was accounted for using the strata statement. Note: For the GLM models a 
gamma distribution was assumed due to the violation of the normality assumption.  
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3.1.4.1 Statistical Tests Assumptions and Sample Size Calculations 
This section discusses the test assumptions as well as sample size calculations 
for the statistical analyses presented in Table 3.4.  Sample size calculations were not 
conducted for statistical tests under objectives 1 and 2 as they involved baseline 
comparisons and descriptive statistics. 
 
Multiple Regression Analysis 
Multiple regression analysis is an example of a general linear model. It 
requires that the data to be analyzed is a random sample from a population in which 
the following assumptions are met: (1) linear relationship between the dependent 
and independent variables; (2) homoscedasticity of variance – the variance of the 
residuals about the predicted dependent variable values must be the same or 
constant for all predicted values; (3) normal distribution of residuals about the 
predicted dependent variable values; (4) independence of errors of prediction; and 
(5) lack of multicollinearity (or correlations) among independent variables. The 
multiple regression model is presented in Figure 3.4. Using the G-Power software, an 
estimated total sample size of 850 patients (power = 0.8; α = 0.05; small effect size (f) 
= 0.02; number of predictors = 11) were required for a multiple regression analysis. 
4,201-203  
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Figure 3.4 Multiple Regression Model 
Y= β0 + β1X1 + β2X2 + … + βnXn  
 Y is the dependent or response variable  
 β0 is the intercept  
 β1 to βn are the regression coefficients  
 X1 to Xn are the independent or predictor variables 
 
Cox Proportional Hazards Regression Analysis 
To address part of objective 4, Cox proportional hazards regression analysis 
was employed. However, a strata statement was included to account for the matched 
nature of the study sample. The Cox proportional hazards regression is an example of 
a survival analysis (which is also an example of a general linear model) that allows 
for control of covariates. It is expressed in the form below in Figure 3.5. The Cox 
proportional hazards regression is a semi-parametric model with model assumptions 
similar to those for parametric models but it makes no assumptions about the form 
or shape of the underlying hazard (h(t)).  It assumes parametric form for the effect of 
the predictors on the hazard and interprets parameter estimates in the same way as 
obtained in parametric models. 
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Figure 3.5 Cox Proportional Hazards Regression Model 
h (t/X) = h (t) exp (X1β1 + ……+ Xnβn) 
 h(t) is the hazard function and represents risk changes with time and it is the non-
parametric part of the model  
 exp represents the effect of covariates 
 X1 to Xn are the predictor variables and are assumed to act addictively on log h(t/x) 
 β1 to βn are the regression coefficients  
 log h(t/x) changes linearly with the βs 
 The effect of the predictors is the same at all times t 
 
Using the PASS 11 software and varying the parameters required for sample 
size calculations over a range of values, the largest sample size obtained was chosen 
as the required sample size for the Cox proportional hazards regression. Table 3.5 
presents the estimates of sample sizes required for the Cox proportional hazards 
regression analysis. Based on the estimates of sample size obtained, an estimated 
total sample size of 1,662 patients (power = 0.8; α = 0.05) was required for the Cox 
proportional hazards regression analysis.31,204,205 
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Table 3.5 Estimates of Sample Size for Cox-Proportional Hazard Regression 
Analysis  
B (log Hazard ratio)a 1.5 1.5 1.5 1.5 1.5 
P(Overall Event Rate)b 0.3 0.35 0.4 0.45 0.5 
R-squaredc 0.1 0.1 0.1 0.1 0.1 
Total Sample Size 1292 1108 969 862 776 
 
B (log Hazard ratio)a 1.5 1.5 1.5 1.5 1.5 
P(Overall Event Rate)b 0.3 0.35 0.4 0.45 0.5 
R-squaredc 0.2 0.2 0.2 0.2 0.2 
Total Sample Size 1454 1246      
1091
 
1091 
969 873 
 
B (log Hazard ratio)a 1.5 1.5 1.5 1.5 1.5 
P (Overall Event Rate)b 0.3 0.35 0.4 0.45 0.5 
R-squaredc 0.3 0.3 0.3 0.3 0.3 
Total Sample Size 1662 1424 1246 1108 997 
 
B (log Hazard ratio)a 2.0 2.0 2.0 2.0 2.0 
P(Overall Event Rate)b 0.3 0.35 0.4 0.45 0.5 
R-squaredc 0.1 0.1 0.1 0.1 0.1 
Total Sample Size 727 623 546 485 437 
 
B (log Hazard ratio)a 2.0 2.0 2.0 2.0 2.0 
P(Overall Event Rate)b 0.3 0.35 0.4 0.45 0.5 
R-squaredc 0.2 0.2 0.2 0.2 0.2 
Total Sample Size 818 701 614 546 491 
 
B (log Hazard ratio)a 2.0 2.0 2.0 2.0 2.0 
P (Overall Event Rate)b 0.3 0.35 0.4 0.45 0.5 
R-squaredc 0.3 0.3 0.3 0.3 0.3 
Total Sample Size 935 801 701 623 561 
Y = dependent variable; X = independent variables (IV); α = 0.05 (two tailed), β = 0.20 (power = 80%) 
a Known as the regression coefficient defined as the predicted change in log(base e) hazards at one unit change 
in X1  when the other covariates are held constant 
b Denotes the the proportion of subjects in which the event of interest occurs during the duration of the study 
(Based on values reported in the across studies in the literature). The modeled event was medication 
discontinuation over a 12-month follow-up period 
 c The value achieved when X1  is regressed on the other IVs or covariates in the regression 
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Generalized Linear Models 
Generalized linear models (GLMs) are flexible generalizations of ordinary 
linear regression. They are used to relate responses to linear combinations of 
predictor variables and can be used for analyses in which the response variables have 
either normal or non-normal distributions.206 A general linear model (e.g., linear 
regression) can be defined as a GLM with a normal distribution and an identity link 
function.206 GLMs consist of 3 components: the response or dependent variable 
distribution which is also called the exponential family; a linear predictor; and a link 
function.206 The exponential family is the particular distribution (e.g., normal, 
exponential, gamma, inverse Gaussian, Poisson, binomial, categorical, multinomial 
and Bernoulli) from which the response variable (Y) is derived. The variance of the 
distribution of the response variable (Y) is a function (v) of the mean of the 
distribution (μ) and possibly, the dispersion parameter (ϕ).207 The linear predictor 
(η) incorporates information about the independent variables (X) into the model 
while the link function (g) provides the relationship between the linear predictor (η) 
and the mean of the distribution function (μ). The relationship among the 
components of the GLMs is presented in Figure 3.6. Examples of commonly used 
distributions and their canonical link functions are also presented in Table 3.6.  
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Figure 3.6 Relationships across Components of Generalized Linear Models 
η = Xβ   
E(Y) = μ = g-1(Xβ) = g-1(η) 
Var (Y) = ϕ w-1 V (μ) = ϕ w-1 V (g-1 (Xβ)) = ϕ w-1 V (g-1(η))   
 X = the independent variables 
 β = the unknown parameters which can be estimated using maximum likelihood 
 Xβ = the linear combination of unknown parameters and is equivalent to the link 
predictor (η)  
 E(Y) = the expected value of the response or dependent variable (Y) 
 μ = the mean of the distribution 
 g = link function 
 Var (Y) = the variance of the distribution (i.e., dependent variable (Y)) and this is a 
function (v) of the mean of the distribution and possibly, the dispersion parameter (ϕ) 
 W is a prior weight that specifies the precision of Y 
 
 
  
Adapted from: Breslow NE. Generalized linear models: checking assumptions and strengthening conclusions. 
http://biostat.georgiahealth.edu/~dryu/course/stat9110spring12/land16_ref.pdf.  Accessed May 1, 2012 
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Table 3.6 Common Distributions, Uses and Canonical Link Functions  
Distribution Support of 
Distribution 
Typical Uses Link Name 
Normal Real : (- ∞, + ∞) Linear-response data Identity 
Exponential Real: (0, + ∞ ) Exponential-response 
data, scale parameters 
Inverse or log 
Gamma 
Inverse Gaussian  Inverse squared 
Poisson Integer: (0, +∞) Count of occurrences 
in fixed amount of 
time/space 
Log 
Bernoulli Integer: (0,1) Outcome of single 
yes/no occurrence 
Logit 
Binomial Integer: (0,N) Count of number of 
‘yes’ occurrences out 
of N yes/no 
occurrences 
Categorical 
 
Integer: (0, K) Outcome of  single  K-
way occurrence K-vector of integer: 
(0,1), where exactly 
one element in the 
vector has the value 1 
Multinomial K-vector of  integer:  
(0, N) 
Count of occurrences 
of different  types 
(1…K) out of  N total  
K-way occurrences 
 
In general, the key assumptions that underlie GLMs include: 1) statistical 
independence of the observations; 2) correct specification of the variance function 
(V); 3) correct specification of the dispersion effect ϕ; 4) correct specification of the 
link function (g); 5) correct form for the explanatory variables (X); and 6) lack of 
undue influence of individual observations.207  
 
Logistic Regression Analysis 
To address objective 3 and part of objective 4, a conditional logistic regression 
analysis was employed to account for the matched nature of the sample.  Logistic 
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regression is an example of generalized linear regression with the response or 
dependent variable having a binomial distribution. The following assumptions are 
required in order to employ a logistic regression model: 1) observations have to be 
independent of one another; and 2) the dependent variable has to be a dichotomous 
variable.   The logistic regression model is presented in Figure 3.7. Using the G-Power 
software, and varying the parameters required for sample size calculations over a 
range of values, the largest sample size obtained was chosen as the required sample 
size for the logistic regression. Table 3.7 presents the estimates of sample sizes 
required for the logistic regression analysis. Based on the estimates of sample size 
obtained, an estimated total sample size of 1,214 patients (power = 0.8; α = 0.05) was 
required for the logistic regression analysis. 4,201-203 
Figure 3.7 Logistic Regression Model 
Logit [Ө (x)] = log [Ө(x) / 1-Ө(x)] = β0 + β1x1 + β2x2 + ……. + βnxn 
 Ө (x) = Probability of success 
 1-Ө(x) = Probability of failure  
 β0 = Constant of equation 
 β1 to βn = Regression coefficients 
 X1 to Xn = Independent or predictor variables 
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Table 3.7 Estimates of Sample Size for Logistic Regression Analysis 
Odds Ratio 1.5 2.0 2.5 3.0 
Pr(Y=1|X=1)Hoa 0.03 0.03 0.03 0.03 
R-squaredb 0.1 0.1 0.1 0.1 
Total Sample 
Size 
944 226 112 74 
 
Odds Ratio 1.5 2.0 2.5 3.0 
Pr(Y=1|X=1)Hoa 0.03 0.03 0.03 0.03 
R-squaredb 0.2 0.2 0.2 0.2 
Total Sample 
Size 
1062 255 126 83 
 
Odds Ratio 1.5 2.0 2.5 3.0 
Pr(Y=1|X=1)Hoa 0.03 0.03 0.03 0.03 
R-squaredb 0.3 0.3 0.3 0.3 
Total Sample 
Size 
1214   291 144 95 
Y = dependent variable; X = independent variables (IV); α = 0.05 (two tailed), β = 0.20 (power = 80%), a Poisson 
distribution was assumed for the IV of interest (X1) 
a Denotes the the probability of an event under Ho (lowest possible value which translates to highest possible 
sample size after evaluating the values reported across studies in the literature). The modeled event was dose-
escalation rate over a 12-month follow-up period 
 b The value achieved when X1 is regressed on the other IVs or covariates in the regression 
 
  
Generalized Linear Model with Gamma Distribution 
Generalized linear model with gamma distribution is one of the recommended 
approaches for analyzing data with a response or dependent variable that is positive 
and continuous.208 Unlike the transformation-based approaches, back transformation 
is not required as estimations are carried out directly on the scale of the raw data. 
They are more robust to outliers and more suitable for analyzing very heavy-tailed 
data.208 For the present study, a GLM (with gamma distribution) estimated using 
generalized estimation equation (GEE) to account for the matched nature of the 
  113 
sample was used to analyze part of objective 4, and objectives 5, 6 and 7.  The 
following assumptions are required to be met: 1) observations have to be 
independent of one another; and 2) the dependent variable has to be continuous. 
Little information exists in the literature with respect to sample size 
calculation for GLMs with gamma distribution.  However, based on information from 
the literature, it can be assumed that the sample size required for a gamma 
distribution will not be greater than the required sample size for a normal 
distribution at any given power level.209 In estimating the required sample size for a 
GLM with gamma distribution, one can estimate the required sample size for a linear 
multiple regression and assume that if this is met, the study will be adequately 
powered to detect significant differences.  Using the G-Power software, for the linear 
multiple regression, an estimated total sample size of 850 patients (power = 0.8; α = 
0.05; small effect size (f) = 0.02; number of predictors = 11) was required.  A summary 
of the sample sizes required for each of the statistical analytical tests conducted is 
presented below in Table 3.8. Based on these values, a total sample size of 1,662 
subjects was required to address the study objectives. 
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Table 3.8 Summary of Sample Sizes for the Statistical Analytical Tests 
Statistical 
Analytical Tests 
Cox Proportional 
Hazards 
Regression  
Logistic Regression Generalized Linear 
Models (with 
Gamma 
Distribution) 
Required Sample 
Size 
1,662 1,214 850 
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CHAPTER 4: RESULTS 
4.1  CHAPTER OVERVIEW 
This chapter presents a detailed description of the study results. First, the 
patients’ selection process based on the inclusion criteria is presented. Then 
information on patients’ demographic profile and other study covariates are shown. 
Finally, the study objectives and the results of all associated statistical analyses are 
presented.  
4.2 EXTRACTION OF ELIGIBLE PATIENTS IN THIS STUDY 
A total of 43,330 subjects had an RA diagnosis and of those, 38,404 (88.6%) 
had no prescriptions for a biologic agent during the study period. This left a sample 
size of 4,926 of which the remaining inclusion/exclusion criteria were applied to 
obtain the final sample.  Of those, 1,542 met the study criteria.  Approximately 13% 
(N = 194; 12.6%) of these subjects had only one claim for a study TNF inhibitor within 
the 12-month study period while 1,348 subjects had at least 2 claims for the same 
study TNF inhibitor. Table 4.1 shows the study’s inclusion criteria with the 
corresponding sample sizes after implementation of each criterion.  
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  Table 4.1:  Patient Attrition in the Texas Medicaid Database 
Criteria Subjects Excluded Subjects Remaining 
N % N % 
Initial  Sample 43,330 100.0 
No prescription for a biologic agent within the 
study perioda 
38,404 88.6 4,926 11.4 
No prescription for study TNF inhibitors (ETN, 
ADA or IFX) within the identification periodb 
474 1.1 4,452 10.3 
Had any RA biologic in pre-index period 1,267 2.9 3,185 7.4 
Had claims for 2 or more study TNF inhibitors 
(ETN, ADA or IFX)  on the index date 
0 0.0 3,185 7.4 
Missing value for age 23 0.1 3,162 7.3 
Age < 18 on index date 91 0.2 3,071 7.1 
Age > 63 on index date 77 0.2 2,994 6.9 
Not continuously enrolled 180 days prior to  
index date 
436 1.0 2,558 5.9 
Not continuously enrolled 365 days after 
index date 
543 1.3 2,015 4.7 
No diagnosis of  RA in pre-index period  (180 
days prior to index date) 
254 0.6 1,761 4.1 
Had diagnosis for another disease indication 
(PsO, PsA, UC, Crohn’s, AS, JIA, NHL and CLL) 
in addition to RA diagnosis 
217 0.5 1,544 3.6 
Subjects on a SC drug with a J-Code 2 0.0 1,542 3.6 
Off-label use of drug prior to RA indication 
approval 
0 0.0 1,542 3.6 
Final sample 1,542c  
  ADA = Adalimumab; AS = Ankylosing spondylitis; CLL = Chronic lymphocytic leukemia; Crohn’s = Crohn’s 
disease; ETN = Etanercept; IFX = Infliximab; JIA = Juvenile idiopathic arthritis; NHL = Non-Hodgkin’s 
lymphoma; PsA = Psoriatic arthritis; PsO = Plaque psoriasis; SC = Subcutaneous; TNF = Tumor necrosis factor; 
UC = Ulcerative colitis 
  a July 1, 2003 to August 31, 2011 
   b January 1, 2004 to August 31, 2010 
  c 194 subjects had only one claim for a study TNF inhibitor within the 12-month study period while 1,348 
subjects had at least 2 claims for the same study TNF inhibitor within the 12-month study period 
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4.3 DESCRIPTIVE STATISTICS 
Baseline demographic and clinical characteristics of the entire study sample 
are presented below with full details shown in Table 4.2.  
4.3.1 Demographic Characteristics 
The majority of the sample (71.5%) was between 45-63 years of age, Hispanic 
(54.0%) and female (88.7%).   
4.3.2 Clinical Characteristics 
Among the three study TNF inhibitors, most of the subjects were prescribed 
ETN at index (37.5%), followed closely by IFX (36.5%), and then ADA (26.0%).  
Almost 70 percent (69.6%) of the sample used DMARDs in the pre-index period, with 
methotrexate (55.6%) being the most commonly prescribed DMARD therapy. Over 
40 percent (42.9%) of the sample received glucocorticoids in the pre-index period. 
Over one-third received prednisone (34.4%). The remaining oral glucocorticoids 
were used by approximately 6 percent (5.8%) of the sample. Approximately 8 percent 
(8.1%) of the sample received injectable glucocorticoids in the pre-index period.  
Over 70 percent (71.7%) of the sample used pain medications with narcotic 
analgesics (47.4%) being the most commonly prescribed. The majority of the sample 
were on at least 2 non-study RA-related medications (70.9%) and had a Charlson 
Comorbidity Index score ranging from 1-2 (96.8%) in the pre-index period. Slightly 
over 40 percent (41.2%) of the sample had a rheumatologist who prescribed their 
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index medication, while less than 10 percent (9.8%) had a general for family practice 
physician as the prescriber. A large percentage of subjects were in the ‘other’ (42.8%) 
category, which included various specialties within internal medicine. Of the 9,086 
total visits, the majority (83.6%) were for RA-related ambulatory care. Less than 1 
percent (0.3%) of the sample had an inpatient visit (RA and non-RA related). 
  119 
  Table 4.2:  Baseline Summary Statistics for Final Sample 
Demographic & Clinical Characteristics N % 
Age groups 
18-34 136 8.8 
35-44 304 19.7 
45-54 532 34.5 
55-63 570 37.0 
Total 1,542 100.0 
Race/ethnicity 
Caucasians 420 27.2 
African Americans 163 10.6 
Hispanics 832 54.0 
Others 127 8.2 
Total 1,542 100.0 
Gender 
Females 1,368 88.7 
Males 174 11.3 
Total 1,542 100.0 
Index TNF inhibitor 
Etanercept 578 37.5 
Adalimumab 401 26.0 
Infliximab 563 36.5 
Total 1,542 100.0 
Pre-index DMARDs utilization 
Yes 1,074 69.6 
No 468 30.4 
Total 1,542 100.0 
Types of DMARDsa 
Methotrexate 858 55.6 
Leflunomide 138 8.9 
Sulfasalazine 168 10.9 
Hydroxychloroquine 287 18.6 
Other DMARDsb 11 0.7 
Pre-index glucocorticoid utilization 
Yes 662 42.9 
No 880 57.1 
Total 1,542 100.0 
Types of  oral glucocorticoidsa 
Dexamethasone 3 0.2 
Hydrocortisone 0 0.0 
Methylprednisolone 84 5.4 
Prednisolone 3 0.2 
Prednisone 530 34.4 
Cortisone 0 0 
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  Table 4.2:  Baseline Summary Statistics for Final Sample Contd. 
Demographic & Clinical Characteristics N % 
Types of glucocorticoid injectionsa   
Corticotropin 0 0.0 
Dexamethasone 13 0.8 
Hydrocortisone 0 0.0 
Methylprednisolone 57 3.7 
Prednisolone 0 0.0 
Triamcinolone 55 3.6 
Pain medications 
Yes 1,105 71.7 
No 437 28.3 
Total 1,542 100.0 
Types of pain medicationsa 
NSAIDs 354 23.0 
COXIBs 278 18.0 
Narcotic  analgesics 731 47.4 
Tramadol 295 19.1 
Total number of non-study RA-related 
medications 
  
0  181 11.7 
1 268 17.4 
2 402 26.1 
3 378 24.5 
≥4 313 20.3 
Total 1,542 100.0 
Charlson Comorbidity Index score   
1-2 1,493 96.8 
3-4 47 3.0 
≥5 2 0.1 
Total 1,542 99.9c 
Specialty of prescribing physician 
Rheumatologist 635 41.2 
General or family practice 151 9.8 
Othersd 660 42.8 
Missing 96 6.2 
Total 1,542 100.0 
Health care resource utilization (# of visits) 
RA-related ambulatory caree 7,593 83.6 
RA-related inpatient caree 21 0.2 
Non-RA related ambulatory care 1,462 16.1 
Non-RA related inpatient care 10 0.1 
Total visits 9,086 100.0 
COXIB = cox-2 inhibitors; DMARD = disease modifying anti-rheumatic drugs; NSAIDs = non-steroidal anti-
inflammatory drugs; RA = Rheumatoid arthritis; TNF = tumor necrosis factor 
a Groups are not mutually exclusive as subjects may have used more than one medication 
b Azathioprine, chloroquine, cyclosphosphamide, cyclosporine, minocycline, and sodium  aurothiomalate (gold) 
c Does not add up to 100.0% due to rounding error 
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d Different specialties within internal medicine 
e Visits associated with ICD-9-CM code 714.0x 
4.4 STUDY OBJECTIVES 
4.4.1 Objective 1:  Description and Comparison of Baseline Characteristics 
Objective 1 was to describe and compare baseline socio-demographics and 
clinical characteristics of Texas Medicaid RA patients on etanercept (ETN), 
adalimumab (ADA) or infliximab (IFX). A description of the baseline socio-
demographics and clinical characteristics have been presented in Table 4.2. A 
summary of baseline demographic and clinical characteristics comparisons are 
presented here with full details shown in Table 4.3.  Overall, at baseline, there were 
no significant differences on all demographic characteristics among the 3 study 
groups (ETN, ADA & IFX). However, all clinical characteristics revealed significant 
differences. In general, IFX users seemed to be less severe. Although IFX users had 
more health care visitsd, their total costs at baseline were significantly lower.  
Demographic Characteristics 
When comparing ETN, ADA, and IFX, there were no statistically significant 
differences in age (p=0.1761), gender (p=0.5345) or race/ethnicity (p=0.8320).  
  
                                                          
d Primarily physician visits 
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Clinical Characteristics 
A significantly (p < 0.0001) lower proportion of subjects on IFX (62.0%) used 
DMARDs in the pre-index period when compared to ETN (73.4%) and ADA (75.1%) 
users. A significantly (p < 0.0001) lower proportion of subjects on IFX used 
glucocorticoids (29.0%) when compared to ETN (49.7%) and ADA users (52.9%). 
Similarly, a significantly (p < 0.0001) lower proportion of subjects on IFX used pain 
medications (56.7%)  when compared to ETN (81.5%) and ADA users (78.6%). 
Subjects on IFX also had a significantly (p < 0.0001) lower mean number of non-study 
RA-related medications (1.9±1.5) when compared to ETN (2.7±1.4) and ADA 
(2.5±1.3) users.  Subjects on IFX had a significantly (p < 0.0045) higher Charlson score 
(1.3±0.6) compared to ETN (1.2±0.5) and ADA (1.2±0.5) users. A significantly (p < 
0.0001) lower proportion of subjects on IFX (32.3%) had a rheumatologist prescribe 
the index medication when compared to ETN (46.0%) and ADA (46.6%) users. 
Regarding RA-related healthcare utilizationb (i.e., physician visits), there was a 
significant (p < 0.0001) difference among all study medications, with subjects on IFX 
having significantly more visits (6.5±5.3) than ETN (4.0±4.0) or ADA (4.1±2.9).  
Regarding non RA-related health care utilizatione (i.e., physician visits), IFX users had 
significantly (p < 0.0001) more visits (1.4±1.9) than ETN (0.7±1.3) or ADA (0.8±1.2). 
                                                          
e For the healthcare utilization and costs means were reported but non-parametric tests were used 
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Regarding total healthcare utilization costsa (medical and medication costs), IFX 
users had significantly (p=0.0308) lower costs ($1,854±2,620) compared to ETN 
($2,433±2,790) or ADA ($2,153±2,900). 
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Table 4.3:  Comparison of Baseline Characteristics by Type of TNF Inhibitor 
(Unmatched Population) 
 ETN 
(N=578) 
ADA 
(N=401) 
IFX 
(N=563) 
p-value 
Age, Mean(±SD)a  49.7(±10.0) 50.3(±10.0) 50.8(±9.3) 0.1761 
Females (%)b 89.6 89.0 87.6 0.5345 
Race/ethnicity (%)b    0.8320 
      Hispanics 53.5 53.6 54.7  
      Caucasians 26.6 26.9 28.1  
      African Americans 10.4 11.5 10.1  
      Others 9.5 8.0 7.1  
DMARD utilization (%)b 73.4 75.1 62.0 < 0.0001 
Glucocorticoid utilization (%)b 49.7 52.9 29.0 < 0.0001 
Pain medication (%)b 81.5 78.6 56.7 < 0.0001 
Total number of non-study RA-
related medications,   
   Mean(±SD)a 
 
 
2.7(±1.4)c 
 
 
2.5(±1.3)c 
 
 
1.9(±1.5) 
< 0.0001 
Charlson Comorbidity Indexd 
   Median 
   Mean(±SD) 
 
1.0e 
1.2(±0.5) 
 
1.0e 
1.2(±0.5) 
 
1.0 
1.3(±0.6) 
0.0045 
Specialty of prescribing physician 
(%)b, f 
   < 0.0001 
      Rheumatologist 46.0 46.6 32.3  
      General/ family practice 8.7 9.0 11.6  
      Others 45.3 44.5 39.1  
      Missing 0.0 0.0 17.1  
RA-related health care utilizationd,g-i 
    Median 
    Mean(±SD) 
 
3.0 
4.0(±4.0) 
 
3.0 
4.1(±2.9) 
 
5.0 
6.5(±5.3) 
< 0.0001 
Non-RA related health care 
utilizationd,e,i  
    Median 
    Mean(±SD)  
 
0.0e 
0.7(±1.3) 
 
0.0e 
0.8(±1.2) 
 
1.0 
1.4(±1.9) 
< 0.0001 
Pre-index total health care 
utilization costs ($) d,e,j 
    Median 
    Mean(±SD) 
 
 
1583e 
2433(±2790) 
 
 
1432e 
2153(±2900) 
 
 
1229 
1854(±2620) 
0.0308 
ADA = adalimumab; DMARD = disease modifying anti-rheumatic drugs; ETN = etanercept; IFX = infliximab;  
RA = rheumatoid arthritis; TNF = tumor necrosis factor 
a ANOVA 
b Chi-square.  
c Pairwise comparison test (i.e., Duncan); like letters were not significantly different  
d  Kruskal Wallis   
e Pairwise comparison test (i.e.,  Wilcoxon test with Type 1 error correction using Bonferroni); like letters were 
not significantly different  
f  This variable was dropped in further analysis due to missing data on >10% of IFX patients 
g Pairwise comparison test (i.e.,  Wilcoxon test with Type 1 error correction using Bonferroni) showed 
significant difference among each of the three groups 
h Visits associated with ICD-9-CM code 714.0x 
i Ambulatory and inpatient visits 
  125 
j Total direct medical and medication costs in the pre-index period, adjusted to 2011 US dollars 
 
4.4.1.2:  Use of Propensity Score Matching 
Propensity score matching is a method commonly used in observational 
studies to reduce the impact of treatment selection bias by balancing study covariates 
across the comparison groups. A subject’s propensity score (PS) is defined as the 
probability of the subject receiving a specific treatment given the subject’s observed 
covariates values. While PS matching is aimed at mimicking randomization, its 
effectiveness is highly dependent on the quality of the covariates introduced into the 
logistic regression model since PS matching only controls for known or overt biases. 
The procedure requires one to: 1) identify plausible covariates; 2) conduct a logistic 
regression to generate the PS scores; 3) conduct a PS match; and 4) test for balance 
between matched groups.199  
For the present study, since the comparison groups differed on baseline 
clinical characteristics, PS matching was conducted.199 PSs were generated using 
multinomial logistic regressionf and the study groups were matched using a 3-way 
match (nearest neighbor) with caliper set at 0.05.200 To determine if a balance was 
achieved among the matched groups, differences between matched pairs were 
                                                          
f Multinomial logistic regression is a regression model that generalizes logistic regression by allowing more 
than 2 discrete outcomes.  
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evaluated on each of the study covariates using a paired t-test or signed rank test for 
continuous data and the McNemar's test for binary data. Bonferroni correction was 
used to control for type 1 error due to multiple comparisons. Results of the matched 
groups are presented in Table 4.4.  Based on the results obtained from the balance 
test (Table 4.4), it can be inferred that the PS matching balanced the covariates across 
the comparison groups. However, 46.7% of the original sample (N = 1542) was lost 
during the PS matching process with a final matched sample of 822 remaining.        
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Table 4.4:  Comparison of Baseline Characteristics by Type of TNF Inhibitor: Propensity-Score (Caliper) 3-Way 
Matcheda† 
 ETN 
N=274 
ADA 
N=274 
p-
value 
ETN 
N=274 
IFX 
N=274 
p-
value 
ADA 
N=274 
IFX 
N=274 
p-
value 
Age, Mean(±SD)b  49.1 
(±9.8) 
48.9 
(±9.9) 
0.7638 49.1 
(±9.8) 
48.7 
(±9.6) 
0.6619 48.9 
(±9.9) 
48.7 
(±9.6) 
0.8710 
Females (%)c 88.3 88.3 1.0000 88.3 87.2 0.7982 88.3 87.2 0.7914 
Hispanics (%)c 54.0 52.6 0.7910 54.0 54.4 1.0000 52.6 54.4 0.7327 
DMARD utilization (%)c 71.5 69.0 0.5341 71.5 75.9 0.2299 69.0 75.9 0.0558 
Glucocorticoid utilization (%)c 43.8 45.3 0.7275 43.8 43.1 0.9022 45.3 43.1 0.5560 
Pain medication (%)c 75.6 77.7 0.4885 75.6 80.3 0.1112 77.7 80.3 0.3916 
Total number of non-study RA-
related medications,  Mean(±SD)b  
2.4 (±1.3) 2.4 (±1.3) 1.0000 2.4 (±1.3) 2.5 (±1.3) 0.3297 2.4 (±1.3) 2.5 (±1.3) 0.3174 
Charlson Comorbidity Index,    
Mean(±SD)d 
1.2 (±0.5) 1.2 (±0.5) 0.3679 1.2 (±0.5) 1.2 (±0.5) 0.5508 1.2 (±0.5) 1.2 (±0.5) 0.7994 
RA-related health care resource 
utilization,d-f   Median 
Mean(±SD) 
 
3.0  
4.1(±3.3) 
 
3.0  
4.1(±2.7) 
 
0.5188 
 
3.0  
4.1(±3.3) 
 
4.0 
4.5(±2.8) 
 
0.0313 
 
3.0  
4.1(±2.7) 
 
4.0 
4.5(±2.8) 
 
0.0430 
Non-RA related health care resource 
utilization,d-f   Median 
Mean(±SD) 
 
0.0  
0.8(±1.3) 
 
0.0  
0.8(±1.2) 
 
0.9650 
 
0.0  
0.8(±1.3) 
 
0.0 
0.9(±1.3) 
 
0.1679 
 
0.0  
0.8(±1.2) 
 
0.0 
0.9(±1.3) 
 
0.2472 
Pre-index total health care resource 
utilization cost ($),d,g    Median 
Mean(±SD) 
 
1477  
2097 
(±1955) 
 
1376 
1988 
(±1890) 
 
0.7230 
 
1477  
2097 
(±1955) 
 
1651 
2210 
(±2152) 
 
0.2383 
 
1376 
1988 
(±1890) 
 
1651 
2210 
(±2152) 
 
0.0747 
ADA = adalimumab; DMARD = disease modifying anti-rheumatic drugs; ETN = etanercept; IFX = infliximab; RA = rheumatoid arthritis; TNF = tumor necrosis 
factor 
a Caliper set at 0.05 
b For the matched analysis, differences between matched pairs were evaluated using paired T test 
c For the matched analysis, differences between matched pairs were evaluated using the McNemar's test 
d For the matched analysis, differences between matched pairs were evaluated using the signed rank test 
e Visits associated with ICD-9-CM code 714.0x 
f Ambulatory and inpatient visits 
g Total direct medical and medication costs in the pre-index period, adjusted to 2011 US dollars; 
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†Bonferroni correction was used to control for type 1 error due to multiple comparisons with a prior p value set at 0.0167 (0.05/n , where n=3 which is the 
number of comparisons) 
Source of macros: Rassen JA, Doherty M, Huang W, Schneeweiss S.  Pharmacoepidemiology Toolbox.  Boston, MA. http://www.hdpharmacoepi.org 
Article reference: Rassen JA, Shelat AA, Franklin JM, Glynn RJ, Solomon DH, Schneeweiss S. Matching by propensity score in cohort studies with three 
treatment groups. Epidemiology (Cambridge, Mass.). 2013; 24(3):401-409. 
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4.4.1.3 Demographic and Clinical Characteristics of the Matched Sample 
Matched subjects’ demographic and clinical characteristics at baseline are 
presented in Table 4.5. Subjects were within the ages of 18 and 63 years inclusive. 
The mean age (±SD) was 48.9(±9.8) years, and the majority of the subjects were 
between 45 and 63 years (69.2%), Hispanic (53.7%) and female (88.0%).  Over 70 
percent (72.1%) of the sample used DMARDs in the pre-index period, with 
methotrexate (58.2%) being the most commonly prescribed DMARD therapy. Over 
40 percent (44.0%) of the matched sample received glucocorticoids in the pre-index 
period. Over one-third received prednisone (36.6%). The remaining oral 
glucocorticoids were used by approximately 6 percent (5.9%) of the sample. 
Approximately 7 percent (7.3%) of the sample received injection glucocorticoids in 
the pre-index period.  Over 70 percent (77.9%) of the sample used pain medications 
with narcotic analgesics (53.2%) being the most commonly prescribed. The majority 
of the sample were on at least 2 non-study RA-related medications (75.9%) and had 
a Charlson score ranging from 1-2 (97.1%) in the pre-index period. The mean of total 
non_study RA-related medications used and mean Charlson score were 2.4 (±1.3) and 
1.2 (±0.5) respectively. Of the 4,149 total pre-index clinical visits, the majority 
(84.1%) were for RA-related ambulatory and inpatient care. The mean visits for RA-
related and non RA-related ambulatory and inpatient care were 4.2(±2.9) and 
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0.8(±1.2) visits, respectively. The mean pre-index healthcare utilization cost was 
$2,098(±2,001).   
  Table 4.5:  Baseline Summary Statistics for Matched Sample 
Demographic & Clinical Characteristics N % 
Age groups 
18-34 77 9.4 
35-44 176 21.4 
45-54 292 35.5 
55-63 277 33.7 
Total 822 100.0 
Race/ethnicity 
Caucasians 226 27.5 
African Americans 84 10.2 
Hispanics 441 53.7 
Others 71 8.6 
Total 822 100.0 
Gender 
Females 723 88.0 
Males 99 12.0 
Total 822 100.0 
Index TNF inhibitor   
Etanercept 274 33.3 
Adalimumab 274 33.3 
Infliximab 274 33.3 
Total 822 99.9a 
Pre-index DMARDs utilization 
Yes 593 72.1 
No 229 27.9 
Total 822 100.0 
Types of DMARDs utilizationb   
Methotrexate 478 58.2 
Leflunomide 75 9.1 
Sulfasalazine 79 9.6 
Hydroxychloroquine 145 17.6 
Other DMARDsc 6 0.7 
Pre-index glucocorticoid utilization 
Yes 362 44.0 
No 460 56.0 
Total 822 100.0 
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  Table 4.5:  Baseline Summary Statistics for Matched Sample Contd. 
Demographic & Clinical Characteristics N % 
Types of Oral glucocorticoidsb   
Dexamethasone 1 0.1 
Hydrocortisone 0 0.0 
Methylprednisolone 48 5.8 
Prednisolone 0 0.0 
Prednisone 301 36.6 
Cortisone 0 0.0 
Types of glucocorticoid injectionsb   
Corticotropin 0 0.0 
Dexamethasone 7 0.9 
Hydrocortisone 0 0.0 
Methylprednisolone 25 3.0 
Prednisolone 0 0.0 
Triamcinolone 28 3.4 
Pain medications 
Yes 640 77.9 
No 182 22.1 
Total 822 100.0 
Types of pain medicationsb 
NSAIDs 212 25.8 
COXIBs 161 19.6 
Narcotic  analgesics 437 53.2 
Tramadol 138 16.8 
Total number of non-study RA-related medications   
0  41 5.0 
1 157 19.1 
2 242 29.4 
3 218 26.5 
≥4 164 20.0 
Total 822 100.0 
Charlson Comorbidity Index score   
1-2 798 97.1 
≥3 24 2.9 
Total 822 100.0 
Health care resource utilization (# of visits) 
RA-related ambulatory and Inpatient cared 3,489 84.1 
Non-RA related ambulatory and Inpatient care 660 15.9 
Total visits 4,149 100.0 
COXIB = cox-2 inhibitors; DMARD = disease modifying anti-rheumatic drugs; NSAIDs = non-steroidal anti-
inflammatory drugs; RA = Rheumatoid arthritis; TNF = tumor necrosis factor 
a Does not add up to 100.0% due to rounding error 
b Groups are not mutually exclusive as subjects may have used more than one medication 
c Examples of other DMARDs: azathioprine, chloroquine, cyclosphosphamide, cyclosporine, minocycline, and 
sodium  aurothiomalate (gold); 
d Visits associated with ICD-9-CM code 714.0x 
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4.4.2 Objective 2:  Description of Medication Dosing Patterns 
Objective 2 was to describe medication dosing patterns (initial dose and dose 
category changes) among ETN, ADA and IFX users. For ADA and ETN, doses were 
calculated in terms of weekly doses by converting the days supply field into weeks 
and the quantity dispensed into milligrams. However, for IFX, dosing patterns could 
not be assessed due to lack of unit of service information needed to verify the quantity 
of vials administered (per Healthcare Common Procedure Coding System J-codes).    
The average starting weekly dose for patients on ETN was 50.1mg (±6.2). 
Ninety-six percent of patients on ETN had a starting weekly dose equivalent to the 
manufacturer’s recommended weekly dose of 50mg. A small percentage of patients 
(1.8%) on ETN had starting doses greater than 50mg.  At the end of the 12-month 
follow-up period, the average weekly dose for patients on ETN was 52.1mg (±15.4) 
with 96 percent of patients receiving the manufacturer’s recommended weekly dose 
of 50mg. A small percentage of patients (3.3%) received doses greater than 50mg 
weekly at the end of the follow-up period. However, this was an 80 percent increase 
over the proportion of patients who started at doses greater than 50mg weekly.  The 
average starting weekly dose for patients on ADA was 22.6mg (±7.8). A total of 87.6 
percent of patients on ADA had a starting weekly dose of 20mg equivalent to the 
manufacturer’s recommended dose of 4omg every other week. Twelve percent of 
patients on ADA had starting doses greater than 20mg. At the end of the 12-month 
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follow-up period, the average weekly dose for patients on ADA was 24.5mg (±9.7) 
with 79.6 percent of patients receiving a weekly dose of 20mg equivalent to the 
manufacturer’s recommended dose of 4omg every other week. Approximately 20.4 
percent of patients on ADA had doses greater than 20mg at the end of the follow-up 
period. This was a 70 percent increase over the proportion of patients who started at 
doses greater than 20mg weekly. Table 4.6 shows the descriptive statistics relating to 
the starting and ending weekly doses of patients on ETN and ADA. 
Table 4.6: Medication Starting Doses by Type of TNF Inhibitor (N = 548) 
 Starting Weekly Doses Ending Weekly Doses 
Doses in Mg N % N % 
Etanercept (ETN) 
25 6 2.2 2 0.7 
50 263 96.0 263 96.0 
75 3 1.1 3 1.1 
100 2 0.7 3 1.1 
150 0 0.0 1 0.4 
200 0 0.0 2 0.7 
Total 274 100.0 274 100.0 
≤ 50 269 98.2 265 96.7 
>50 5 1.8 9 3.3 
Total 274 100.0 274 100.0 
Adalimumab (ADA) 
10 1 0.4 0 0.0 
20 240 87.6 218 79.6 
30 3 1.1 5 1.8 
40 25 9.1 44 16.1 
60 5 1.8 6 2.2 
80 0 0.0 1 0.4 
Total 274 100.0 274 100.0 
≤20 241 88.0 218 79.6 
>20 33 12.0 56 20.4 
Total 274 100.0 274 100.0 
Infliximab (IFX)* 
TNF= tumor necrosis factor 
*IFX dose pattern could not be assessed  
  134 
4.4.3 Objective 3:  Dose Escalation  
Objective 3 was to determine if the likelihood of having a dose escalation 
among ETN users differs significantly compared to ADA and IFX users while 
controlling for covariates. A patient was classified as having a dose escalation if the 
average weekly dose for all the subsequent prescriptions for the index TNF therapy 
exceeded the weekly dose of their index prescription by 150 percent. In addition, the 
average weekly dose for all subsequent prescriptions must be greater than 50mg for 
ETN or 20mg for ADA.  For IFX, since the unit of service information was not available 
in the medical claims to determine the quantity of vials administered, cost 
information associated with the Healthcare Common Procedure Coding System J-
code 1745 (J-code for infliximab) was used as a proxy. All J-code 1745 costs were 
adjusted to 2011 US dollars using the medical consumer price index from the U.S. 
Bureau of Labor Statistics current data. Then average of all J-code 1745 subsequent 
costs was compared to the index J-code 1745 cost and if the average cost exceeded 
the index cost by 150 percent the patient was assumed to have a dose escalation. 
Overall 6.8 percent of the study sampleg had a dose escalation.  A total of 2.2 percent 
of patients on ETN had a dose escalation while 8.4 percent and 9.9 percent on IFX and 
ADA respectively, had a dose escalation. Based on unadjusted pair-wise comparison 
(McNemar’s test), the proportion of patients who had a dose escalation was 
                                                          
g See Appendix A for detailed result 
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significantly lower for patients on ETN compared to patients on ADA (S = 14.2258; df 
= 1; p < 0.0001) or IFX (S = 10.7037; df = 1; p = 0.0015).  
4.4.3.1  Dose Escalation (Conditional Logistic Regression Model) 
To determine if the likelihood of having a dose escalation among ETN users 
differs significantly compared to ADA and IFX users while controlling for covariates, 
a conditional logistic regression was conducted. The dependent variable was dose 
escalation status and the probability modeled was that of having a dose escalation. 
The independent variable was type of TNF inhibitor (ADA, ETN and IFX) therapy and 
ETN was selected as the reference therapy.  The study covariates introduced into the 
model were age, gender, race/ethnicity, pre-index use of other RA-related 
medications (DMARDs, glucocorticoids and pain medications), total number of non-
study RA-related medications used at index, Charlson Comorbidity Index score, pre-
index RA and non-RA related visits, pre-index healthcare utilization cost.  
Multicollinearity among the covariate variables (i.e., continuous variables) was 
assessed using a multiple linear regression model.  Tolerance coefficients for the 
predictor variables ranged from 0.885 (pre-index RA related visits) to 0.954 
(Charlson Comorbidity Index score).  The variance inflation factor (VIF), which is the 
inverse of tolerance, ranged from 1.048 (Charlson Comorbidity Index score) to 1.130 
(pre-index RA related visits).  Tolerance coefficient values greater than 0.1 and VIF 
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values less than 10 is an indication that there was no multicollinearity amongst the 
covariates.  
Table 4.7 shows the detailed results of the conditional logistic regression 
model comparing the likelihood of having a dose escalation by type of TNF inhibitor 
therapy while controlling for covariates.  The results of the model fit with or without 
the model parameters (explanatory) variables was inconclusive with the likelihood 
ratio test (p = 0.0215) indicating a rejection of the null hypothesis that all slope 
parameters are equal to zero while the Wald test (0.2735) and the score test (p = 
0.0908) result failed to reject the null. A rejection of the null indicates that removing 
the explanatory variables will reduce the fit of the model while failing to reject the 
null indicates that removing the explanatory variables will not impact the model fit.  
Since leaving all the explanatory variables in the model will not impact the model fit, 
they were retained.  Compared to patients on ETN, the odds of having a dose 
escalation were ≈ 5 [Odds Ratio (OR) = 4.605 [95% CI = 1.605-12.677], p = 0.0031] 
and ≈ 8 [Odds Ratio (OR) = 7.520, [95% CI = 2.461-22.983], p = 0.0004] times higher 
for IFX and ADA patients, respectively, while controlling for other variables in the 
model.  None of the covariates was significantly related to the dependent variable.  
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H1: The likelihood of having a dose escalation is significantly lower among RA 
patients on ETN compared to patients on ADA and IFX while controlling for covariates.  
(Not Rejected) 
Table 4.7: Conditional Logistic Regression Analysis Comparing the Likelihood 
of Dose Escalation among TNF Inhibitors (N = 822) 
 Odds 
Ratio 
95% CI Wald X2  p-value 
Medication Type† 
Adalimumab 7.520 2.461 22.983 12.5286 0.0004* 
Infliximab 4.605 1.673 12.677 8.7343 0.0031* 
Covariates 
Age 1.016 0.964 1.071 0.3589 0.5491 
Male† 1.001 0.216 4.635 0.0000 0.9994 
Non-Whites†  0.605 0.124 2.939 0.3883 0.5332 
Pre-index DMARD non-use 0.181 0.009 3.507 1.2777 0.2583 
Pre-index pain medications non-use 0.733 0.009 61.360 0.0190 0.8905 
Pre-index glucocorticoids non-use 0.191 0.006 5.963 0.8890 0.3458 
Pre-index RA related visits 1.223 0.499 3.000 0.1934 0.6601 
Pre-index non-RA related visits 1.526 0.380 6.128 0.3546 0.5515 
Total number of non-study RA-
related medications 
0.347 0.079 1.525 1.9631 0.1612 
Pre-index total utilization cost 1.000 0.999 1.001 0.0501 0.8229 
Charlson Comorbidity Index 1.599 0.529 4.837 0.6907 0.4059 
RA = rheumatoid arthritis; TNF = tumor necrosis factor 
†Reference categories: Etanercept, females, whites, DMARD users, glucocorticoid users and pain medication 
users. Note: Race was dichotomized into two groups (Whites and others) due to small cell sizes. 
Model Fit Statistics: likelihood ratio = 25.2373, df = 13, p = 0.0215; Score = 20.1803, df = 13, p = 0.0908; Wald = 
15.5630, df = 13, p = 0.2735 
*significant at p < 0.05 
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4.4.4 Objective 4:  Medication Use Patterns 
Objecive 4 was to determine if medication use patterns (adherence, 
persistence, discontinuation, and switching) among ETN users differ significantly 
compared to ADA and IFX users while controlling for covariates. Adherence was 
assessed both continuously and dichotomously. 
4.4.4.1 Medication Adherence 
To determine if medication adherence (continuous MPR) to ETN differs 
significantly compared to ADA and IFX, MPR was computed as a proxy for adherence 
for all the study subjects.  For IFX users, the medical claims file lacked information on 
days supply but it contained information on date of service. Days supply information 
was computed based on the time interval expected between subsequent drug 
infusions as specified by the manufacturer and adjustments were made to avoid 
overlap between subsequent infusions.  Table 4.8 shows the manufacturer 
recommended infusion intervals for IFX.  
Table 4.8 Expected Number of Infusions in 1 year for Infliximab (Remicade®) 
Infusion # 1 2 3 4 5 6 7 8 9 
Week 0 2 6 14 22 30 38 46 54 
Day 0 14 42 98 154 210 266 322 378 
Since the study subjects were biologic-naïve (no biologic in the 6-month pre-index period), their first date of service 
associated with the J-code 1745 was assumed to be day 0 and the week was assumed to be week 0 with the infusion 
as their first infusion for IFX 
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4.4.4.1a Medication Adherence (Unadjusted Analysis- Paired T-Test) 
Overall mean adherence (±SD) to the study TNF inhibitor therapies was 52.5 
percent (±29.5).  Results of unadjusted pair-wise comparison)h showed that mean 
MPR (±SD) was significantly lower for ETN users (48.8%±28.7) compared to IFX 
users (55.7%±31.9; p = 0.0045) but not significantly different compared to ADA users 
(53.0%±27.3; p = 0.0779). 
4.4.4.1b Medication Adherence (GLM-GEE Model) 
To determine if medication adherence to ETN differs significantly compared 
to ADA and IFX while controlling for covariates, a generalized linear model (GLM), 
which was estimated using a generalized estimating equation (GEE), was used. The 
dependent variable was TNF inhibitor medication adherence (continuous MPR) and 
the independent variable was type of TNF inhibitor therapy. The same covariates 
used in the conditional logistic regression for dose escalation were introduced in the 
GLM.  For the GLM, a gamma distribution and a log link was specified as the normality 
assumption was rejected based on the significance of the KS test (p < 0.01).  Table 4.9 
shows the detailed results of the GLM model estimated using a GEE. The GEE 
parameter estimate results showed that compared to patients on ETN, patients on 
IFX were significantly (p =c 0.0171) more adherent to their TNF inhibitor therapy 
                                                          
h See Appendix B for detailed result 
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while controlling for other variables in the model. There was no significant difference 
in adherence to TNF inhibitor therapy between ETN and ADA users while controlling 
for other variables in the model.  Regarding the covariates, age (p = 0.0265), gender 
(p = 0.0026), pre-index RA-related visits (p = 0.0038) and Charlson Comorbidity 
Index score-CCI (p = 0.0232) were statistically significant related to TNF inhibitor 
medication adherence while controlling for other variables in the model.  Older age 
and increase in pre-index RA-related visits were significantly associated with an 
increase in TNF inhibitor therapy medication adherence.  An increase in the CCI score 
was significantly associated with a decrease in TNF inhibitor therapy medication 
adherence.  Compared to female subjects, male subjects were significantly (p = 
0.0026) more adherent to their TNF inhibitor therapy while controlling for other 
variables in the model.  
Ho2A: There is no significant difference in medication adherence to ETN compared to 
ADA and IFX while controlling for covariates. (Rejected) 
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Table 4.9: Generalized Linear Regression Analysis Comparing Medication 
Adherence among TNF Inhibitors (N = 822) 
 Estimate 95% CI Z p-value 
Medication Type† 
Adalimumab 0.0744 -0.0180 0.1669 1.58 0.1144 
Infliximab 0.1109 0.0198 0.2020 2.39 0.0171* 
Covariates 
Age 0.0051 0.0006 0.0095 2.22 0.0265* 
Male† 0.1494 0.0520 0.2467 3.01 0.0026* 
Non-Whites†  -0.0664 -0.1519 0.0191 -1.52 0.1277 
Pre-index DMARD non-use -0.1195 -0.2396 0.0007 -1.95 0.0513 
Pre-index pain medications non-
use 
0.0060 -0.1088 0.1208 0.10 0.9183 
Pre-index glucocorticoids non-
use 
-0.0717 -0.1653 0.0220 -1.50 0.1335 
Pre-index RA related visits 0.0187 0.0060 0.0314 2.89 0.0038* 
Pre-index non-RA related visits -0.0198 -0.0561 0.0165 -1.07 0.2845 
Total number of non-study RA-
related medications 
-0.0169 -0.0654 0.0316 -0.68 0.4938 
Pre-index total utilization cost 0.0000 -0.0000 0.0000 0.52 0.6002 
Charlson Comorbidity Index -0.0989 -0.1843 -0.0135 -2.27 0.0232* 
RA = rheumatoid arthritis; TNF = tumor necrosis factor 
†Reference categories: Etanercept, females, whites, DMARD users, glucocorticoid users and pain medication 
users. Note: Race was dichotomized into two groups (Whites and others) due to small cell sizes. 
*significant at p < 0.05 
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4.4.4.1c Medication Adherence (Unadjusted Analysis-McNemar’s Test) 
Overall, 23.5 percent of the study sample were adherent (MPR ≥80%). A total 
of 21.2 percent of patients on ETN were adherent while 32.9 percent and 16.4 percent 
on IFX and ADA respectively, were adherent.i Based on unadjusted pair-wise 
comparison, the proportion of adherent patients was significantly lower for patients 
on ETN compared to patients on IFX (S = 18.5780; df = 1; p < 0.0001) but not 
significantly different compared to ADA (S = 2.1392; df = 1; p = 0.1766). 
4.4.4.1d Medication Adherence (Conditional Logistic Regression Model) 
To determine if the likelihood of adhering (dichotomous MPR) to ETN differs 
significantly compared to ADA and IFX while controlling for covariates, a conditional 
logistic regression was conducted. The dependent variable was medication 
adherence status based on patients’ adherence (MPR values). The probability 
modeled was that of being adherent (MPR ≥ 80%). The independent variable was type 
of TNF inhibitor (ADA, ETN and IFX) therapy and ETN was selected as the reference 
therapy. The same covariates used in the prior analysis were used in the conditional 
logistic regression model.  Table 4.10 shows the detailed results of the conditional 
logistic regression model comparing the likelihood of being adherent by type of TNF 
inhibitor therapy while controlling for covariates.  The results of the model fit with or 
                                                          
i See Appendix A for detailed result 
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without the model parameters (explanatory) variables was significant (p < 0.05), 
indicating a rejection of the null hypothesis that all slope parameters are equal to 
zero.  Results of maximum likelihood estimates showed that compared to patients on 
ETN, the odds of being adherent to IFX was ≈ 2 times higher [Odds Ratio (OR) = 2.437, 
[95% CI = 1.592-3.731], p < 0.0001] while controlling for other variables in the model. 
There was no significant difference in the likelihood of being adherent to TNF 
inhibitor therapy between ETN and ADA users while controlling for other variables 
in the model.  None of the covariates was significantly related with the dependent 
variable. Results were robust when sensitivity analyses were conducted at 70 and 90 
percent cut-off values for MPR. 
 
Ho2B: The likelihood of being adherent (MPR≥0.80 or 80%) to ETN does not differ 
significantly compared to ADA and IFX while controlling for covariates. (Rejected) 
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Table 4.10: Conditional Logistic Regression Analysis Comparing the 
Likelihood of being Adherent among TNF Inhibitors (N = 822) 
 Odds 
Ratio 
95% CI Wald X2  p-value 
Medication Type† 
Adalimumab 1.328 0.853 2.066 1.5800 0.2088 
Infliximab 2.437 1.592 3.731 16.8140 <.0001* 
Covariates 
Age 1.000 0.973 1.028 0.0001 0.9931 
Male† 1.431 0.679 3.012 0.8886 0.3458 
Non-Whites†  1.156 0.530 2.522 0.1329 0.7155 
Pre-index DMARD non-use 0.897 0.208 3.861 0.0215 0.8835 
Pre-index pain medications 
non-use 
1.026 0.105 10.053 0.0005 0.9826 
Pre-index glucocorticoids non-
use 
0.936 0.155 5.643 0.0053 0.9421 
Pre-index RA related visits 0.981 0.637 1.511 0.0076 0.9305 
Pre-index non-RA related visits 0.847 0.424 1.694 0.2204 0.6387 
Total number of non-study RA-
related medications 
1.015 0.502 2.053 0.0017 0.9667 
Pre-index total utilization cost 1.000 1.000 1.000 0.8375 0.3601 
Charlson Comorbidity Index 0.690 0.337 1.410 1.0357 0.3088 
RA = rheumatoid arthritis; TNF = tumor necrosis factor 
†Reference categories: Etanercept, females, whites, DMARD users, glucocorticoid users and pain medication 
users. Note: Race was dichotomized into two groups (Whites and others) due to small cell sizes. 
Model Fit Statistics: likelihood ratio = 28.7376, df = 13, p = 0.0071; Score = 28.3537, df = 13, p = 0.0081; Wald = 
25.7999, df = 13, p = 0.0181 
*significant at p < 0.05 
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4.4.4.2a Medication Persistence (Unadjusted Analysis- Paired T-Test) 
To determine if medication persistence to ETN differs significantly compared 
to ADA and IFX, a gap period of 60 days was specified with sensitivity analysis 
conducted using 30-, 45-, 90- and 120-day gap periods.  Overall, based on a 60-day 
gap period, mean persistence (±SD) to the study TNF inhibitor therapies was 203.9 
days (±132.8).  Results of unadjusted pair-wise comparisonj showed that based on a 
60-day gap, mean persistence (±SD) for ETN users (196.7±134.0 days) was not 
significantly different compared to IFX (215.6±133.5 days; p = 0.0730) and ADA users 
(199.4±130.5 days; p = 0.8132). Results of the sensitivity analysis were robust at 30-
, 45-, 90- and 120-day gap periods. 
4.4.4.2b Medication Persistence (GLM-GEE Model) 
To determine if medication persistence to ETN differs significantly compared 
to ADA and IFX while controlling for covariates, a generalized linear model (GLM), 
which was estimated using a generalized estimating equation (GEE), was used. The 
dependent variable was TNF inhibitor medication persistence and the independent 
variable was type of TNF inhibitor therapy. The same covariates used in the previous 
analyses were used in the GLM.  For the GLM, a gamma distribution and a log link was 
specified as the normality assumption was rejected based on the significance of the 
                                                          
j See Appendix B for detailed result 
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KS test (p < 0.01).  Table 4.11 shows the detailed results of the GLM model estimated 
using a GEE. The GEE parameter estimate results showed that compared to patients 
on ETN, there was no significant difference in ADA or IFX users’ persistence to TNF 
inhibitor therapy while controlling for other variables in the model.   
Regarding the covariates, age (p = 0.0206), pre-index RA-related visit (p = 
0.0009), gender (p = 0.0043) and Charlson comorbidity index (CCI) score (p = 0.0291) 
were significantly related to persistence to TNF inhibitor therapy while controlling 
for other variables in the model.  Older age and increase in pre-index RA-related visits 
were associated with increase in persistence to TNF inhibitor therapy.  An increase in 
the CCI score was associated with a significant decrease in persistence on TNF 
inhibitor therapy. Compared to female subjects, male subjects were significantly 
more persistent to their TNF inhibitor therapy while controlling for other variables 
in the model.  Results were robust when sensitivity analyses were conducted using 
90- and 120-day gap periods.  Only pre-index RA-related visit was significantly 
related to persistence when a 30-day gap period was specified.  With the 45-day gap 
period, only pre-index RA-related visit and gender were significantly related to 
persistence with male subjects being more persistent compared to female subjects. 
   
Ho3: There is no significant difference in medication persistence to ETN compared to 
ADA and IFX while controlling for covariates. (Not Rejected) 
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Table 4.11: Generalized Linear Regression Analysis Comparing Medication 
Persistence among TNF Inhibitors (N=822) 
 Estimate 95% CI Z p-value 
Medication Type† 
Adalimumab 0.0040 -0.1075 0.1154 0.07 0.9443 
Infliximab 0.0721 -0.0298 0.1739 1.39 0.1656 
Covariates 
Age 0.0061 0.0009 0.0113 2.32 0.0206* 
Male† 0.1715 0.0538 0.2892 2.86 0.0043* 
Non-Whites†  -0.0564 -0.1577 0.0449 -1.09 0.2748 
Pre-index DMARD non-use -0.0871 -0.2159 0.0416 -1.33 0.1847 
Pre-index pain medications non-
use 
-0.0043 -0.1345 0.1259 -0.06 0.9482 
Pre-index glucocorticoids non-
use 
-0.0601 -0.1700 0.0499 -1.07 0.2845 
Pre-index RA related visits 0.0203 0.0050 0.0356 2.61 0.0092* 
Pre-index non-RA related visits -0.0199 -0.0600 0.0203 -0.97 0.3320 
Total number of non-study RA-
related medications 
0.0009 -0.0522 0.0539 0.03 0.9741 
Pre-index total utilization cost 0.0000 -0.0000 0.0000 0.97 0.3298 
Charlson Comorbidity Index -0.1094 -0.2077 -0.0111 -2.18 0.0291* 
RA= Rheumatoid arthritis; TNF= tumor necrosis factor 
†Reference categories: Etanercept, females, whites, DMARD users, glucocorticoid users and pain medication 
users. Note: Race was dichotomized into two groups (Whites and others) due to small cell sizes. 
*significant at p < 0.05 
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4.4.4.3 Medication Discontinuation 
Discontinuation was defined as the presence of greater than a 60-day gap 
period between consecutive prescriptions or a switch from an index TNF inhibitor 
therapy. Sensitivity analyses were conducted using 30-, 45-, 90- and 120-day gap 
periods. Medication discontinuation was assessed dichotomously using conditional 
logistic regression and continuously using Cox-proportional hazard regression. 
4.4.4.3a Medication Discontinuation (Unadjusted Analysis- McNemar’s Test) 
Overall 64.8 percent of the study sample discontinued their index TNF 
inhibitor therapy. Approximately 67 percent (66.8%), 62.0 percent and 65.7 percent 
of patients on ETN, IFX and ADA respectively, discontinued their therapy.k Based on 
unadjusted pair-wise comparison, the proportion of patients on ETN who 
discontinued index TNF inhibitor therapy was not significantly different compared to 
those on IFX (S = 1.4956; df = 1; p = 0.2589) and ADA (S = 0.0720; df = 1; p = 0.8581). 
Results of sensitivity analysis were robust at 30-, 45-, 90- and 120-day gap periods. 
4.4.4.3b Medication Discontinuation (Conditional Logistic Regression Model) 
To determine if the likelihood of discontinuing ETN differs significantly 
compared to ADA and IFX while controlling for covariates, a conditional logistic 
                                                          
k See Appendix A for detailed result 
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regression was conducted. The dependent variable was medication discontinuation 
status. The probability modeled was discontinuation of the index TNF inhibitor 
therapy. The independent variable was type of TNF inhibitor (ADA, ETN and IFX) 
therapy and ETN was selected as the reference therapy. The same covariates as used 
in prior analyses were used in the conditional logistic regression model.   
Table 4.12 shows the detailed results of the conditional logistic regression 
model comparing the likelihood of discontinuing index TNF inhibitor therapy by type 
of TNF inhibitor therapy while controlling for covariates.  The results of the model fit 
with or without the model parameters (explanatory) variables was not significant 
(p>0.05) indicating a failure to reject the null hypothesis that all slope parameters are 
equal to zero.  Results of maximum likelihood estimates showed that compared to 
patients on ETN, there was no significant difference in ADA or IFX users likelihood to 
discontinue index TNF inhibitor therapy while controlling for other variables in the 
model.  Regarding the covariates, only CCI was significantly related to the likelihood 
of discontinuing index TNF inhibitor therapy and for every unit increase in CCI score, 
the odds to discontinue index TNF inhibitor therapy were ≈2 times higher while 
controlling for other variables in the model [Odds Ratio (OR) = 1.931, [95% CI = 
1.028-3.629], p = 0.0409]. Results were robust when sensitivity analyses were 
conducted using 45, 90- and 120-day gap periods with none of the covariates 
significantly related to the dependent variable.  When a 30-day gap period was 
specified, the odds to discontinue index TNF inhibitor therapy was 36.2 percent lower 
for IFX patients compared to ETN patients while controlling for other variables in the 
model [Odds Ratio (OR) = 0.638, [95% CI = 0.420-0.970], p = 0.0356]. There was no 
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significant difference in the likelihood to discontinue index TNF inhibitor therapy 
between ETN and ADA users while controlling for other variables in the model.  None 
of the covariates was significantly related to the dependent variable.  
 
Ho4: The likelihood of discontinuing ETN does not differ significantly compared to ADA 
and IFX while controlling for covariates. (Not Rejected) 
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Table 4.12: Conditional Logistic Regression Analysis Comparing the 
Likelihood of Discontinuing Index TNF Inhibitor Therapy (N = 822) 
 Odds 
Ratio 
95% CI Wald X2  p-value 
Medication Type† 
Adalimumab 0.957 0.660 1.387 0.0543 0.8158 
Infliximab 0.854 0.595 1.228 0.7226 0.3953 
Covariates 
Age 0.998 0.975 1.021 0.0313 0.8597 
Male† 0.793 0.410 1.535 0.4728 0.4917 
Non-Whites†  0.709 0.344 1.463 0.8645 0.3525 
Pre-index DMARD non-use 1.325 0.360 4.875 0.1791 0.6722 
Pre-index pain medications 
non-use 
3.894 0.494 30.718 1.6642 0.1970 
Pre-index glucocorticoids non-
use 
1.342 0.267 6.751 0.1270 0.7215 
Pre-index RA related visits 1.276 0.857 1.900 1.4360 0.2308 
Pre-index non-RA related visits 1.815 0.961 3.427 3.3730 0.0663 
Total number of non-study RA-
related medications 
0.545 0.285 1.041 3.3839 0.0658 
Pre-index total utilization cost 1.000 0.999 1.000 4.7213 0.0298 
Charlson Comorbidity Index 1.931 1.028 3.629 4.1803 0.0409* 
TNF = tumor necrosis factor 
†Reference categories: Etanercept, females, whites, DMARD users, glucocorticoid users and pain medication 
users. Note: Race was dichotomized into two groups (Whites and others) due to small cell sizes. 
Model Fit Statistics: likelihood ratio = 17.0324, df = 13, p = 0.1978; Score = 16.8305, df = 13, p = 0.2072; Wald = 
15.7274, df = 13, p = 0.2642 
*significant at p < 0.05 
 
 
  152 
4.4.4.3c Medication Discontinuation (Cox-Proportional Hazards Regression 
Model) 
 To determine if duration of medication use (i.e., persistence) prior to 
discontinuation of ETN differs significantly compared to ADA and IFX while 
controlling for covariates, a Cox proportional hazards regression model was used.  An 
important step in utilizing a Cox proportional hazards regression model lies in 
ensuring that appropriate covariates and censoring mechanisms are selected and that 
the assumption of proportionality of hazards is not violated.210,211 The 
proportionality of hazards assumption suggests that the shapes of the survival 
functions are similar for all the treatment groups and that the effect of each covariate 
is independent of time. A violation of this assumption implies that the coefficient of 
the variable being estimated by the model is an average effect of the variable over the 
range of times observed in the data.210  A commonly used approach in testing for the 
assumption lies in introducing an interaction of each study covariate and the natural 
logarithm of time (survival time) into the model and check for the significance of each 
interaction term.210  Other approaches to test for the proportionality assumption 
involve visually checking the lines (shapes) of the survival functions for each 
treatment level to see if they are parallel or plotting scaled Schoenfield residuals 
against time to determine if a relationship exists between the covariate and time. 211 
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 Results of the proportionality assumption test are presented in Table 4.13.  
The exposure variable was independent of time since it was defined at the point of 
entry into the cohort. Patients were censored if they did not discontinue index TNF 
therapy within the follow-up period. Discontinuation was defined as presence of 
greater than a 60-day gap period between two consecutive prescriptions or a switch 
from an index TNF inhibitor therapy. The survival time was the duration of time of 
continuous therapy on index TNF inhibitor therapy without switching or having 
greater than a 60-day gap period between consecutive prescriptions.   
Table 4.13:  Test for Proportionality of Hazards for Covariates 
Covariates‡ Wald Chi-
Square 
 Hazard 
Ratio 
95% Hazard Ratio CI 
 
P-Value 
Age 6.5029 0.848 0.747 0.963 0.0108* 
Male† 1.5757 0.109 0.003 3.470 0.2094 
Non-Whites†  2.8815 29.864 0.591 1507.956 0.0896 
Pre-index DMARD non-use 6.3923 0.000 0.000 0.131 0.0115* 
Pre-index pain medications 
non-use 
5.7331 0.000 0.000 0.105 0.0166* 
Pre-index glucocorticoids 
non-use 
4.1045 0.000 0.000 0.693 0.0428* 
Pre-index RA related visits 4.2765 3.220 1.063 9.756 0.0386* 
Pre-index non-RA related 
visits 
4.7194 13.678 1.292 144.856 0.0298* 
Total number of non-study 
RA-related medications 
0.0713 0.673 0.037 12.317 0.7895 
Pre-index total utilization 
cost 
0.0546 1.000 0.999 1.001 0.8152 
Charlson Comorbidity Index 6.5341 0.000 0.000 0.129 0.0106* 
‡Interaction with the natural logarithm of survival time have been tested for each variable. 
†Reference categories: Etanercept, females, whites, DMARD users, glucocorticoid users and pain medication 
users. Note: Race was dichotomized into two groups (Whites and others) due to small cell sizes. 
Model Fit Statistics: likelihood ratio = 799.6396, df = 24, p < 0.0001; Score = 443.6858, df = 24, p < 0.0001; Wald = 
14.9826, df = 24, p = 0.9213; Proportionality test X2 = 11.8434, df = 11, p = 0.3755 
*significant at p < 0.05 
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The proportionality assumption was not met for age, pre-index use of other RA-
related medications (DMARDs, glucocorticoids and pain medications), Charlson 
Comorbidity Index score, pre-index RA and non-RA related visits.  None of these 
interactions were expected because all of these variables were defined at index. 
Despite the interactions observed with each of these variables and survival time, they 
were all retained in their original forms during the Cox regression analysis since an 
interpretation of significant effects in terms of “average effects” is acceptable when 
variable effects are independent of time.210  However, in sensitivity analysis, 
interaction terms of age, pre-index use of other RA-related medications (DMARDs, 
glucocorticoids and pain medications), Charlson Comorbidity Index score, pre-index 
RA and non-RA related visits and natural logarithm of survival time were entered into 
the model to estimate the effect of exposure.  Overall, mean survival time (±SD) on 
the study TNF inhibitor therapies prior to discontinuation was 120.4 days (±84.9).l 
The mean survival times (±SD) prior to discontinuation were 116.5±85.5 days, 
127.5±90.1 days and 117.7±78.9 days, respectively, for ETN, IFX and ADA users. 
Table 4.14 shows the results of the Cox-proportional hazards regression 
model comparing the duration of medication use (i.e., persistence) prior to 
discontinuation of index therapy among ETN, ADA and IFX users while controlling for 
                                                          
l See Appendix B for detailed result 
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covariates. The results of the model fit with or without the model parameters 
(explanatory) variables was significant (p < 0.05) indicating a rejection of the null 
hypothesis that all slope parameters are equal to zero.  Results of maximum 
likelihood estimates showed that there was no significant difference in the duration 
of medication use prior to discontinuation (survival time) when ETN users were 
compared to either ADA or IFX users while controlling for other variables in the 
model.  None of the covariates was significantly related with the dependent variable.  
For the sensitivity analysis, when interaction terms of age, pre-index use of other RA-
related medications (DMARDs, glucocorticoids and pain medications), Charlson 
Comorbidity Index score, pre-index RA and non-RA related visits and natural 
logarithm of survival time were entered into the model, the hazard ratios of ADA vs 
ETN [Hazard Ratio (HR) = 0.818 [95% CI = 0.566-1.183], p = 0.2865] and IFX vs ETN 
[Hazard Ratio (HR) = 0.776 [95% CI = 0.533-1.131], p = 0.1876] remained non-
significant.  
 
Ho5: There is no significant difference in duration of medication use (i.e., persistence) 
prior to discontinuation of ETN compared to ADA and IFX users while controlling for 
covariates. (Not Rejected) 
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Table 4.14: Cox Proportional Hazards Regression Model Comparing Survival 
Time Prior to Discontinuation of Index Therapy among TNF 
Inhibitors Users  
 Hazard  
Ratio 
95% Hazard Ratio CI 
 
Wald X2  p-value 
Medication Type† 
Adalimumab 0.867 0.682 1.100 1.3812 0.2399 
Infliximab 0.784 0.612 1.004 3.7278 0.0535 
Covariates 
Age 0.991 0.977 1.006 1.4358 0.2308 
Male† 0.674 0.435 1.045 3.1087 0.0779 
Non-Whites†  1.048 0.644 1.705 0.0349 0.8518 
Pre-index DMARD non-use 0.947 0.393 2.283 0.0145 0.9043 
Pre-index pain medications 
non-use 
0.994 0.251 3.932 0.0001 0.9934 
Pre-index glucocorticoids non-
use 
0.802 0.272 2.364 0.1605 0.6887 
Pre-index RA related visits 0.976 0.748 1.273 0.0319 0.8582 
Pre-index non-RA related visits 1.001 0.659 1.521 0.0000 0.9953 
Total number of non-study RA-
related medications 
0.822 0.534 1.264 0.7998 0.3712 
Pre-index total utilization cost 1.000 1.000 1.000 0.3703 0.5429 
Charlson Comorbidity Index 1.167 0.784 1.739 0.5789 0.4468 
TNF = tumor necrosis factor 
†Reference categories: Etanercept, females, whites, DMARD users, glucocorticoid users and pain medication 
users. Note: Race was dichotomized into two groups (Whites and others) due to small cell sizes. 
Model Fit Statistics: likelihood ratio = 24.6730, df = 13, p = 0.0255; Score = 23.9996, df = 13, p = 0.0311; Wald = 
23.1066, df = 13, p = 0.0404 
*significant at p < 0.05 
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4.4.4.4a Medication Switching (Unadjusted Analysis- McNemar’s Test) 
Medication switching was defined as starting a RA biologic agent that is 
different from the index TNF inhibitor therapy. Overall 11.9 percent of the study 
sample switched from their index TNF inhibitor therapy. A total of 10.6 percent, 11.7 
percent and 13.5 percent of patients on ETN, IFX and ADA respectively, switched from 
index TNF inhibitor therapy.m Based on unadjusted pair-wise comparison, the 
proportion of patients on ETN who switched from index TNF inhibitor therapy was 
not significantly different compared to those on IFX (S = 0.1636; df = 1; p = 0.7877) 
and ADA (S = 1.0323; df = 1; p = 0.3742). 
4.4.4.4b Medication Switching (Conditional Logistic Regression Model) 
To determine if the likelihood of switching from ETN to another biologic agent 
differs significantly compared to ADA and IFX while controlling for covariates, a 
conditional logistic regression was conducted. Medication switching was defined as 
starting an RA biologic agent that is different from the index TNF inhibitor therapy. 
The dependent variable was medication switch status. The probability modeled was 
switching from the index TNF inhibitor therapy. The independent variable was type 
of TNF inhibitor (ADA, ETN and IFX) therapy and ETN was selected as the reference 
                                                          
m See Appendix A for detailed result 
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therapy. The same covariates used in prior analysis were used in the conditional 
logistic regression model.   
 Table 4.15 shows the detailed results of the conditional logistic regression 
model comparing the likelihood of switching from index TNF inhibitor therapy by 
type of TNF inhibitor therapy while controlling for covariates.  The results of the 
model fit with or without the model parameters (explanatory) variables were 
inconclusive with the likelihood ratio test (p = 0.0150) and score test (p = 0.0468) 
indicating a rejection of the null hypothesis that all slope parameters are equal to zero 
while the Wald test (p = 0.0980) result failed to reject the null. Since leaving all the 
explanatory variables in the model would not reduce the model fit, all the explanatory 
variables were retained in the model.  Results of maximum likelihood estimates 
showed that compared to patients on ETN, there was no significant difference in ADA 
or IFX users’ likelihood to switch from index TNF inhibitor therapy while controlling 
for other variables in the model.  Regarding the covariates, age, race, pre-index pain 
medication use, pre-index RA-related visit, pre-index non RA-related visit and total 
number of non-study RA-related medications were significantly related to the 
likelihood to switch from index TNF inhibitor therapy while controlling for other 
variables in the model.  For every year increase in age, the odds of switching from 
index TNF inhibitor therapy was 3.3 percent lower while controlling for other 
variables in the model [Odds Ratio (OR) = 0.967, [95% CI = 0.937-0.997], p = 0.0341].  
For every unit increase in RA-related visits, the odds of switching from index TNF 
  159 
inhibitor therapy was ≈ 3 times higher while controlling for other variables in the 
model [Odds Ratio (OR) = 2.661, [95% CI = 1.243-5.698], p = 0.0117]. For every unit 
increase in non RA-related visits, the odds of switching from index TNF inhibitor 
therapy was ≈ 5 times higher while controlling for other variables in the model [Odds 
Ratio (OR) = 4.689, [95% CI = 1.431-15.363], p = 0.0107]. For every unit increase in 
total number of non-study RA-related medications, the odds of switching from index 
TNF inhibitor therapy was 76.7 percent lower while controlling for other variables in 
the model [Odds Ratio (OR) = 0.233, [95% CI = 0.075-0.723], p = 0.0117]. Compared 
to White subjects, the odds of switching from index TNF inhibitor therapy was 82.1 
percent lower for non-White subjects while controlling for other variables in the 
model [Odds Ratio (OR) = 0.179, [95% CI = 0.044-0.725], p = 0.0159]. Compared to 
those who used pain medications in the pre-index period, the odds of switching from 
index TNF inhibitor therapy was 88 times higher for non-pain medication users while 
controlling for other variables in the model[Odds Ratio (OR) =  88.40, [95% CI =1.889-
>999.999], p = 0.0224].   
Ho6: There is no significant difference in the likelihood of switching from index TNF 
inhibitor therapy to another biologic agent among ETN users compared to ADA and IFX 
users while controlling for covariates. (Not Rejected) 
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Table 4.15: Conditional Logistic Regression Analysis Comparing the 
Likelihood of Switching from Index TNF Inhibitor Therapy (N = 
822) 
 Odds 
Ratio 
95% CI Wald X2  p-value 
Medication Type† 
Adalimumab 1.533 0.858 2.742 2.0784 0.1494 
Infliximab 1.107 0.623 1.967 0.1204 0.7286 
Covariates 
Age 0.967 0.937 0.997 4.4892 0.0341* 
Male† 1.249 0.488 3.194 0.2153 0.6427 
Non-Whites†  0.179 0.044 0.725 5.8125 0.0159* 
Pre-index DMARD non-use 2.784 0.298 26.034 0.8059 0.3693 
Pre-index pain medications 
non-use 
88.400 1.889 >999.999 5.2173 0.0224* 
Pre-index glucocorticoids non-
use 
4.965 0.283 87.023 1.2027 0.2728 
Pre-index RA related visits 2.661 1.243 5.698 6.3494 0.0117* 
Pre-index non-RA related visits 4.689 1.431 15.363 6.5112 0.0107* 
Total number of non-study RA-
related medications 
0.233 0.075 0.723 6.3622 0.0117* 
Pre-index total utilization cost 0.999 0.999 1.000 6.2065 0.0127 
Charlson Comorbidity Index 2.301 0.768 6.893 2.2139 0.1368 
RA = rheumatoid arthritis; TNF = tumor necrosis factor 
†Reference categories: Etanercept, females, whites, DMARD users, glucocorticoid users and pain medication 
users. Note: Race was dichotomized into two groups (Whites and others) due to small cell sizes. 
Model Fit Statistics: likelihood ratio = 26.3961, df = 13, p = 0.0150; Score = 22.5955, df = 13, p = 0.0468; Wald = 
19.8892, df = 13, p = 0.0980 
*significant at p < 0.05 
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4.4.4.4c Medication Switching (GLM-GEE Model) 
To determine if duration of medication use (i.e., persistence) prior to 
switching from index TNF inhibitor therapy among ETN users differs significantly 
compared to ADA and IFX users while controlling for covariates, a generalized linear 
model (GLM), which was estimated using a generalized estimating equation (GEE), 
was used.  The dependent variable was TNF inhibitor medication persistence prior to 
switch and the independent variable was type of TNF inhibitor therapy. The same 
covariates used in the previous analyses were used in the GLM.  Overall, based on a 
60-day gap period, mean persistence (±SD) to the study TNF inhibitor therapies prior 
to switching was 140.3 days (±93.7). The mean persistence values (±SD) prior to 
switch were 138.7±90.4 days, 142.5±103.9 days and 139.6±89.5 days, respectively, 
for ETN, IFX and ADA users.n 
For the GLM, a gamma distribution and a log link was specified as the 
normality assumption was rejected based on the significance of the KS test (p < 0.01).  
Table 4.16 shows the detailed results of the GLM model estimated using a GEE. The 
GEE parameter estimate results showed that compared to patients on ETN, there was 
no significant difference in ADA or IFX users’ persistence to TNF inhibitor therapy 
prior to switch while controlling for other variables in the model.  Regarding the 
                                                          
n See Appendix B for detailed result 
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covariates, only gender (p = 0.0242) and CCI were significantly (p = 0.0414) related 
to persistence to TNF inhibitor therapy prior to switch. An increase in CCI score was 
associated with a significant decrease in persistence to TNF inhibitor therapy prior to 
switching while controlling for other variables in the model.  Compared to female 
subjects, male subjects were significantly more persistent on TNF inhibitor therapy 
prior to switch while controlling for other variables in the model. Results were robust 
when sensitivity analyses were conducted using 45, 90- and 120-day gap periods. 
When a 30-day gap period was specified, in addition to the above, healthcare 
utilization was significantly and positively related to persistence to TNF inhibitor 
therapy prior to switch.  
 
Ho7: There is no significant difference in duration of medication use (i.e., persistence) 
prior to switching from index TNF inhibitor therapy among ETN users compared to 
ADA and IFX users while controlling for covariates. (Not Rejected) 
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Table 4.16: Generalized Linear Regression Analysis Comparing Medication 
Persistence among TNF Inhibitors prior to Switch (N = 98) 
 Estimate 95% CI Z p-value 
Medication Type† 
Adalimumab 0.0273 -0.2748 0.3294 0.18 0.8592 
Infliximab 0.0274 -0.3180 0.3729 0.16 0.8763 
Covariates 
Age 0.0069 -0.0047 0.0186 1.16 0.2448 
Male† 0.4419 0.0576 0.8262 2.25 0.0242* 
Non-Whites†  0.1117 -0.1875 0.4109 0.73 0.4643 
Pre-index DMARD non-use -0.0154 -0.3329 0.3020 -0.10 0.9240 
Pre-index pain medications non-
use 
0.0232 -0.3070 0.3534 0.14 0.8903 
Pre-index glucocorticoids non-
use 
-0.2000 -0.5023 0.1024 -1.30 0.1949 
Pre-index RA related visits 0.0231 -0.0190 0.0651 1.08 0.2822 
Pre-index non-RA related visits -0.0184 -0.1398 0.1029 -0.30 0.7659 
Total number of non-study RA-
related medications 
-0.0105 -0.1363 0.1154 -0.16 0.8704 
Pre-index total utilization cost 0.0000 -0.0001 0.0001 0.29 0.7744 
Charlson Comorbidity Index -0.3095 -0.6069 -0.0121 -2.04 0.0414* 
RA = rheumatoid arthritis; TNF = tumor necrosis factor 
†Reference categories: Etanercept, females, whites, DMARD users, glucocorticoid users and pain medication 
users. Note: Race was dichotomized into two groups (Whites and others) due to small cell sizes. 
*significant at p < 0.05 
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4.4.5 Healthcare Utilization Cost 
Objective 5 was to determine if total healthcare utilization cost for ETN users 
differs significantly compared to ADA and IFX users while controlling for covariates.  
Total healthcare cost was defined as the total direct costs (i.e., medical and medication 
costs combined) to the Texas Medicaid program in the post-index period for users on 
each of the study TNF inhibitors, adjusted to 2011 US dollars using the medical 
consumer price index from the U.S. Bureau of Labor Statistics current data.  
4.4.5.1a Healthcare Utilization Cost (Unadjusted Analysis- Signed-Ranked Test) 
Overall, the median total healthcare cost (mean±SD) incurred by the study 
subjects in the post-index period was $16,488 ($16,477±9,228). Median total 
healthcare costs (mean±SD) were $18,670 ($18,299±9,074), $16,575 
($16,325±8,469) and $13,171 ($14,808±9,792) for ADA, ETN and IFX users, 
respectively.o  Result of unadjusted analysis indicated that compared to ETN users, 
median overall cost was significantly higher (p = 0.0170) for ADA users and was 
significantly lower (p = 0.0175) for IFX users. 
                                                          
o See Appendix C for detailed result 
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4.4.5.1b Total Healthcare Utilization Cost (GLM-GEE Model) 
To determine if total healthcare utilization cost for ETN users differs 
significantly compared to ADA and IFX users while controlling for covariates, a 
generalized linear model (GLM), which was estimated using a generalized estimating 
equation (GEE), was used. The dependent variable was total healthcare utilization 
cost and the independent variable was type of TNF inhibitor therapy. The same 
covariates used in the previous analyses were used in the GLM.  A gamma distribution 
and a log link was specified for the model as the normality assumption was rejected 
based on the significance of the KS test (p < 0.01).  Table 4.17 shows the detailed 
results of the GLM model estimated using a GEE. The GEE parameter estimate results 
showed that total healthcare cost in the post-index period was significantly higher (p 
= 0.0049) for ADA users compared to ETN users while controlling for other variables 
in the model.  Total healthcare cost in the post-index period was significantly lower 
(p = 0.0005) for IFX users compared to ETN users while controlling for other 
variables in the model. Regarding the covariates, only pre-index DMARD use (p = 
0.0038), pre-index RA-related visit (p = 0.0155) and pre-index total utilization cost 
(p <.0001) were significantly related to total healthcare cost in the post-index period.  
An increase in pre-index RA-related visit or pre-index total utilization cost was 
associated with a significant increase in total healthcare cost in the post-index period 
while controlling for other variables in the model.  Compared to subjects on DMARDs, 
subjects who were not on DMARDs in the pre-index period had significantly lower 
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total healthcare cost in the post-index period while controlling for other variables in 
the model.   
 
H8: Total healthcare utilization cost is significantly lower for ETN patients compared to 
patients on ADA and IFX while controlling for covariates. (Rejected) 
Table 4.17: Generalized Linear Regression Analysis Comparing Total 
Healthcare Utilization Cost among TNF Inhibitors (N = 822) 
 Estimate 95% CI Z p-value 
Medication Type† 
Adalimumab 0.1215 0.0369 0.2061 2.81 0.0049* 
Infliximab -0.1625 -0.2543 -0.0707 -3.47 0.0005* 
Covariates 
Age -0.0018 -0.0061 0.0026 -0.80 0.4244 
Male† 0.0523 -0.0485 0.1530 1.02 0.3092 
Non-Whites†  -0.0483 -0.1294 0.0329 -1.17 0.2438 
Pre-index DMARD non-use -0.1383 -0.2321 -0.0446 -2.89 0.0038* 
Pre-index pain medications non-
use 
-0.0851 -0.1916 0.0215 -1.56 0.1176 
Pre-index glucocorticoids non-
use 
-0.0114 -0.0933 0.0705 -0.27 0.7854 
Pre-index RA related visits 0.0137 0.0026 0.0248 2.42 0.0155* 
Pre-index non-RA related visits -0.0125 -0.0423 0.0173 -0.82 0.4106 
Total number of non-study RA-
related medications 
0.0266 -0.0093 0.0626 1.45 0.1468 
Pre-index total utilization cost 0.0001 0.0001 0.0001 9.54 <.0001* 
Charlson Comorbidity Index -0.0286 -0.1036 0.0464 -0.75 0.4547 
RA = rheumatoid arthritis; TNF = tumor necrosis factor 
†Reference categories: Etanercept, females, whites, DMARD users, glucocorticoid users and pain medication 
users. Note: Race was dichotomized into two groups (Whites and others) due to small cell sizes. 
*significant at p < 0.05 
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4.4.6 RA-related Healthcare Utilization Cost 
The first part of objective 6 was to determine if RA-related healthcare 
utilization cost for ETN users differs significantly compared to ADA and IFX users 
while controlling for covariates.  RA-related healthcare cost was total RA-related 
direct medical and medication costs (associated with ICD-9-CM code 714.0x) in the 
post-index period, adjusted to 2011 US dollars using the medical consumer price 
index from the U.S. Bureau of Labor Statistics current data.  
4.4.6.1a RA-related Healthcare Utilization Cost (Signed Rank Test) 
Overall, the median RA-related healthcare cost (mean±SD) incurred by the 
study subjects in the post-index period was $13,921 ($13,713±8309). Median total 
RA-related healthcare costs (mean±SD) were $15,987 ($15,777±8005), $13,894 
($13,391±7,421) and $10,283 ($11,972±9,002) for ADA, ETN and IFX users, 
respectively.p Result of unadjusted analysis indicated that compared to ETN users, 
median overall RA-related healthcare cost was significantly higher (p = 0.0010) for 
ADA users and was significantly lower (p = 0.0116) for IFX users. 
                                                          
p See Appendix C for detailed result 
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4.4.6.1b RA-related Healthcare Utilization Cost (GLM-GEE Model) 
To determine if RA-related healthcare utilization cost for ETN users differs 
significantly compared to ADA and IFX users while controlling for covariates, a 
generalized linear model (GLM), which was estimated using a generalized estimating 
equation (GEE), was used. The dependent variable was RA-related healthcare 
utilization cost and the independent variable was type of TNF inhibitor therapy. The 
same covariates used in the previous analyses were used in the GLM.  A gamma 
distribution and a log link was specified for the model as the normality assumption 
was rejected based on the significance of the KS test (p < 0.01).  Table 4.18 shows the 
detailed results of the GLM model estimated using a GEE. The GEE parameter estimate 
results showed that RA-related healthcare cost in the post-index period was 
significantly higher (p = 0.0009) for ADA users compared to ETN users while 
controlling for other variables in the model.  RA-related healthcare cost in the post-
index period was significantly lower (p = 0.0003) for IFX users compared to ETN 
users while controlling for other variables in the model.   Regarding the covariates, 
gender (p = 0.0414), pre-index DMARD use (p = 0.0023), pre-index RA-related visit 
(p < 0.0001), pre-index total utilization cost (p = 0.0011) and CCI (p = 0.0249) were 
significantly related to RA-related healthcare cost in the post-index period.  An 
increase in pre-index RA-related visit or pre-index total utilization cost was 
associated with significant increase in RA-related healthcare cost in the post-index 
period while controlling for other variables in the model. An increase in CCI score was 
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significantly associated with a decrease in RA-related healthcare cost in the post-
index period. Compared to subjects on DMARDs, subjects who were not on DMARDs 
in the pre-index period had significantly lower RA-related healthcare cost in the post-
index period while controlling for other variables in the model. Compared to female 
subjects, male subjects had significantly higher RA-related healthcare cost in the post-
index period while controlling for other variables in the model.   
H9: RA-related healthcare utilization cost is significantly lower for ETN patients 
compared to patients on ADA and IFX while controlling for covariates. (Rejected) 
  
  170 
Table 4.18: Generalized Linear Regression Analysis Comparing RA-related 
Healthcare Utilization Cost among TNF Inhibitors (N = 822) 
 Estimate 95% CI Z p-value 
Medication Type† 
Adalimumab 0.1576 0.0642 0.2510 3.31 0.0009* 
Infliximab -0.1929 -0.2965 -0.0893 -3.65 0.0003* 
Covariates 
Age -0.0033 -0.0081 0.0014 -1.38 0.1678 
Male† 0.1119 0.0044 0.2194 2.04 0.0414* 
Non-Whites†  -0.0589 -0.1493 0.0316 -1.28 0.2020 
Pre-index DMARD non-use -0.1650 -0.2712 -0.0588 -3.04 0.0023* 
Pre-index pain medications non-
use 
-0.0719 -0.1894 0.0455 -1.20 0.2299 
Pre-index glucocorticoids non-
use 
-0.0270 -0.1208 0.0667 -0.57 0.5717 
Pre-index RA related visits 0.0290 0.0164 0.0416 4.50 <.0001* 
Pre-index non-RA related visits -0.0201 -0.0539 0.0137 -1.17 0.2429 
Total number of non-study RA-
related medications 
0.0247 -0.0176 0.0671 1.14 0.2525 
Pre-index total utilization cost 0.0000 0.0000 0.0001 3.26 0.0011* 
Charlson Comorbidity Index -0.0993 -0.1861 -0.0125 -2.24 0.0249* 
RA = rheumatoid arthritis; TNF= tumor necrosis factor 
†Reference categories: Etanercept, females, whites, DMARD users, glucocorticoid users and pain medication 
users. Note: Race was dichotomized into two groups (Whites and others) due to small cell sizes. 
*significant at p < 0.05 
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4.4.7 TNF-Inhibitor Therapy Cost 
The second part of objective 6 was to determine if TNF inhibitor therapy cost 
for ETN users differs significantly compared to ADA and IFX users while controlling 
for covariates. TNF inhibitor therapy cost was defined as total cost of the index TNF 
inhibitor therapy in the post-index period, adjusted to 2011 US dollars using the 
medical consumer price index from the U.S. Bureau of Labor Statistics current data.  
4.4.7.1a TNF-Inhibitor Therapy Cost (Unadjusted Analysis- Signed Rank Test) 
Overall, the median TNF inhibitor therapy cost (mean±SD) incurred by the 
study subjects in the post-index period was $9,512 ($10,879±7,543). Median TNF 
inhibitor therapy costs (mean±SD) were $13,190 ($12,999±7,517), $10,209 
($10,647±6,714) and $6,279 ($8,992±7,834) for ADA, ETN and IFX users, 
respectively.q  Result of unadjusted analysis indicated that compared to ETN users, 
median overall cost was significantly higher (p = 0.0003) for ADA users and was 
significantly lower (p = 0.0005) for IFX users. 
4.4.7.1b TNF-Inhibitor Therapy Cost (GLM-GEE Model) 
To determine if TNF inhibitor therapy cost for ETN users differs significantly 
compared to ADA and IFX users while controlling for covariates, a generalized linear 
                                                          
q See Appendix C for detailed result 
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model (GLM), which was estimated using a generalized estimating equation (GEE), 
was used. The dependent variable was TNF inhibitor therapy cost and the 
independent variable was type of TNF inhibitor therapy. Same covariates used in the 
previous analyses were introduced in the GLM.  A gamma distribution and a log link 
was specified for the model as the normality assumption was rejected based on the 
significance of the KS test (p < 0.01).  Table 4.19 shows the detailed results of the GLM 
model estimated using a GEE. The GEE parameter estimate results showed that TNF 
inhibitor therapy costs were significantly higher (p = 0.0004) for ADA users 
compared to ETN users while controlling for other variables in the model.  TNF 
inhibitor therapy cost was significantly lower (p < 0.0001) for IFX users compared to 
ETN users while controlling for other variables in the model. Regarding the 
covariates, gender (p = 0.0031), pre-index DMARD use (p = 0.0003), pre-index RA-
related visit (p = 0.0006) were significantly related to TNF inhibitor therapy cost.  An 
increase in pre-index RA-related visit was associated with significant increase in TNF 
inhibitor therapy cost while controlling for other variables in the model. Compared 
to subjects on DMARDs, subjects who were not on DMARDs in the pre-index period 
had significantly lower TNF inhibitor therapy cost while controlling for other 
variables in the model. Compared to female subjects, male subjects had significantly 
higher TNF inhibitor therapy cost while controlling for other variables in the model.   
H10: TNF medication cost is significantly lower for ETN patients compared to patients 
on ADA and IFX while controlling for covariates. (Rejected) 
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Table 4.19: Generalized Linear Regression Analysis Comparing TNF Inhibitor 
Therapy Cost among TNF Inhibitors (N = 822) 
 Estimate 95% CI Z p-value 
Medication Type† 
Adalimumab 0.1960 0.0885 0.3035 3.57 0.0004* 
Infliximab -0.2491 -0.3658 -0.1325 -4.19 <.0001* 
Covariates 
Age 0.0001 -0.0055 0.0057 0.04 0.9661 
Male† 0.1744 0.0590 0.2897 2.96 0.0031* 
Non-Whites†  -0.0600 -0.1670 0.0471 -1.10 0.2722 
Pre-index DMARD non-use -0.2380 -0.3679 -0.1081 -3.59 0.0003* 
Pre-index pain medications non-
use 
-0.1294 -0.2707 0.0120 -1.79 0.0728 
Pre-index glucocorticoids non-
use 
-0.0756 -0.1870 0.0357 -1.33 0.1832 
Pre-index RA related visits 0.0263 0.0113 0.0413 3.43 0.0006* 
Pre-index non-RA related visits -0.0115 -0.0537 0.0308 -0.53 0.5949 
Total number of non-study RA-
related medications 
-0.0072 -0.0595 0.0451 -0.27 0.7876 
Pre-index total utilization cost 0.0000 -0.0000 0.0000 0.67 0.5024 
Charlson Comorbidity Index -0.0786 -0.1794 0.0223 -1.53 0.1268 
RA = rheumatoid arthritis; TNF= tumor necrosis factor 
†Reference categories: Etanercept, females, whites, DMARD users, glucocorticoid users and pain medication 
users. Note: Race was dichotomized into two groups (Whites and others) due to small cell sizes. 
*significant at p < 0.05 
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4.4.8  Relationship Between RA-related Healthcare Utilization Cost and 
Medication Adherence and Persistence 
Objective 7 was to determine if RA-related healthcare utilization cost was 
associated with adherence and persistence to TNF inhibitors (ETN, ADA or IFX) while 
controlling for covariates.  A generalized linear model (GLM), which was estimated 
using a generalized estimating equation (GEE), was used. The dependent variable was 
RA-related healthcare utilization cost and the independent variables were adherence 
and persistence to TNF inhibitor therapy. The same covariates used in the previous 
analyses were used in the GLM.   
4.4.8.1  Relationship Between RA-related Healthcare Utilization Cost and 
Medication Adherence (GLM-GEE Model) 
A gamma distribution and a log link was specified for the model as the 
normality assumption was rejected based on the significance of the KS test (p < 0.01). 
Table 4.20 shows the detailed results of the GLM model estimated using a GEE. The 
GEE parameter estimate results showed that adherence to TNF inhibitor therapy was 
positively and significantly (p < 0.0001) associated RA-related healthcare utilization 
cost while controlling for other variables in the model.    Regarding the covariates, age 
(p = 0.0034), pre-index RA-related visits (p = 0.0030), total number of non-study RA-
related medications (p = 0.0340) and pre-index total utilization cost (p = 0.0308) 
were significantly related to RA-related healthcare cost in the post-index period.  An 
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increase in pre-index RA-related visits, total number of non-study RA-related 
medications or pre-index total utilization cost was significantly associated with an 
increase in RA-related healthcare cost in the post-index period while controlling for 
other variables in the model. Older age was associated with a significant decrease in 
RA-related healthcare cost in the post-index period while controlling for other 
variables in the model.   
H11: RA-related healthcare utilization cost is significantly and positively related to TNF 
medication adherence while controlling for covariates. (Not Rejected) 
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Table 4.20: Generalized Linear Regression Analysis Comparing Relationship 
Between RA-related Healthcare Utilization Cost and Medication 
Adherence (N = 822) 
 Estimate 95% CI Z p-value 
Adherence (MPR) 0.0132 0.0116 0.0147 16.60 <.0001* 
Covariates 
Age -0.0069 -0.0115 -0.0023 -2.93 0.0034* 
Male† 0.0227 -0.0811 0.1265 0.43 0.6687 
Non-Whites†  -0.0191 -0.1086 0.0703 -0.42 0.6753 
Pre-index DMARD non-use -0.0391 -0.1415 0.0634 -0.75 0.4550 
Pre-index pain medications non-
use 
-0.0246 -0.1293 0.0800 -0.46 0.6445 
Pre-index glucocorticoids non-
use 
0.0265 -0.0555 0.1085 0.63 0.5265 
Pre-index RA related visits 0.0179 0.0061 0.0297 2.97 0.0030* 
Pre-index non-RA related visits -0.0132 -0.0441 0.0176 -0.84 0.4011 
Total number of non-study RA-
related medications 
0.0441 0.0033 0.0848 2.12 0.0340* 
Pre-index total utilization cost 0.0000 0.0000 0.0001 2.16 0.0308* 
Charlson Comorbidity Index -0.0511 -0.1175 0.0154 -1.51 0.1319 
MPR = medication possession ratio; RA = rheumatoid arthritis; TNF = tumor necrosis factor 
†Reference categories: Etanercept, females, whites, DMARD users, glucocorticoid users and pain medication 
users. Note: Race was dichotomized into two groups (Whites and others) due to small cell sizes. 
*significant at p < 0.05 
 
  177 
4.4.8.2  Relationship Between RA-related Healthcare Utilization Cost and 
Medication Persistence (GLM-GEE Model) 
Table 4.21 shows the detailed results of the GLM model which was estimated 
using a GEE. The GEE parameter estimate results showed that persistence to TNF 
inhibitor therapy was positively and significantly (p < 0.0001) associated RA-related 
healthcare utilization cost while controlling for other variables in the model.    
Regarding the covariates, age (p = 0.0084), pre-index RA-related visits (p = 0.0021), 
and pre-index total utilization cost (p = 0.0436) were significantly related to RA-
related healthcare cost in the post-index period.  An increase in pre-index RA-related 
visits or pre-index total utilization cost was associated with significant increase in RA-
related healthcare cost in the post-index period while controlling for other variables 
in the model. Older age was associated with a significant decrease in RA-related 
healthcare cost in the post-index period while controlling for other variables in the 
model.  Results were robust when sensitivity analyses were conducted using 90- and 
120-day gap periods.  When a 30- or 45-day gap period was specified, in addition to 
the variables above, total number of non-study RA-related medications was 
significantly and positively related to RA-related healthcare cost in the post-index 
period. With the 30-day gap period, CCI was also significantly but negatively related 
to RA-related healthcare cost in the post-index period.  
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H12: RA-related healthcare utilization cost is significantly and positively related to TNF 
medication persistence while controlling for covariates. (Not Rejected) 
Table 4.21: Generalized Linear Regression Analysis Comparing Relationship 
Between RA-related Healthcare Utilization Cost and Medication 
Persistence (N = 822) 
 Estimate 95% CI Z p-value 
Persistence‡  0.0025 0.0021 0.0028 14.83 <.0001* 
Covariates 
Age -0.0062 -0.0107 -0.0016 -2.64 0.0084* 
Male† 0.0296 -0.0779 0.1371 0.54 0.5899 
Non-Whites†  -0.0475 -0.1374 0.0423 -1.04 0.3001 
Pre-index DMARD non-use -0.0829 -0.1878 0.0220 -1.55 0.1213 
Pre-index pain medications non-
use 
-0.0283 -0.1439 0.0872 -0.48 0.6308 
Pre-index glucocorticoids non-
use 
0.0032 -0.0814 0.0878 0.07 0.9417 
Pre-index RA related visits 0.0187 0.0068 0.0307 3.08 0.0021* 
Pre-index non-RA related visits -0.0142 -0.0459 0.0175 -0.88 0.3788 
Total number of non-study RA-
related medications 
0.0291 -0.0122 0.0705 1.38 0.1671 
Pre-index total utilization cost 0.0000 0.0000 0.0001 2.02 0.0436* 
Charlson Comorbidity Index -0.0578 -0.1260 0.0104 -1.66 0.0965 
RA = rheumatoid arthritis; TNF = tumor necrosis factor 
‡Based on a 60-day gap period 
†Reference categories: Etanercept, females, whites, DMARD users, glucocorticoid users and pain medication 
users. Note: Race was dichotomized into two groups (Whites and others) due to small cell sizes. 
*significant at p < 0.05 
 
The results of all hypotheses tested in this study are summarized in Table 4.21. 
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Table 4.21 Results of Hypotheses Testing 
Objectives/ Hypotheses Statistical Analysis Result 
Objective 1: To describe and compare baseline socio-demographics and clinical 
characteristics of Texas Medicaid RA patients on etanercept (ETN), adalimumab (ADA) or 
infliximab (IFX) 
Descriptive statistics  
Objective 2: To describe medication dosing patterns (initial or starting dose and dose 
category changes) among ETN, ADA and IFX users 
Descriptive statistics 
  
 
Objective 3: To determine if the likelihood of having a dose escalation among ETN users differs significantly compared to ADA and IFX users 
while controlling for covariates† 
H1: The likelihood of having a dose escalation is significantly lower among RA patients on ETN 
compared to patients on ADA and IFX while controlling for covariates 
Conditional logistic 
regression 
Not Rejected 
Objective 4: To determine if medication use patterns (adherence, persistence, discontinuation and switching) among ETN users differ 
significantly compared to ADA and IFX users while controlling for covariates† 
Ho2A: There is no significant difference in medication adherence to ETN compared to ADA and 
IFX users while controlling for covariates 
GLM model estimated with 
GEE 
Rejected 
Ho2B: The likelihood of being adherent (MPR≥80%) to ETN does not differ significantly compared 
to ADA and IFX while controlling for covariates 
Conditional logistic 
regression 
Rejected 
Ho3: There is no significant difference in  medication persistence to ETN compared to ADA and 
IFX users while controlling for covariates 
GLM model estimated with 
GEE 
Not Rejected 
Ho4: The likelihood of discontinuing ETN does not differ significantly compared to ADA and IFX 
while controlling for covariates 
Conditional logistic 
regression 
Not Rejected 
Ho5: There is no significant difference in duration of medication use prior to discontinuation of 
ETN compared to ADA and IFX while controlling for covariates 
Cox proportional hazards 
regression 
Not Rejected 
Ho6: There is no significant difference in the likelihood of switching from index TNF inhibitor 
therapy to another biologic agent among ETN users compared to ADA and IFX users while 
controlling for covariates. 
Conditional logistic 
regression 
Not Rejected 
Ho7: There is no significant difference in duration of medication use prior to switching from index  
TNF inhibitor among ETN users compared to ADA and IFX users while controlling for covariates 
GLM model estimated with 
GEE 
Not Rejected 
Objective 5: To determine if  total healthcare utilization cost for ETN users differs significantly compared to ADA and IFX users while 
controlling for covariates† 
H8:Total healthcare utilization cost  is significantly lower for ETN patients compared to patients 
on ADA and IFX while controlling for covariates 
 
GLM model estimated with 
GEE 
Rejected 
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Objectives/ Hypotheses Statistical Analysis Result 
Objective 6: To determine if  RA-related healthcare utilization cost for ETN users differs significantly compared to ADA and IFX users while 
controlling for covariates† 
H9:Total RA-related healthcare utilization cost is significantly lower for ETN patients compared 
to patients on ADA and IFX while controlling for covariate 
GLM model estimated with 
GEE 
Rejected 
H10: TNF medication cost is significantly lower for ETN patients compared to patients on ADA 
and IFX while controlling for covariates 
GLM model estimated with 
GEE 
Rejected 
Objective 7: To determine if RA-related healthcare utilization cost is associated with adherence/persistence to TNF inhibitors (ETN, ADA or 
IFX) while controlling for covariates† 
H11: RA-related healthcare utilization cost is significantly and positively related to TNF 
medication adherence while controlling for covariates 
GLM model estimated with 
GEE 
Not Rejected 
H12: RA-related healthcare utilization cost is significantly and positively related to TNF 
medication persistence while controlling for covariates 
GLM models  estimated 
using GEE 
Not Rejected 
ADA= Adalimumab; ETN=Etanercept; GEE= Generalized estimating equation; GLM= Generalized linear model; IFX=Infliximab; MPR= Medication possession 
ratio; RA=Rheumatoid arthritis; TNF= Tumor necrosis factor 
Covariates include age, gender, pre-index use of other RA-related medications, total number of other RA-related medications use at index, Charlson 
Comorbidity index, pre-index total RA-related visits, pre-index total non-RA related visits and pre-index RA-related healthcare utilization cost
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CHAPTER 5: DISCUSSION AND CONCLUSION 
5.1  CHAPTER OVERVIEW 
This chapter provides a detailed discussion of the study results. The chapter 
begins with a brief review of the study purpose.  This is followed by a discussion of 
the study results with possible explanations provided for study findings. The chapter 
concludes with a discussion regarding study uniqueness and limitations as well as 
suggestions for future research.    
5.2  REVIEW OF STUDY PURPOSE  
The aim of the present study was to evaluate medication use patterns (i.e., 
medication adherence, persistence, switching and dose escalation) of RA patients on 
etanercept (ETN), infliximab (IFX) or adalimumab (ADA) and the associated 
healthcare utilization costs using Texas Medicaid data (prescription and medical 
claims) from July 2003 to August 2011.  While the majority of earlier studies were 
conducted using data from patients enrolled in private health plans or managed care 
organizations, the present study expands on findings using data from patients 
enrolled under Medicaid programs.  
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5.3  STUDY OBJECTIVES  
 Seven objectives and twelve hypotheses were addressed in this study.  Results 
under each study objective are discussed and compared with findings from previous 
studies. 
5.3.1 Objective 1 
Objective 1 was to describe and compare baseline socio-demographics and 
clinical characteristics of Texas Medicaid RA patients on etanercept (ETN), 
adalimumab (ADA) or infliximab (IFX). At baseline, the three study groups presented 
with comparable socio-demographic characteristics (i.e., age, gender and race). 
However, the ETN and ADA groups differed in clinical characteristics from the IFX 
group necessitating the need for a matching procedure to be conducted. After 
matching using propensity scores, the three study groups were not significantly 
different from each other on any of the baseline characteristics. Demographic 
characteristics of the final matched sample (i.e., mean age [48.9±9.8 years] and 
gender [females accounted for 88.0 percent of study population]) were found to be 
within the range of values reported by earlier RA studies that were conducted using 
retrospective database analysis. The reported mean age by these studies ranged from 
48.2±12.5 to 58.0 (SD not provided) years with female population ranging from 73.3-
  183 
88.4 percent.2,4,21-28,30-33,212,213 However, in contrast to other studiesr where the 
majority were White, the present study had a majority Hispanic population 
(53.7%).23-25,33  This result was not surprising as Hispanics have been reported to 
account for a significant proportion (≈ 40%) of the Texas population.214 Furthermore, 
having a majority Hispanic population makes the results of the present study a unique 
contribution to the literature as this population is under-represented in previous RA 
studies. 
Regarding clinical characteristics, the pre-index use of other RA-related 
medications (i.e., DMARDs, glucocorticoids and pain medications) was consistent 
with what was expected for patients presenting with RA due to the nature of the 
disease condition.2,22,25,26,212  Based on the RA treatment guidelines, patients were 
expected to have first initiated treatment on NSAIDs or short-term low-dose 
glucocorticoids and traditional DMARD therapys before starting a TNF-inhibitor 
therapy since they are reserved for patients with suboptimal response to traditional 
DMARD therapy.74 The mean Charlson Comorbidity Index score (CCI) obtained 
(1.2±0.5), mean pre-index RA-related visits (4.2±2.9) and mean all cause visits 
(5.5±3.4) were also within the range of values found in the literature. Earlier studies 
                                                          
r Those that explicitly reported information on race/ethnicity 
s In cases of active disease 
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reported mean CCI values ranging from 0.3 (SD not provided) to 2.2 (SD not 
provided), mean RA-related visits ranging from 2.0 (SD not provided) to 3.4(±3.0) 
and mean all cause visits ranging from 5.0 (SD not provided) to 10.7 (SD not 
provided).4,22,28-31,213 In summary, with the exception of race, the present study 
sample seemed similar to those of other studies regarding demographic and clinical 
characteristics. 
5.3.2 Objectives 2 and 3 
Objective 2 was to describe medication dosing patterns (initial dose and dose 
category changes) among ETN, ADA and IFX users. Objective 3 was to determine if the 
likelihood of having a dose escalation differs significantly among ETN, ADA and IFX 
users while controlling for covariates. As explained earlier under the results section, 
dosing patterns could not be assessed for patients on IFX due to absence of unit of 
service information in the medical claims needed to verify the quantity of vials 
administered (per Healthcare Common Procedure Coding System J-codes).  
The average weekly starting dose for ETN (50.1±6.2mg) obtained in the study 
was comparable to the manufacturer’s recommended weekly dose of 50mg with the 
majority of the patients (98.2%) having a starting weekly dose that was less than or 
equal to 50mg. This was comparable with results in the literature. Previous studies 
reported average starting weekly doses which ranged from 46.5±7.0mg to 50.5 (SD 
not provided) with the proportion of patients having a starting dose that was less 
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than or equal to 50mg ranging from 85.0 to 100.0 percent.26,28,30-32,212  The average 
weekly starting dose for ADA (22.6±7.8mg) was slightly higher than a weekly dose of 
20mg equivalent to the manufacturer’s recommended dose of 40mg every other 
week. However, it was comparable with the average starting weekly dose reported in 
the literature (21±4.8mg to 22.3mg [SD not provided]). 28,32,212 The proportion of 
patients (88.0%) on ADA with a starting weekly dose that was less than or equal to 
20mg was also comparable with results (88.1% to 93.6%) reported in the 
literature.26,28,30-32,212  Based on the starting weekly doses reported above for ETN and 
ADA, it can be inferred that the clinicians followed the manufacturer recommended 
starting doses for the majority of their RA patients.  
Regarding dose escalation, a variety of definitions exist in the literature. In the 
present study, dose escalation was assumed to occur when the average weekly dose 
for all the subsequent prescriptions for the index TNF therapy exceeds the weekly 
dose of the index prescription by 150 percent. For IFX patients, dose escalation was 
calculated based on the ratio of the average of all J-code 1745 subsequent costs to the 
index J-code 1745 cost, with dose escalation identified if the ratio is greater than or 
equal to 1.5 (or 150%).  Based on the study result, a significantly lower proportion of 
patients on ETN (2.2%) had a dose escalation compared to patients on ADA (9.9%; p 
< 0.0001) or IFX (8.4%; p=0.0015). Also ETN patients had a lower likelihood of having 
a dose escalation compared to patients on ADA (p < 0.0004) or IFX (p=0.0031). This 
result was not unexpected as dose escalation/increase is recommended for patients 
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on ADA or IFX in cases of suboptimal treatment response but has not been associated 
with significant improvement in treatment response rates in patients on ETN.18-20,175-
177,215 Dose escalation patterns obtained in the present study were similar to those 
reported across a number of dose escalation studies with the proportion of patients 
having a dose escalation being consistently and significantly lower for ETN compared 
to ADA and IFX.26,28-33,212,216 Across all methods used to define dose escalation, the 
proportions ranged from 0.4 to 10.3 percent, 8.3 to 33.6 percent and 16.4 to 60 
percent for ETN, ADA and IFX, respectively.26,28-33,212,216 The proportion of ETN and 
ADA patients in the present study with a dose escalation were within the range found 
in the literature. However, for IFX, the proportion of those with a dose escalation was 
lower than the values reported in previous studies. Perhaps, compared to the 
previous studies, the IFX patients in the present study seemed to have a less severe 
form of RA. 
A major implication of dose escalation in the management of RA actually lies 
in its impact on patient’s cost of care.174 Studies which compared cost of care between 
patients who had a dose escalation and those who did not reported a significant 
relationship between dose escalation and higher cost.28,31,177 A similar trend was also 
observed in the present study with patients who did not dose escalate having 
significantly lower total healthcare cost (p < 0.0001), RA-related healthcare cost (p < 
0.0001) and TNF inhibitor therapy cost (p=0.0003) compared to patients who dose 
escalated.  
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5.3.3 Objective 4 
Objective 4 was to determine if medication use patterns (adherence, 
persistence, discontinuation and switching) differ significantly among ETN, ADA and 
IFX users while controlling for covariates.  
5.3.3.1 Medication Adherence 
 Overall adherence (mean MPR±SD) and adherence rate (proportion of 
patients with MPR≥ 80%) to TNF inhibitor therapies in the study sample were low. 
Mean MPR was 52.5(±29.5) percent with 23.5 percent of the subjects adherent (MPR 
≥ 80%) to the index TNF inhibitor therapy.  Mean adherence, adherence rate and 
likelihood to adhere to index TNF inhibitor therapy were significantly higher for IFX 
patients compared to ETN patients, but were comparable between ETN and ADA 
patients. While results of indirect comparison showed that efficacy and safety were 
comparable among the three TNF inhibitor therapies, differences in adherence 
between IFX and ETN or ADA may be a function of the route and frequency of 
administration.4 ETN and ADA are administered subcutaneously while IFX is 
administered intravenously (IV). ETN is given once weekly, ADA is given once every 
other week while IFX is given at week 0, 2 and 6, and every 8 weeks thereafter.18-20 Of 
the three TNF inhibitor therapies, IFX is the only one administered at the physician’s 
office since it is given via IV infusion. Perhaps, the patients on IFX adhered better due 
to the appoinment reminder messages that may have been sent by the clinic.  
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 The reasons responsible for the low adherence values may be difficult to 
ascertain as other important information that impacts adherence (e.g., incidence of 
adverse events, lack of treatment response and increased disability) were lacking in 
the administrative claims data used for this analysis. Furthermore, adherence values 
obtained in the present study were lower compared to values obtained in previous 
adherence studies which also used administrative claims data (commercial or 
Medicaid).2,22,23,25 This may be due to the presence of a high Hispanic population 
(53.7%) in the study sample since being of ethnic minority has been associated with 
poor medication adherence.137 In addition, the study subjects were of low 
socioeconomic status (income and education) and subjects may lack adequate 
knowledge/understanding of the disease and its treatment. Other possible factors 
may include poor prior medication-taking behaviors and beliefs.137 Clinicians caring 
for Medicaid patients need to be aware of these factors and should endeavor to work 
with each individual patient to identify patient-specific factors responsible for poor 
TNF-inhibitor therapy adherence.217 Reducing the impact of these factors and 
improving adherence should be included as a major part of the treatment plan for 
each RA patient.  
Despite the low adherence values, the direction of the study results were 
comparable with those of other studies. For studies that examined adherence to ETN 
over a 12-month period, mean adherence (mean MPR) ranged from 65.0 to 83.0 
percent.2,21,23 Similarly, mean MPR values ranged from 63.0 to 85.0 percent for ADA 
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and from 81.0 to 90.0 percent for IFX.2,21,23 When mean proportion of covered days 
(PDC) was used, mean PDC values reported for IFX and ADA were 64.0 and 57.0 
percent, respectively.25 Overall, across these studies, mean adherence, adherent rate 
and likelihood to adhere were significantly higher for IFX compared to ETN but 
comparable between ETN and ADA patients.  
 Compared to the other two Medicaid studiest, the study’s adherence values 
were lower.23,25  This may be a function of how the studies defined and calculated 
adherence as well as differences in patients’ clinical and demographic characteristics 
even though they were all Medicaid patients. Differences in Medicaid requirements 
across the states may also be a contributory factor. The present study defined 
adherence (MPR) as the total days of drug supply divided by 365 with the maximum 
number of days of medication overlap restricted to 14 days and total number of days 
of drug supply not exceeding 365 days. Grijalva et al. defined adherence (MPR) as the 
aggregated number of days supply obtained during the episode divided by the length 
of the episode, excluding the last prescription fill.23 Li et al. defined adherence as the 
number of days covered with the index biologic divided by 365 using the PDC 
approach.25 The PDC method is expected to be more conservative than MPR in 
calculating adherence for cases of drug switches, therapeutic duplication, or multiple 
                                                          
t The previous studies used Medicaid data from the following states: Tennesse, California, New York and 
Florida. 
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drug use within the same therapeutic class, none of which was the case in the present 
study. Differences may also be a function of how days supply was adjusted/computed, 
especially for IFX, which was only documented in the medical claims data being 
administered in the physician’s office, resulting in no documentation of days supply.   
Covariates identified to be significantly associated with adherence were age, 
gender, pre-index RA-related visits and Charlson Comorbidity Index score (CCI). Age 
and RA-related visits were positively related with adherence while a negative 
relationship was observed between CCI and adherence. Male subjects were more 
adherent compared to female subjects. None of the previous studies reported any 
relationship between adherence and these covariates with the exception of age. 
Borah et al. reported a lower likelihood to being adherent with an increase in age.2 
Adherence studies in other chronic disease states (e.g., diabetes) have reported 
inconsistent results regarding the relationship between age, gender, CCIu and 
adherence.218-223 Good patient-physician relationships have been found to improve 
adherence and as such it seems logical that increased pre-index RA-related visits was 
associated with an increase in adherence.137 Also, having a negative relationship 
between CCI and adherence would be expected as an increase in CCI score is 
indicative of more comorbid disease conditions leading to an increase in treatments 
                                                          
u CCI was used as a proxy for disease severity. studies evaluating adherence in other chronic diseases 
have used different proxies but found inconsistent relationship with adherence 
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(drug therapies) which may negatively impact adherence. Since RA negatively affects 
mobility and productivity, male subjects may be more adherent in order to stay 
productive and continue working.  
5.3.3.1 Medication Persistence, Discontinuation and Switching 
Overall mean persistence (±SD) was low with a high proportion of patients 
discontinuing index medication. Mean persistence for the entire study sample was 
203.9(±132.8) days with 64.8 percent of the subjects discontinuing index TNF 
inhibitor therapy. Mean persistence values (discontinuation rate) for the individual 
TNF inhibitor therapies were 196.7±134.0 days (66.8%), 199.0±130.5 days (65.7%) 
and 215.6±133.5 days (62.0%), respectively for ETN, ADA, and IFX patients. Mean 
persistence, proportion of patients who discontinued index therapy and likelihood to 
discontinue index therapy were comparable when patients on ETN were compared 
to patients on either IFX or ADA.  Similarly, persistence prior to discontinuation was 
also found to be comparable when patients on ETN were compared to patients on 
either IFX or ADA. 
Reasons responsible for low persistence values may be difficult to identify. 
However, factors proposed to have been responsible for low adherence values could 
also have accounted for the low persistence values. Compared to other studies which 
used administrative data claims to evaluate persistence and/or discontinuation, the 
mean persistence values obtained in the present study were lower and 
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discontinuation rates were higher. However, the overall direction of the study results 
was similar with results from four of the previous studies.2,25,26,212 Across these 
studies, mean persistence ranged from 243 to 301 days (SD not provided), 231 to 284 
days (SD not provided) and 281 to 298 days (SD not provided) for ETN, ADA and IFX 
patients, respectively.4,28,31,212 Discontinuation rates ranged from 19.7 to 50.0 
percent, 20.6 to 44.4 percent and 18.8 to 48.3 percent for ETN, ADA and IFX patients, 
respectively. 25,26,212   
Overall direction of study results was not consistent with results obtained 
from studies by Tang et al. and Harrison et al. Both studies found significant 
differences in mean persistence among the TNF-inhibitor therapies.4,212 However, it 
is important to note that all the previous studies with the exception of Tang et al. and 
Harrison et al. used a definition of persistence/discontinuation similar to that used in 
the present study. Tang et al. and Harrison et al. defined persistence as the number of 
days between the first and last filled prescription/infusion without accounting for 
gaps between claims/infusion.   
 As with adherence, similar covariates were also significantly related to 
persistence. Age and pre-index RA-related visits were positively related to 
persistence, while a negative relationship was observed with CCI. An increase in CCI 
score was associated with an increased likelihood to discontinue index TNF inhibitor 
therapy, which was consistent with the association between CCI and adherence. As 
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with adherence, male subjects had better persistence compared to their female 
counterparts. Since adherence and persistence are related, the same reasons might 
hold for why these covariates were related to both. Previous studies found similar 
significant relationships between persistence/discontinuation and age22, gender2 and 
CCI.4,22   
Regarding switching from index TNF inhibitor therapy to another biologic, 
11.9 percent of the study sample switched at one point within the 12-month follow-
up period. The proportion of patients on ETN (10.6%) who switched and likelihood 
to switch from index therapy were comparable with those of patients on either IFX 
(11.7%) or ADA (13.5%).  These switch rates were comparable with those reported 
by Fisher et al. (ETN [12.2%]; ADA [9.1%] and IFX [10.4%]) but were higher than 
those reported by Li et al. (ETN [4%] and ADA [4%]). However, the overall study 
direction were similar as both studies reported no significant difference in proportion 
of patients that switched across the study TNF inhibitor therapies.25,212 
 Covariates associated with the likelihood to switch from index TNF inhibitor 
therapy include age, race, pre-index pain medication use, pre-index RA-related visits, 
pre-index non RA-related visits and total number of non-study RA-related 
medications.  Increase in age, pre-index RA-related visits and pre-index non RA-
related visits were associated with a higher likelihood to switch. Increase in total 
number of non-study RA-related medications was associated with a lower likelihood 
  194 
to switch. Compared to those who were on pain medications, subjects who were not 
on pain medications in the pre-index period were more likely to switch while non-
whites were less likely to switch compared to their White counterparts. Reasons 
responsible for these associations are unknown. However, with regard to pre-index 
RA-related and non RA-related visits, frequent visits to a physician may be indicative 
that the patient was not getting the desired anticipated relief from a prescribed 
medication which could increase the likelihood of switching. Furthermore, patients 
on pain medications in the pre-index period may be less likely to switch as they might 
have been advised by their clinicians to increase the dose of their pain medications 
when adequate relief was not achieved with the TNF-inhibitor therapy. A similar 
reason could account for why an increase in total number of non-study RA-related 
medications was associated with a lower likelihood to switch.  
5.3.4 Objectives 5 and 6 
Objectives 5 and 6 were to determine if total healthcare utilization costs 
(medical and medication costs) and RA-related healthcare utilization costs (medical 
and medication costs) differ significantly among ETN, ADA and IFX users while 
controlling for covariates. Overall, the median (mean±SD) total healthcare cost, RA-
related healthcare cost and TNF inhibitor therapy costs incurred by the study subjects 
in the post-index period were $16,488 ($16,477±9,228), $13,921 ($13,713±8309) 
and $9,470 ($10,851±7,537), respectively.  It is important to note that total 
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healthcare cost and RA-related healthcare cost were primarily driven by TNF 
inhibitor therapy cost.  TNF inhibitor therapy cost accounted for 65.9 percent and 
79.1 percent of total healthcare cost and RA-related healthcare cost, respectively. 
Total healthcare costs, RA-related healthcare costs and TNF inhibitor therapy 
costs were significantly lower for ETN compared to ADA patients but significantly 
higher for ETN and ADA compared to IFX patients. When compared to results from 
previous retrospective database studies, the pattern of higher cost with ADA 
compared to ETN was consistent. However, previous studies reported higher costs 
with IFX compared to ETN. 2,28,29,31,183,224-226  The major difference between the 
present study and the previous cost studies lies in the type of study data. The present 
study analyzed Medicaid data while the other studies evaluated data from private 
health plans or managed care organizations. Differences in the level of rebates 
negotiated with pharmaceutical manufacturers by the private and Medicaid plans 
may contribute to the inconsistency.   
Covariates significantly associated with the total healthcare cost include pre-
index DMARD medication use, pre-index RA-related visits and pre-index cost. 
Covariates significantly associated with RA-related cost include gender, pre-index 
DMARD use, pre-index RA-related visits, pre-index total healthcare cost and CCI. 
Covariates significantly associated with TNF inhibitor therapy cost include gender, 
pre-index DMARD use and pre-index RA-related visits.   
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Increase in pre-index RA-related visits and pre-index total healthcare cost 
were associated with increase in cost while increase in CCI score was associated with 
a decrease in cost. Compared to those who were on DMARD medications, subjects 
who were not on DMARD medications in the pre-index period had lower cost while 
males had higher cost compared to their female counterparts. Increase in pre-index 
RA-related visits and pre-index total healthcare cost may be indicative of either a high 
level of disease severity or not achieving the desired treatment response which can 
lead to a higher cost. On the other hand, non-use of DMARDs in the pre-index period 
could also be indicative of a low level of disease severity which can be associated with 
lower cost.  Tang et al. reported a positive relationship between pre-index total 
healthcare cost, CCI and total healthcare cost and lower total healthcare costs among 
female subjects compared to males. 4 
5.3.5 Objective 7 
Objective 7 was to determine if RA-related healthcare utilization cost was 
associated with adherence/persistence to TNF inhibitors (ETN, ADA or IFX) while 
controlling for covariates. RA-related healthcare utilization cost was significantly and 
positively related to both adherence and persistence.  Separate GLM-GEE models 
were used to test the relationship as adherence and persistence were highly and 
positively correlated (r = 0.88513; p < 0.0001) with each other.  This positive 
relationship was expected and was comparable with results from previous studies.2,4 
  197 
Borah et al. reported significantly higher total cost of care among adherent patients 
on either ETN or ADA.2 Tang et al. also reported a positive relationship between 
persistence and total healthcare cost.4 RA is a chronic disease condition and if 
remission does not occur, optimal adherence/persistence to prescribed medication 
serves as the major approach to improving patients’ symptoms, physical functioning 
and quality of life while slowing the progression of the disease. Since TNF inhibitors 
account for a majority of both RA-related healthcare cost and total healthcare cost, 
increase in adherence/persistence means patients “take” their medication and 
therefore costs will also increase.  
Covariates significantly associated with the RA-related healthcare cost include 
age, pre-index RA-related visits, pre-index total healthcare cost and total number of 
non-study RA related medications used at index. A positive relationship was observed 
between all these covariates (except age) and RA-related healthcare cost. As indicated 
in the previous section, increase in pre-index RA-related visits, pre-index total 
healthcare cost and and total number of non-study RA related medications used at 
index may be indicative of either a high level of disease severity or not achieving the 
desired treatment response which can lead to higher costs.  
5.4 STUDY LIMITATIONS 
The present study is unique as it is the first study to the best of our knowledge 
to evaluate all medication use pattern parameters (medication adherence, 
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persistence, discontinuation, switching and dose escalation) and associated 
healthcare utilization costs across RA patients on etanercept, adalimumab and 
infliximab using Medicaid data. However, the study has limitations which needs to be 
considered when interpreting the study results.  
The first study limitation lies with the use of administrative claims data. 
Administrative claims data are developed for the purpose of reimbursement rather 
than research. The presence of a claim for a TNF-inhibitor therapy (i.e., ETN or ADA) 
in the prescription claims data does not necessarily mean that the patient used the 
medication. However, for IFX, in the absence of fraudulent claims, the presence of a 
HCPCSv J-code 1745 in the medical claims data indicates that it was infused. Second, 
the non-randomized distribution of the study groups and presence of baseline 
differences in clinical characteristics could introduce bias (i.e., selection bias) in the 
study results.  Although, propensity score (PS) matching and multivariate analyses 
were used to control for selection/channeling bias and confounding on known 
variables, there is the prossibility that the study groups may still differ in unknown 
or unmeasured parameters that were not available in the data set (e.g., disease 
activity and disability). These may have contributed to the differences observed in 
the study outcomes. In addition, the use of PS matching resulted in a significant 
                                                          
v Healthcare Common Procedure Coding System 
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decrease in the study sample size, causing a decrease in power. This may have be 
responsible for the inability to detect significant differences among study groups on 
some of the dependent variables. 
Third, days supply information were computed based on manufacturer 
recommended infusion intervals for patients on IFX. This may not be consistent with 
the actual interval in days between infusions for the respective patient and may be 
responsible for the higher adherence values observed with IFX patients compared to 
those on ETN or ADA. In addition, due to the need to obtain IFX infusion at the 
physician’s office and perphaps, receiving appointment reminder messages regarding 
these visits could have accounted for the higher adherence values among IFX patients.  
Fourth, due to absence of unit of service information in the medical claims to 
determine the quantity of vials administered for patients on IFX, cost information 
associated with the HCPCS J-code 1745 was used as a proxy to determine dose 
esclation. This may have either overestimated or underestimated dose escalation 
rates in this study group.  
Fifth, cost analyses were based on direct cost to the Texas Medicaid program 
and may not reflect the actual cost of therapy or service provided.  While, the use of 
biologics have been shown to significantly impact productivity costs, these were not 
assessed in the cost analyses due to lack on data. Sixth, due to lack of information on 
clinical factors (e.g., incidence of adverse events, lack of response or presence of 
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suboptimal response) reasons for dose escalation, nonadherence, discontinuation 
and switching from index TNF inhibitor therapy could not be evaluated. Seventh, the 
present study only analyzed 12 months of post-index data for biologic-naïve patients. 
Study outcomes may differ if patients were followed for a longer time period as RA is 
a chronic disease condition. Finally, the study sample had an over-representation of 
women, minorities (Hispanics) and people of lower socioeconomic status compared 
to the general U.S. population and thus cannot be generalized.   
5.5  CONCLUSIONS, RECOMMENDATIONS AND SUGGESTIONS FOR FUTURE RESEARCH 
The main purpose of the present study was to evaluate medication use 
patterns (e.g., medication adherence, persistence, switching and dose escalation) of 
rheumatoid arthritis (RA) patients on etanercept (ETN), infliximab (IFX) or 
adalimumab (ADA) and the associated healthcare utilization costs using Texas 
Medicaid data.  The study results suggest that ETN was associated with lower rates of 
dose escalation compared to ADA or IFX.  However, adherence was better and 
associated healthcare costs were lower with the use of IFX.  
In general, clinicians need to be aware of factors that impact RA patients’ 
medication use behaviors. Clinicians caring for Medicaid patients with RA need to be 
aware that this group of patients present with poor medication use behaviors. 
Clinicians should endeavor to work with each individual patient to identify patient-
specific factors responsible for poor medication use behaviors with TNF-inhibitor 
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therapies. Reducing the impact of these factors and improving medication use 
behaviors (especially adherence and persistence) should be included as a major part 
of the treatment plan for each RA patient. RA patients need to be adequately educated 
on the chronic nature of the disease as well as the importance of adhering and 
persisting to their TNF-inhibitor therapy as poor medication adherence/persistence 
negatively impacts the RA disease process. The Texas Health and Human Services 
Commission should invest in programs (e.g., patient education) aimed at improving 
RA patients’ medication use behaviors. Such programs will go a long way in improving 
patients’ disease condition, overall health related quality of life and productivity. In 
addition, in the long term, patients’ risk of developing RA-related complications or 
comorbid conditions and their associated cost will be reduced.  
Future research using Medicaid data can evaluate medication use patterns 
over a longer study period and can extend comparisons to include the new biologics. 
It will also be interesting to evaluate the relationship between medication use 
patterns and other clinical (e.g., disease activity) and humanistic parameters (i.e., 
HRQoLw and work productivity parameters).   
 
 
                                                          
w Health related quality of life 
  202 
Appendices  
 
 
  203 
Appendix A:  Results of Unadjusted Analyses (McNemar's Test) 
 Proportion of Patients with Dose Escalation‡ 
 N % Statistic (S) P- value† 
ETN (N=274) 6 2.2  
ADA (N=274) 27 9.9 14.2258 < 0.0001* 
IFX (N=274) 23 8.4 10.7037 0.0015* 
Overall (N=822) 56 6.8  
     
 Proportion of Adherent Patients (MPR≥80%) ‡ 
 N % Statistic (S) P- value† 
ETN (N=274) 58 21.2  
ADA (N=274) 45 16.4 2.1392 0.1766 
IFX (N=274) 90 32.9 18.5780 < 0.0001* 
Overall (N=822)  193 23.5  
     
 Proportion of Patients who Discontinued Index TNF-inhibitor Therapy‡ 
 N % Statistic (S) P- value† 
ETN (N=274) 183 66.8  
ADA (N=274) 180 65.7 0.0720 0.8581 
IFX (N=274) 170 62.0 1.4956 0.2589 
Overall (N=822) 533 64.8  
     
 Proportion of Patients who Switched from Index TNF-inhibitor 
Therapy‡ 
 N % Statistic (S) P- value† 
ETN (N=274) 29 10.6  
ADA (N=274) 37 13.5 1.0323 0.3742 
IFX (N=274) 32 11.7 0.1636 0.7877 
Overall (N=822) 98 11.92  
ADA= Adalimumab; ETN=Etanercept; IFX=Infliximab; MPR=Medication possession ratio;  
‡ADA and IFX were individually compared to ETN. 
 †Bonferroni correction was used to control for type 1 error due to multiple comparisons with a prior p value set 
at 0.025 (0.05/n , where n=2 which is the number of comparisons) 
*significant at p < 0.025 
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Appendix B:  Results of Unadjusted Analyses (Paired T-Test) 
 Medication Adherence (MPR)‡ 
 Mean  (±SD) 95% CI Statistic (T) P-value† 
ETN (N=274) 48.8 (±28.7) 45.4 - 52.3  
ADA (N=274) 53.0 (±27.3) 49.8 - 56.3 1.77 0.0779 
IFX (N=274) 55.7 (±31.9) 51.9 - 59.5 2.87 0.0045* 
Overall (N=822) 52.5 (±29.5) 50.5 - 54.5  
     
 Medication Persistence (60-day gap period)‡ 
 Mean (±SD) 95% CI Statistic (T) P-value† 
ETN (N=274) 196.7 (±134.0) 180.8 - 212.7  
ADA (N=274) 199.4 (±130.5) 183.8 - 214.9 0.24 0.8132 
IFX (N=274) 215.5 (±133.5) 199.7 – 231.4 1.80 0.0730 
Overall (N=822) 203.9 
(±132.8) 
194.8 – 213.0  
     
 Time to Discontinuation (60-day gap period)§ 
 Mean (±SD) 95% CI   
ETN (N=183) 116.5 (±85.5) 104.1 – 129.0 
ADA (N=180) 117.7 (±78.9) 106.1 – 129.3 
IFX (N=170) 127.5 (±90.1) 113.9 – 141.2 
Overall (N=533) 120.4 (±84.9) 113.2 – 127.6  
     
 Time to Medication Switch§ 
 Mean (±SD) 95% CI   
ETN (N=29) 138.7 (±90.4) 104.3 – 173.1 
ADA (N=37) 139.6 (±89.5) 109.8 – 169.5 
IFX (N=32) 142.5 (±103.9) 105.1 – 180.0 
Overall (N=98) 140.3 (±93.7) 121.5 – 159.1 
ADA= Adalimumab; ETN=Etanercept; IFX=Infliximab; MPR=Medication possession ratio;  
‡ADA and IFX were individually compared to ETN. 
 †Bonferroni correction was used to control for type 1 error due to multiple comparisons with a prior p value set 
at 0.025 (0.05/n , where n=2 which is the number of comparisons) 
§Paired analysis could not be conducted due to presence of un-paired groups 
*significant at p < 0.025 
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Appendix C:  Results of Unadjusted Analyses (Signed- Rank-Test) 
 Total Healthcare Utilization Cost‡ 
 Median Mean  (±SD) 95% CI Statistic 
(S) 
P-value† 
ETN (N=274) $16,575 $16,325 (±8,469) $15,317 - $17,331  
ADA (N=274) $18,670 $18,299 (±9,074) $17,220 - $19,378 3122.5 0.0171* 
IFX (N=274) $13,171 $14,808 (±9,792) $13,643 - $15,972 3110.5 0.0175* 
Overall 
(N=822) 
$16,488 $16,477 (±9,228) $15,845 - $17,109  
      
 RA-related Healthcare Utilization Cost‡ 
 Median Mean (±SD) 95% CI Statistic 
(S) 
P-value† 
ETN (N=274) $13,894 $13,391 (±7,421) $12,508 - $14,273  
ADA (N=274) $15,987 $15,777 (±8,005) $14,825 - $16,729 4291.5 0.0010* 
IFX (N=274) $10,283 $11,972 (±9,002) $10,902 - $13,043 3302.5 0.0116* 
Overall 
(N=822) 
$13,921 $13,713 (±8,309) $13,145 - $14,282  
      
 TNF-Inhibitor Therapy Costs‡ 
 Median Mean (±SD) 95% CI Statistic 
(S) 
P-value† 
ETN (N=274) $10,209 $10,647 (±6,714) $9,848 - $11,445  
ADA (N=274) $13,190 $12,999 (±7,517) $12,105 - $13,893 4740.5 0.0003* 
IFX (N=274) $6,279 $8,992 (±7,834) $8,061 - $9,924 4531.5 0.0005* 
Overall 
(N=822) 
$9,512 $10,879 (±7,543) $10,363 - $11,396  
ADA= Adalimumab; ETN=Etanercept; IFX=Infliximab  
‡ADA and IFX were individually compared to ETN. 
 †Bonferroni correction was used to control for type 1 error due to multiple comparisons with a prior p value set 
at 0.025 (0.05/n , where n=2 which is the number of comparisons) 
*significant at p < 0.025 
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